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Interactions between membranes and proteins are crucial in numerous biological processes.
Therefore, the membrane is not only composed of lipids forming the lipid bilayer but also
crowded with proteins. [1] A vast amount of proteins are constituted of cytoskeleton com-
ponents extensively interacting with the lipid bilayer either through adaptor proteins or
through direct interactions. [2] This mesh-like protein network lining the interior of the
plasma membrane is also denoted as the membrane skeleton and is crucial for membrane
stability and shape. [3,4] Apart from its structural influence, it has also been shown to alter
the diffusion rate of lipids and other membrane protein components leading to the formu-
lation of the fence and picket model. [5] According to the fence model, protein movement
across the membrane is slowed down due to the membrane skeleton corralling membrane
proteins in a fence-like fashion. The picket model explains the similar deceleration of
lipid diffusion with transmembrane proteins, which are immobilized by interaction with
the membrane skeleton, acting as picket-like barriers restricting lipid movement. There-
fore, local lipid composition is apparently influenced by the membrane skeleton mesh
size altering the membrane heterogeneity. [6,7] Moreover, by influencing the diffusion rates
as well as linking membrane protein complexes to the membrane skeleton, this protein
network might be the driving force of local membrane protein and lipid domains. [8,9] All
these findings have led to the hypothesis that the dynamic formation of the membrane
skeleton is an important regulating mechanism adapting the membrane composition to
environmental changes by fine-tuning the local membrane morphology. [6,10] However, the
membrane itself as well as the protein/membrane interplay, that is the membrane skele-
ton, are highly complex systems. The regulating mechanisms are not fully understood
although computational methods as well as fluorescence microscopy studies have tried
to shed light on the underlying principles. [11] Moreover, numerous studies have been con-
ducted in vivo or in vitro to gain an insight into the interactions of cytoskeletal components
with the membrane. [4,12,13] In addition to recombinant downscaled protein variants, [14,15]
also prokaryotic cytoskeletal components [6] as well as polymers [16,17] have been employed
as model systems to reduce complexity. Yet many aspects of the membrane skeleton
affecting membrane topology and composition remain unclear. Therefore, an artificial
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model system with specific interaction sites for the interactions between the cytoskele-
ton and the membrane might provide a better understanding of the membrane skeleton
dynamics.
In this thesis, the design, synthesis and analysis of an artificial model system is presented
to identify the prerequisites for an aggregational system on lipid bilayer surfaces, lead-
ing the way for the expansion to higher organized superstructures. These studies should
provide the basis for a peptide network on model membranes mimicking the membrane
skeleton. The model system was devised to form aggregates by specific interaction as well
as possess hydrophobic interaction sites for the attachment to lipid bilayer surfaces. In
a bottom-up approach, β-peptides were selected as the scaffold. These artificial peptides
have gained attention in the last decades due to their capability to form stable secondary
structures at short sequence lengths which are not proteolytically degraded. [18,19] Espe-
cially the 14-helix, which has already been thoroughly characterized, has been of great
interest due to its highly stable environment-independent structure. [20,21] This helix topol-
ogy is distinguished by its regular three-sided structure containing three β-amino acids
per helix turn and it was determined that no side chain interactions are required for helix
formation allowing a variety of functionalization. [22,23] For the formation of aggregates,
nucleobase-functionalized β-peptides, also denoted as β-peptide nucleic acid (β-PNA), were
identified as promising targets since previous studies have demonstrated that β-PNA are
capable of forming oligomers through molecular recognition. [24–27] The duplex formation
occurs similar to DNA duplexes in antiparallel orientation and its stability is controllable
by the sequence composition. [25,28] Apart from investigating higher oligomer formation in
solution, this specific β-PNA/β-PNA interaction has so far been incorporated in a SNARE
model system. To investigate the membrane fusion mediated by this protein complex, the
original coiled-coil interaction sites were replaced with β-PNA strands. [26,29,30]
Based on the preceding studies, the model system for this work was designed to exhibit
a minimal number of three nucleobases per interaction site to keep complexity as low as
possible. In addition, sequence motifs comprising only of guanine (G) or cytosine (C)
were not incorporated because it has been shown that sequences with high CG content
are prone to interact unspecifically. [31] To achieve attachment of the β-PNA strands to the
lipid bilayer surface, the β-peptide was modified with a hydrophobic moiety which would
autonomously insert into the lipid bilayer, thereby anchoring it on the membrane surface.
For these hydrophobic anchors, myristyl alcohol and cholesterol were chosen since they
both have been shown to play a role in partitioning of the lipid bilayer. [1,32] The β-PNA
strand itself was rendered hydrophilic to prevent its incorporation into the membrane.
Additionally, the incorporation of sterically constrained β-amino acids was supposed to
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ensure 14-helix formation. [19] Ultimately, different fluorescent labels were incorporated
for analytical purposes. Two different model systems were realized with a minimal nu-
cleobase motif of three nucleobases per interaction site. During synthesis of the β-PNA
strands, the initial SPPS conditions were optimized to achieve a more efficient synthesis
in regards of time and reagent consumption. [29] One system was designed with two nucle-
obase and two hydrophobic membrane interaction sites per β-PNA strand, hence denoted
the bifacial model system, whereas the other system was designed with one nucleobase
and one hydrophobic membrane interaction site and therefore denoted the monofacial
model system. Initially, the secondary structure of all obtained β-peptides was analyzed
by CD spectroscopy to ensure the desired 14-helix formation was present before further
investigations were performed to find out which requirements have to be met regarding β-
PNA/β-PNA and β-PNA/membrane interactions. With soluble β-PNA variants, different
spectroscopic methods, such as UV, CD and fluorescence spectroscopy, were employed to
answer the question how sequence composition of the nucleobase interaction sites affects
the stability of dimer formation and whether dimer formation is specific. In particular,
FRET experiments were a valuable tool to determine spatial proximity and therefore in-
teraction between different components. [33,34] Furthermore, FRET analysis was employed
to investigate the capability of the β-peptides with hydrophobic modifications to attach
it to both vesicle and bicelle membrane surfaces. It was complemented by CD spectro-
scopic analysis to examine if the β-PNA/membrane interaction would disturb secondary
structure formation of the β-peptides. Ultimately, the same spectroscopic methods were
utilized to answer the question if β-PNA/β-PNA duplex formation is possible when one





Networks & Model Systems
2.1. Biological Membranes & the Membrane Skeleton
The cell membrane separates the cell from the outside acting as a protective barrier.
Apart from protection and distinction from the environment, biological membranes are
essential for many other functions, such as signal transduction, compartmentalization for
enzymatic reactions, cell motility and regulation of molecule transfer. Lipids represent
essential components of membranes and have an amphiphilic structure consisting of a
hydrophilic head group and a hydrophobic alkyl chain region. As amphiphilic molecules,
they spontaneously form lipid bilayers in aqueous environments driven by the hydrophobic
effect (Figure 2.1).
In 1972, the fluid mosaic model was postulated by Singer and Nicolson describing
the membrane as a two-dimensional liquid in which the lipids and embedded proteins are
freely moving, in a motion denoted as lateral diffusion. [35] Although this model yielded a
major advance in the understanding of membrane structure, it soon became obvious that
biological membranes are not as fluid as originally assumed. [36] The lipid bilayer, initially
thought to be sparsely scattered with membrane proteins, actually proved to be crowded
with a multitude of membrane proteins. These proteins are involved in numerous crucial
processes, serving as receptors in signal transduction, as extra- or intracellular recognition
sites or as transporters for substances across the membranes. [37] Additionally, membrane
shape and stability is provided by proteins interacting with the lipid bilayer. [11,14]
The detection of detergent-insoluble membrane fractions indicated that membranes
are more heterogenous than initially suspected leading to the formulation of the lipid raft
model. [9] These rafts are self-assembling structures enriched with cholesterol, sphingolipids
and saturated phospholipids in a size range of 10-200 nm and exhibit a more ordered
structure (liquid-ordered phase, Lo) than the surrounding membrane which is in liquid-
disordered (Ld) state (Figure 2.1). [38] Moreover, these inhomogeneities are thought to
recruit membrane proteins forming functional multi-molecular complexes involved in endo-
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and exocytosis as well as in cell motility. [39,40] However, rafts could only be detected in
model membrane systems. [10] Since the detection in living cells has been difficult due to
their dynamics and size, the concept of rafts is a subject of debate. [41] Nevertheless, there
is growing evidence for the existence of protein and lipid domain formation and their
importance in biological processes. [1,40,42]
Figure 2.1. Schematic model of a biological membrane composed of a lipid bilayer with
heterogeneous composition where saturated lipids, cholesterol, glycolipids,
glycosylphosphatidylinositol (GPI)-anchored proteins and lipidated proteins
accumulate forming lipid domains amidst unsaturated lipids. The membrane
skeleton constituted from cortical actin is proposed to regulate the formation
and size of the phase separation. Reprinted by permission from Nature Pub-
lishing Group: Nature Reviews Molecular Cell Biology (Ref. [9]), copyright
(2017).
The formation of lipid domains appears to be driven by lipid immiscibility since it
can be observed in model membranes consisting merely of lipid mixtures. [6,9] For the
regulation of domain size and distribution several models are discussed. Electrostatic
interactions between charged lipids and proteins as well as the formation of lipid shells
around membrane proteins forming functional clusters have been proposed as regulating
forces. [43–45] Moreover, it has been shown that cytoskeletal components influence the phase
separation. [6] The cytoskeleton composed of actin filaments as well as other components
has been detected to extensively interact with the plasma membrane mediated by adap-
tor proteins or by direct electrostatic interactions. [2,46] The resultant cytoplasmic network
lines the cytoplasmic surface of the membrane forming a mesh-like superstructure also
denoted as the membrane skeleton. [5] Not only does this network stabilize and shape the
membrane, it has also been shown to influence diffusion of lipids and membrane proteins
altering the local heterogeneity. [6] Comparing the phase-separation behavior of ternary
6
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model membranes with and without the presence of actin filaments showed that actin
massively altered the distribution and size of Lo and Ld domains inhibiting macroscopic
phase separation. This could explain why the detection of lipid domains on living cells
has been unsuccessful so far. [7] In high-speed single-molecule tracking experiments, both
membrane proteins and lipids have been detected to show a confined diffusion pattern
on a short-term scale whereas long-term diffusion seemed to occur in a hop-like fashion
between the confined spaces. [5,8] These observations led to the formulation of the picket
and fence model illustrated in Figure 2.2. [5] According to this model, the actin filaments
in close proximity to the membrane act as diffusion barriers corralling membrane proteins
in confined compartments in a fence-like manner. Additionally, membrane proteins asso-
ciated with the membrane skeleton function as picket-like barriers directing lipid diffusion
to behave in a similar fashion as membrane protein diffusion. [4] The interaction between
membrane and actin filaments enables dynamic fine-tuning of the membrane composition
as a cellular response to environmental challenges. [6,10] Kusumi et al. propose three levels
of membrane organizing principles, combining the membrane partitioning by the mem-
brane skeleton with fluctuating formation of lipid domains and dynamic oligomerization
of membrane proteins. [4] However, the interplay between the membrane of living cells and
the membrane skeleton is a highly complex system which is yet to be fully understood. [2,5]
To gain an insight into the interdependence between membrane domain formation, the
membrane skeleton and the resulting compartmentalization of lipids and proteins in the
plasma membrane, numerous studies have been conducted in vivo or in vitro. [12,13,47] In
living cells, methods such as small-angle neutron scattering and single-molecule tracking
could provide valuable data about the lateral composition and fluctuation of the lipid
bilayer. [39,48] Additionally, a massive progress in the refinement of optical methods such
as fluorescence and electron microscopy (EM) has facilitated imaging of the membrane
skeleton to visualize the structural organization of the membrane skeletal network in
much higher detail than before. [46,47] Nevertheless, model systems are a valuable tool to
investigate the underlying principles for the interaction between the membrane skeleton
and the plasma membrane. They allow investigations in a simplified setting, thereby
specifically focussing on the region of interest.
In vitro studies performed with actin and ezrin, which is one of the adaptor proteins
linking actin to the lipid bilayer, on model membranes (described in Section 2.2) showed
that ezrin mediates attachment of filamentous actin (f-actin) to the membrane when it
is activated by binding of l-α-phosphatidylinositol 4,5-bisphosphate (PIP2). [12] When f-
actin was attached to different phases of lipid bilayers via phalloidin, the influence of
this model membrane skeleton on phase separation could be visualized revealing that the
7
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Figure 2.2. Schematic illustration of the fence (left) and picket (right) model from the
cytoplasmic side of the membrane. In the fence model, diffusion of trans-
membrane proteins is constricted by the membrane skeleton (MSK), which
is in close proximity to the membrane, resulting in a characteristic diffusion
pattern. In the picket model, lipid diffusion is restricted in a similar manner
to the transmembrane protein by MSK-anchored membrane proteins. Re-
published with permission of Annual Reviews, from Paradigm Shift of the
Plasma Membrane Concept from the Two-Dimensional Continuum Fluid to
the Partitioned Fluid: High-Speed Single-Molecule Tracking of Membrane
Molecules. A. Kusumi, C. Nakada, K. Ritchie, K. Murase, K. Suzuki, H.
Murakoshi, R. S. Kasai, J. Kondo, T. Fujiwara, 34:351-378, copyright 2005;
permission conveyed through Copyright Clearance Center, Inc. [8]
presence of f-actin inhibits the formation of macroscopic phase separation. [7] Addition-
ally, it was determined that f-actin attracts the Ld phase even when it was attached to
lipids preferentially segregating to the Lo phase showing that f-actin effectively prevents
phase separation at low temperatures. In another in vitro study, a prokaryotic tubulin
homolog FtsZ was employed to model a membrane skeletal network and its influence on
phase separation of a quaternary lipid bilayer. [6] FtsZ, which had previously been shown
to spontaneously polymerize on GUVs and supported lipid bilayers, was fused with yellow
fluorescent protein (YFP). [49] Fluorescence imaging of liposomes with varying concentra-
tions of FtsZ fused with YFP revealed that this prokaryotic membrane skeletal component
prevents large-scale phase separation similar to f-actin.
Aside from cytoskeletal proteins of eukaryotic or prokaryotic origin, artificial systems
have been developed to mimic the membrane skeleton and its influence on the lipid bilayer.
Stauch et al. developed a polymer network consisting of N -isopropylacrylamide (NIPAM)
and tetraethylene glycol dimethacrylate (TEGDM) coupled to the inner leaflet of a li-
posome with 1,2-distearyl-3-octaethylene glycol glycerol ether methacrylate (DOGM). [16]
After UV-induced polymerization of the monomers, the resulting polymer-containing lipo-
somes exhibited increased stability against solubilization and thus might be a useful model
8
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system for enhanced membrane stability conveyed by membrane skeleton interactions.
Moreover, a similar polymer-derived system composed ofN -(3-N,N -dimethylaminopropyl)
methacrylamide (DMAPMA) instead of NIPAM was devised. [17] Because the monomers
were localized at the lipid bilayers at high pH, UV-induced polymerization at pH 10
yielded a lamellar polymer structure lining the inner leaflet of the liposome (Figure 2.3).
The pronounced stability against solubilization might render these polymer-stabilized li-
posomes a suitable model system for cytoskeletal-induced resistance of cell membranes
against bile salts which is still under investigation.
Figure 2.3. Schematic illustration of the polymer formation on the inner liposome leaflet.
Left: At pH 10, the DMAPMA monomers (red) are uncharged and im-
mersed into the lipid bilayer together with the membrane anchor DOGM
(blue). Center: Upon addition of the crosslinker TEGDM (not shown) and
UV-irradiation a lamellar polymer structure is formed. Right: After the pH
is decreased to pH 6, the DMAPMA units are protonated and, as a result,
detach from the bilayer as a result. Reprinted with permission from tmayer,
D., Thomann, R., Bakowsky, U., & Schubert, R. (2006). Synthesis of a poly-
mer skeleton at the inner leaflet of liposomal membranes: Polymerization
of membrane-adsorbed pH-sensitive monomers. Biomacromolecules, 7(5),
1422-1428. Copyright 2006 American Chemical Society. [17]
Other artificial model systems utilized the higher aggregates constituted by rationally
designed DNA origami, which is the folding of a DNA single strand into a target structure
held together by strategically placed staple strands. [50] Block-shaped helical origami-DNA
bundles were attached to lipid bilayer surfaces via cholesterol-modified oligonucleotides
and allowed for modular assembly of various structures by the addition of different adaptor
strands. [51] When the DNA origami blocks were polymerized on SUV surfaces, a deforma-
tion of the vesicle was observed. Additionally, triskelion-shaped structures were designed
inspired by the triskelion structure of clathrin and successfully assembled on lipid bilayers
as well. Moreover, in an attempt to mimic the membrane-curvature inducing properties of
BAR domains, helical origami-DNA bundles were designed with similar shapes although
9
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the resultant DNA scaffolds were fivefold enlarged in comparison to the original protein. [52]
The curved origami-DNA was modified with cholesterol via a triethylene glycol spacer as
hydrophobic interaction sites. Upon addition to liposomes binding and deformation of
the lipid bilayers as well as formation of lipid nanotubes could be observed (Figure 2.4).
Figure 2.4. Confocal images showing the successful interaction between BAR-mimicking
origami-DNA bundles and lipid bilayers forming lipid nanotubes covered
with the BAR-mimic in green (left and right) as well as liposomes without
attached origami-DNA which retained their spherical shape in red (a). Cryo-
EM image showing the perpendicular orientation of the origami DNA bundle
to the long axis of the lipid nanotubes with the black arrow indicating the
nanotube surface (b). Based on the recorded images, a model of a lipid
nanotube coated with the curved origami-DNA bundle has been generated
(c). The figure is taken and slightly modified (additional cryo-EM image
has been left out) from Ref. [52], , published under the Creative Commons
(CC BY-NC-ND 4.0) license.
These results show that protein complexes inducing structural change of biological
membranes can be recreated by artificial structures. Therefore, the interest was sparked
if similar structures mimicking membrane skeletal protein oligomers could be generated
with other scaffold systems that might be less susceptible to hydrolysis in comparison to
DNA but still offer specific interaction to form networks.
10
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2.2. Model Membrane Systems
The high complexity of biological membranes because of an intricate lipid composition and
the abundance of membrane proteins complicates the study of single processes, although
great progress has been made in the last decade. [39,47] Therefore, a wide variety of model
systems has been developed for simplification and standardization of lipid bilayers in
experimental setups enabling detailed studies. [53] Illustrations shown in Figure 2.5 give
an overview of different systems which offer a diversity of topologies and compositions for
differing requirements. In general, these model systems can be differentiated as solution-
phase-suspended and solid-supported model systems as well as as artificial lipid mixtures
and natural membranes derived from cells.
Figure 2.5. Overview of selected membrane model systems to examine biological mem-
branes symbolized by the schematic cell in the center. The depicted
model systems are vesicles (A), lipid microtubulus-connected giant vesi-
cles (B), multi-layered solid-supported bilayers (C), nanodiscs stabilized by
membrane scaffolding proteins (D), supported bilayers (E), cell membrane
patches attached to solid supports (F), tethered bilayers on solid supports
(G), vesicles immobilized by DNA duplex formation (H) and in silico simu-
lations. Reprinted from Current opinion in chemical biology, 11, Y.-H. M.
Chan, S. G. Boxer, Model membrane systems and their applications. 581-7,
Copyright 2007, with permission from Elsevier. [53]
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Vesicles, also denoted as liposomes, are one type of commonly employed membrane
system suspended in solution and are often prepared from defined lipid mixtures (Fig-
ure 2.5(A)). [54] In case of artificial vesicles, lipid composition and size can be controlled
via different preparation methods and apart from research they also found application
in drug delivery systems. [55,56] These spherical model membrane systems are classified by
size with small unilamellar vesicles (SUVs) being smaller than 100 nm, large unilamellar
vesicles (LUVs) exhibiting a size range of 100–1000 nm and GUVs being larger than 1 µm
in diameter. [56,57] While SUVs and LUVs are prepared from multilamellar vesicles (MLV)
by sonication or extrusion, GUVs can be prepared by electroformation or hydration above
liquid phase transition temperature for extended time periods. [57–59] Apart from simplified
lipid mixtures, which are only an approximation to the complex lipid composition of bio-
logical membranes, giant plasma membrane vesicles (GPMV) can also be obtained from
live cells by inducing vesiculation through chemical stress. [10] Since liposomes display a
curved membrane topology, nanodiscs and bicelles have been developed to obtain planar
lipid bilayers in solution (Figure 2.5(D)). [60,61] Nanodiscs exhibit a uniform diameter be-
cause the lipid bilayer size is controlled by a membrane scaffolding protein that surrounds
it, whereas bicelles are fully composed of lipids and therefore, are more variable in size.
Since planar model membranes in solution are limited in size for stability reasons, solid-
supported bilayers can be employed when large-scale membranes are investigated. Among
other methods, SUVs prepared from artificial lipid mixtures can be exposed to hydrophilic
supports to obtain planar bilayers (Figure 2.5(C) and (E)). [62] For solid-supported bilayers
of biological origin, cells are immobilized between two poly-l-lysine-coated glass supports
and the membrane is subsequently ripped off the cells by separating the glass supports
(Figure 2.5(F)). [63] These solid-supported membranes are applicable in a variety of imag-
ing and analysis methods, however, a decreased lateral mobility of incorporated trans-
membrane proteins has been observed due to close proximity to the solid support. [53]
Therefore, porous substrates have been utilized obtaining freestanding pore-spanning
membranes. [64,65] Other solutions apply long tethers or polymer layers to act as spacers
(Figure 2.5(G)). [66,67] Additionally, immobilization of individual vesicles on solid supports
has been applied to visualize single molecule processes (Figure 2.5(H)). [68] Depending on
the focus of study, more complex assemblies are required and have been realized in the last
decades, such as ruptured GUVs on solid-supported bilayers to investigate tight junctions
or GUVs connected by lipid microtubules to form networks (Figure 2.5(B) and (C)). [53]
For investigations on lipid bilayers in this thesis, LUV and bicelle suspensions were
chosen for being established methods utilized in spectrometric bulk measurements, ease
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of preparation and good replicability. As depicted in Figure 2.6, LUVs (a) have a spherical
shape with a high membrane curvature, whereas bicelles (b) show a planar topology.
Figure 2.6. Schematic depiction of the membrane model systems employed in this thesis,
large unilamellar vesicles (LUVs, a) and bicelles (b), in cross-section side
view with long-chain lipid head groups colored in yellow and short-chain
lipid head groups shown in green.
The size of LUVs (diameter of 100–1000 nm) is controlled during the extrusion process,
where a MLV suspension is channeled through a filter with defined pore size. [69] The resul-
tant LUV suspensions typically show a narrow size distribution, therefore being regarded
as monodisperse (Figure 2.7). Additionally, they exhibit a higher stability than SUVs
whose smaller size leads to a higher curvature, resulting in higher strain on the membrane
which leads to spontaneous fusion. In contrast to the formation of GUVs, the prepa-
ration of LUVs from MLV suspensions is uncomplicated and straightforward. However,
the preparation of asymmetric bilayers is not possible. [70] Other aspects to consider are
the change of original lipid composition when working with lipid mixtures and possible
lipid loss during LUV formation. [71] Nevertheless, LUVs are a practicable model system
especially when single lipid compositions are employed and lipid concentration is not of
high interest. Since they enclose compartments thereby separating an internal volume
from the external solvent, they provide the advantage of spatial separation of substances.
Especially for studying transport processes across membranes, membrane fusion, drug
interaction with lipid bilayers or cell adhesion, the internal volume of the liposome can
be loaded with sensors enabling visualization of events. [53,72–74] Due to this property and
their biocompatibility, vesicles also found application in drug delivery systems to encap-
sulate active molecules and to enable targeted transport when decorated with site-specific
ligands. [55,56,75]
Commonly, bicelles are described as flat bilayer disks whose patch of bilayer com-
posed of long chain (lc) phospholipids is encircled with short chain (sc) phospholipids
13

















1 10 100 1.000 10.000
Figure 2.7. Exemplary mean size distribution plot of an LUV suspension with a mean
hydrodynamic diameter of 133.8 nm prepared by extrusion through a poly-
carbonate membrane with 100 nm pore size.
as the detergent at the rim. [61] Frequently, a combination of 1,2-dimyristoyl-sn-glycero-3-
phosphocholine (DMPC) as the lc component and 1,2-dihexanoyl-sn-glycero-3-phosphocholine
(DHPC) as the sc detergent component is employed and therefore well characterized. [76,77]
Most commonly, bicelles are prepared from lipid films obtained from the lc component
which is decomposed upon addition of solvent containing the sc detergent resulting in
the formation of bicelles. The formation process can be accelerated by repeated heating,
cooling and shaking cycles but numerous additional procedures exist in which also the
reconstitution of transmembrane proteins during bicelle preparation is possible. [61,78] The
size of this discoidal model membrane is dependent on temperature, lipid concentration
and the value q. This important descriptor of bicelle topology is the ratio of lc lipid con-
centration to sc lipid concentration with q = [DMPC]/[DHPC]. The larger the q-value,
the larger is the radius of the formed bicelles because the areas of the center Acenter and
the rim Arim are determined by the ratio of lc and sc lipid concentration: [79]





(πR + 2r)r (2.1)
with r being the radius of the rim and R being the radius of the bilayer patch for an
ideal bicelle as depicted in Figure 2.8. Summation of r and R gives the total radius r′
of the bicelle. The thickness of the lipid bilayer is denoted as t, which is t = 0.4 nm for
DMPC/DHPC bicelles. [79]
However, investigations concerning the morphology and how it is influenced by lipid
composition, ionic strength or temperature have shown a wide variation of shapes present
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Figure 2.8. Schematic depiction of an ideal bicelle disc with dark grey head groups rep-
resenting DMPC (lc phospholipid) and light grey head groups representing
DHPC (sc phospholipid). Reprinted from Biochimica et Biophysica Acta -
Biomembranes, 1664, L. Van Dam, G. Karlsson, K. Edwards, Direct obser-
vation and characterization of DMPC/DHPC aggregates under conditions
relevant for biological solution NMR. 241-256, Copyright 2004, with permis-
sion from Elsevier. [79]
in sample solutions such as mixed cylindrical micelles, branched structures and perforated
bilayers. [76,79,80] This is partly due to the fact that the sc detergent in the bicelle rim is in
equilibrium with free detergent in solution lowering its effective concentration in the bi-
celle. Moreover, molecular modeling studies also showed that completely bicellar topology
only exists in narrow temperature and q-value ranges. [81] Nevertheless, bicelles have been a
useful tool for spectroscopic methods providing a planar membrane topology, which is con-
venient for the investigation of transmembrane and other membrane-associated proteins.
In addition, bicelles have also been successfully utilized for in vitro cell-free expression
of membrane proteins. [82,83] In NMR, bicelles with a q below 2.3, which are denoted as
isotropic bicelles, have proven to be a valuable tool because they are able to rapidly re-
orient in solvent. This enables an improved resolution for the structural investigation
of membrane proteins. [76] The usage of larger aligned bicelles in NMR could even en-
hance resolution of globular proteins in solution because the bicellar alignment induces
preferential orientation of the proteins as well. [61]
For fluorescence or CD spectroscopic studies, sometimes very low bicelle concentrations
are necessary because of the sensitivity of the method and the interfering scattering ef-
fect of the bicelles. However, at lower concentrations the bicellar size starts fluctuating
forming more complex structures. [76,77] As it can be seen in Figure 2.9, this leads to a
polydisperse sample with additional populations of larger size than the discoidal species.
Regarding stability, bicelles have been shown to exhibit a high stability in concentrated
solutions as long as the concentration of the sc component is above its critical micellar
concentration (cmc) and the temperature is below the transition temperature of the lc
lipid component. [80] Concentration-dependent stability is explained by an intense decrease
of the effective sc lipid concentration at the rim when the cmc is not reached leading to
15
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the uncontrolled formation of higher aggregates and formation of precipitate. In addi-
tion, exceeding the transition temperature resulted in a localization of sc lipids into the
planar part of bicelles diluting its effective concentration even more. This is thought
to be caused by the phase change from solid-ordered (So) to liquid-disordered (Ld) in
which the planar bilayer patch of the bicelles becomes more fluid and allows insertion
of the sc detergent whereas the So phase being regularly and tightly packed prevents sc
detergent insertion. To overcome stability issues at low concentrations, investigations
have been made with other sc lipids which exhibit a lower cmc showing that indeed the
lower cmc leads to higher stability of bicelle formation at low concentrations. [77] Addition-
ally, other lipid combinations have been proposed for bicelle systems unaffected to other
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Figure 2.9. Exemplary mean size distribution plot of a bicelle suspension with a mean
hydrodynamic diameter of 30.35 nm and 332.2 nm for the different size
populations prepared from DMPC and DHPC with a q of 2.
2.3. β-Peptides & β-Amino Acids
Artificial peptides consisting of α-amino acids have widely been used to mimic proteins and
examine structure-function relations. [86–89] Apart from being used to investigate biological
processes such as signaling or disease progression on a cellular scale, short stable scaffolds
have been of great interest in the development of antibiotics and peptide-based drugs. [90–93]
In addition to the canonical α-amino acids, non-native amino acids have been utilized to
mimic structure elements or to introduce new functionalities. [94,95] Especially β-peptides
have garnered a lot of attention since they form stable, well-defined helical structures
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starting from a sequence length of 6 β-amino acids. [18] These helical structures, which have
been thoroughly investigated and documented over the last decades, are stable towards
proteolytic degradation because of their structure. [96,97]
Predominantly, β-amino acids differ from α-amino acids in having an additional methy-
lene group between the amino and carboxy functionality of the backbone, which results
in more diverse substitution patterns and conformations (Figure 2.10). Depending on
the position of the substituent, β-amino acids are classified as β2-amino acids, with the
side chain located at the Cα-position, β3-amino acids, with the side chain located at the
Cβ-position, or β2,3-amino acids, with substituents at both positions. [98] As a result of
the additional α-methylene group, the structure of β-peptides is characterized by four
torsion angles instead of three with the contribution of an additional rotation axis by the
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Figure 2.10. Schematic overview of α-amino acids as well as the different forms of β-
amino acids with their respective substitution patterns. [98]
In nature, β-amino acids can be found in numerous active compounds. The most com-
mon representative possibly might be β-alanine which is, among others, a component of
pantothenic acid (B5), an essential vitamin and precursor of coenzyme A. [98,99] Apart from
β-alanine, which has no side chain and therefore no chiral center, other β-amino acids that
do exhibit chirality call for enantio-selective synthetic procedures. Therefore, a variety
of different synthetic methods has been described in literature for the preparation of dif-
ferently substituted species. [98–100] In the case of β3-amino acids, the Arndt-Eistert
homologation may be the most widely used synthetic method to obtain enantiomerically
pure products. [101] In this two-step homologation, the corresponding α-amino acid is first
converted into a diazoketone by applying diazomethane after the active acid anhydride
has been formed with isobutyl chloroformate. Then, the diazoketone undergoes a silver(I)-
catalyzed Wolff rearrangement and the resultant ketene is immediately hydrolyzed to
the corresponding carboxylic acid. [102,103]
As already stated, β-peptides have been shown to form stable helical structures secured
by hydrogen bonds between the backbone amide proton and oxygen atom (Figure 2.12).
Apart from helical conformations, β-peptides are also able to adopt sheet-like or turn
17
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Figure 2.11. Comparison of the torsion angles of α- and β-amino acids. [96]
conformations under certain conditions. The nomenclature of the helices is based on
the size of the ring formed by the hydrogen bonds and so far five different helical con-
formations have been identified, the 8-, 10-, 12-, 10/12- and 14-helix. [96] The preferred
helical conformation can be influenced by the introduced β-amino acids. While all-β3-
or all-β2-peptides have been shown to mainly form 14-helices, sequences composed of al-
ternating β2- and β3-amino acids form 10/12-helices. [22] The 12-helix has been detected
for β-peptides consisting of cyclopentane-β-amino acid derivatives, whereas the 8- and
10-helices were so far only detected for short sequences containing oxetane-β-amino acids
































































Figure 2.12. Schematic overview of the observed β-helix types with the corresponding
hydrogen-bonding pattern in comparison to the α-helix consisting of α-
amino acids. [96]
Of all the helical conformations presented, the 14-helix (also denoted 314-helix or 31-
helix in literature) is of special interest and has thoroughly been analyzed with CD spec-
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Figure 2.13. Theoretical model of an idealized 14-helix in side (left) and top view (right)
from N - to C -terminus (generated with Avogadro). [104,105]
troscopy and NMR because of its regular and pronounced structure. [20,21] Especially CD
spectroscopy has become a convenient tool to identify β-peptide secondary structures be-
cause the 14-helix exhibits a characteristic CD spectra pattern. Forming a 14-membered
ring between N-H at position (i) and C=O at position (i+2), the 14-helix exhibits a
helical pitch of 5 Å and three β-amino acids per turn resulting in a regular three-sided
helix, which is illustrated in Figure 2.13. The helical conformation can further be sta-
bilized by the incorporation of the conformationally constrained β-amino acid trans-2-
aminocyclohexanecarboxylic acid (ACHC) leading to higher environment-independent
stability even at elevated temperatures (Figure 2.14). [19,23] Moreover, the incorporation of
β-amino acids that exhibit branching at the first side chain carbon atom adjacent to the
backbone have been determined to stabilize the 14-helix as well. [106] Side chains are not
involved in interactions needed to stabilize 14-helix formation which enables free choice
regarding functionalization of the helix faces. [22,23] As a consequence, β-pepides have been
employed as model systems for transmembrane proteins and functionalized with moieties
for self-assembly. [107–109] Furthermore, the self-assembly of coiled-coil-like triple helices
with amphiphilic β-peptides has been reported. [110] The 14-helical conformation of the
β-peptides was shown to be unperturbed by incorporation into membranes as well as
by introduction of bulky functionalized β-amino acid building blocks. Taking these as-
pects into consideration, this β-peptide conformation constitutes a convenient scaffold to
examine interaction modes mediated by specific interaction sites.
2.4. β-Peptide Nucleic Acids
First described by Nielsen et. al, peptide nucleic acids (PNA) had initially been devel-
oped as DNA analogues for gene-targeted therapy. For this purpose, the natural DNA
backbone consisting of 2-deoxyribose linked by phosphodiester bonds was replaced with a
19




Figure 2.14. Structure of the conformationally constrained β-amino acid trans-2-
aminocyclohexanecarboxylic acid (ACHC) which promotes 14-helix forma-
tion. [19,106]
peptidic polyamide backbone composed of 2-aminoethylglycine units (Figure 2.15(a) and
(b)). [111] The resultant aminoethylglycine-PNA with its outstanding duplex stability and
interesting helix topology sparked the development of other PNA forms. One example
is the alanyl-PNA which, as the name suggests, is based on the amino acid alanine and
whose duplex exhibits a linear topology when the sequence consists of nucleo-amino acids
with alternating configuration. [112,113] Proceeding from alanyl-PNA, homologation of the
peptide backbone leads to homoalanyl-PNA which is constructed from nucleo-β-amino
acid building blocks. [114–116] The additional methylene group in the backbone leads to
the nucleobases being oriented in the same direction, therefore, obviating the need for
alternating configuration of the monomers. Apart from the linear topology of duplex
formation, results also indicated higher-ordered structures which might stem from non-
Watson-Crick base paring modes. The structural differences of the described PNA species
in comparison to DNA are illustrated in Figure 2.15 showing the variation in backbone
composition.
Based on the preferential helical conformation of β-peptides which has been explained
in the previous Section 2.3, it was investigated whether duplex formation of 14-helical
β-peptides is feasible. [28,117] For this, nucleo-β-amino acids were introduced at every third
position of the sequence. This means the nucleobases are oriented to the same direction
and located next to each other when the 14-helix is formed, resulting in a linear preorgani-
zation of the nucleobases (Figure 2.16(a)).1 In addition, the effects of side chain homolo-
gation were investigated by elongating the side chain from a methylene unit to an ethy-
lene unit resulting in the nucleobase-modified β-peptide illustrated in Figure 2.16(b). [24]
Based on Maruzen models, antiparallel duplex formation was expected for the 14-helical
β-peptides (Figure 2.16(c)). While stable duplex formation was observed for methylene-
linked nucleobases, stability for the ethylene-linked nucleobases appeared to be very low
possibly due to a higher conformational flexibility of the linker unit.
1Hereafter, 14-helical β-peptides containing nucleobase functionalization linked at every third sequence
position via a methylene unit will also be denoted as β-PNA.
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Figure 2.15. Structures of DNA (a), aeg-PNA (b), alanyl-PNA (c) and homoalanyl-PNA








































Figure 2.16. Structures of the β-PNA variants with the nucleobase either linked to β-
homoalanine (a) or 3-aminopentanoic acid (b) as well as a model of the
expected antiparallel duplex formation between two β-PNA strands (c).
Figure (c): © 2007 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. [31]
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Further studies conducted with antiparallel or parallel complementary β-PNA sequences
showed higher stabilities for the dimers of antiparallel oriented sequences indicating that
this orientation is preferred for duplex formation. [25] However, it was also revealed that
parallel oriented strands are able to interact as well, albeit with a much lower stability.
This preferential antiparallel duplex formation was explained by a postulated tilted inter-
action mode with the nucleobases not being perpendicularly oriented to the helix axis but
slightly tilted (Figure 2.17). [117,118] Due to the slightly tilted conformation of the nucle-
obases, antiparallel duplex formation displays a higher stability because the nucleobases
are oriented planar to each other which is a requirement for correct Watson-Crick base
pairing. [119,120] Additionally, it could be demonstrated that, with increasing GC content
of the nucleobase sequences, duplex stability could be increased. However, it was hy-
pothesized that the extraordinarily high stabilities of sequences featuring only guanine
and cytosine nucleobases might be caused by non-Watson-Crick base pairing, e.g. via the
Hoogsteen pairing site. [27,121] By using homo-nucleo-β-peptides of all nucleobases, it was
tested whether 14-helical β-PNA strands show interaction modes other than Watson-Crick
base pairing. [31] While thymine (all-T-β-peptides) provided highest specificity, adenine
(all-A-β-peptides) appeared to be slighty prone for unspecific interactions. Unspecific ag-
gregation similar to aromatic interaction modes detected in the case of tyrosine-mediated
aggregation had been observed for all-G- and all-C-β-peptides. [122] Hence, these results
are also in line with the propensity of CG-rich sequences for unspecific interactions.
Figure 2.17. Schematic model of antiparallel (left) and parallel (right) duplex formation
for the tilted orientation of nucleobases. © 1993 Wiley-VCH Verlag GmbH
& Co. KGaA, Weinheim. [118]
The β-PNA/β-PNA dimerization had been applied in a model system for SNARE-
mediated membrane fusion, replacing the coiled-coil recognition motif of the wild-type
SNARE complex. [30] The rigid structure of β-PNA interaction units was shown to mediate
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vesicle fusion whereas a longer β-peptide resulted in a slower fusion, appearing to control
fusion rate in a distance-dependent manner.
Apart from dimer formation, the formation of higher aggregates in solution was inves-
tigated. [26,123] Therefore, two helix faces of a β-peptide were functionalized with nucle-
obases and examined whether interaction occured (Figure 2.18(a)). Exploiting the linear
preorganization of nucleobases on the helix faces, both self-complementary and non-self-
complementary β-PNA strands exhibited a high propensity to form aggregates as well as a
high stability of the resulting structure. Based on the large size of the formed aggregates
and geometry of the β-PNA, two possible aggregation modes have been proposed, which
are illustrated in Figure 2.18(b) and (c) with β-peptides either aggregating in a tube-like
or band-like shape.
a)	   b)	  
c)	  
Figure 2.18. Model of the β-PNA strands functionalized with nucleobases at two helix
faces and their expected antiparallel duplex formation (a) as well as the
possible aggregation modes of either circular tube-like aggregates (b) or
band-like aggregates (c). © 2009 Wiley-VCH Verlag GmbH & Co. KGaA,
Weinheim. [26]
In summary, β-PNA is a subclass of 14-helical β-peptides and exhibits reliable sequence-
to-structure relationships. With the predictability of the β-PNA structure and linear
design-to-function properties this artificial platform can be implemented in a variety of
applications ranging from bio-mimicking models to engineered nano materials. The flex-
ibility regarding side chain functionalization as well as the possibility to freely combine
functional modifications facilitate coupling of β-PNA/β-PNA duplex formation with other
interaction modes such as attachment to membrane surfaces for protein model systems.
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2.5. Investigation of Interactions
In order to investigate the influence of an artificial membrane skeleton model system on
the structure of lipid bilayers, interactions between the model system monomers among
each other and attachment to the lipid bilayer surface have to be validated first. Therefore,
a wide assortment of methods has been established in the last decades adjusted to the
respective experimental requirements. In the following, the spectroscopic methods applied
in this thesis will be elucidated.
Temperature-dependent UV (ultra violet) spectroscopy is an invaluable tool for the
assessment of nucleobase pairing stability and was initially established for studying DNA
and RNA duplex formations. [124,125] Subsequently, this method was also successfully ap-
plied for the investigation of PNA/DNA as well as PNA/PNA duplex formation. [126–128]
Nucleobases absorb in a wavelength range of 240–280 nm and during duplex formation
of complementary strands, parallel alignment conveyed by hydrogen bonds between the
nucleobases occurs. The resultant conformational immobilization and proximity of the
aromatic heterocyclic moieties also lead to interjacent hydrophobic π-π-stacking interac-
tions. This base stacking decreases the absorbance of the nucleobases and therefore, an
increase of absorbance is observed when the strands are separated by heating and destack-
ing of the nucleobases occus, which is denoted as hyperchromicity. The sigmoidal curve
shape of the resultant temperature-dependent UV absorption plots indicates cooperative
dissociation. The temperature at the inflection point is denoted as the melting temper-
ature Tm at which 50 % of the duplex is dissociated. [121] Base stacking has also been
found in β-PNA duplexes as indicated by the reported melting curves. [24–26] Therefore,
with the nucleobases already preorganized in a linear fashion, a tilted structure has been
postulated since a distance of about 3.4 Å is needed for efficient base stacking whereas
the helical pitch of the 14-helix has been shown to be 5 Å. [117,129]
Circular dichroism (CD) spectroscopy is a well established method for the analysis of
secondary structures of peptides as well as oligonucleotides. In principle, the differential
absorption of left- and right-handed circularly polarized light by a conformationally fixed
chiral chromophore is detected. [130–133] As already stated in Section 2.3, this method
has been employed to thoroughly characterize the varying helical conformations of β-
peptides. [134,135] Similar to typical α-peptide secondary structures, the β-helices exhibit
distinct CD curve shapes in the far UV wavelength range. In the case of a left-handed
14-helix, a global minimum of around 215 nm, a global maximum of around 195 nm as
well as a zero crossing between 200 nm and 205 nm can be observed, and in the case of
a right-handed 14-helix, the CD curve shape is mirrored horizontally. [23,96,129] For single
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β-PNA strands, the presence of an additional CD signal at the nucleobase absorption
band with a maximum of 270 nm due to potential conformational preorganization of the
nucleobases was detected. [24–26] Moreover, the relative increase of this maximum upon
dimer formation offers the possibility to apply temperature-dependent CD spectroscopy
as an alternative method for duplex stability determination. [121,136,137]
Fluorescence spectroscopy is a highly sensitive and straightforward method suitable for
a multitude of applications such as colocalization studies, examining fluorescence sensors
and interaction studies. [138] Often observed for molecules with expanded aromatic systems
(fluorophores), fluorescence is the emission of light hνF when electrons of a fluorophore
transition from the electronically excited state S1 to the electronic ground state S0 (Fig-
ure 2.19). Prior to this, the electrons are excited from the ground state S0 to a higher
vibrational electronic level S1∗ or S2 by the absorption of light hνA followed by internal
conversion and vibrational relaxation to the lowest vibrational level in the electronically
exited state S1. [138] These relaxation processes lead to a decreased energy of the electrons.
As a consequence, the emitted light is shifted to longer wavelengths in relation to the
wavelength of the absorbed light which is denoted as the Stokes shift. Apart from in-
ternal conversions in the excited state or vibrational relaxation, the solvent polarity can
have an effect on the emission properties. As depicted in Figure 2.19 the excited S1 state
causes a change in the electric dipole moment of the fluorophore which causes the solvent
dipoles to rearrange before the fluorescent light is emitted. The solvent rearrangement,
also termed solvent relaxation, results in a decreased energy level of the fluorophore. This
solvatochromic effect can be highly pronounced increasing with higher solvent polarity
rendering the corresponding fluorophores environment-sensitive probes e.g. for structural
changes of biomolecules, incorporation of transmembrane peptides into lipid bilayers or
localization of molecules at the water/lipid interface of membranes. [139–141]
Förster resonance energy transfer (FRET) is a distance-dependent nonradiative en-
ergy transfer between two fluorophores, one denoted as the donor and the second as
the acceptor. Instead of fluorescence emission, the energy of the donor in state S1 is
transferred to an adjacent acceptor by dipole interactions. Therefore, emission of the
acceptor can be observed upon excitation of the donor fluorophore whose fluorescence is
quenched. [33,138,142] The FRET efficiency EFRET is inversely proportional to the donor-
acceptor distance r to the power of six:
EFRET =
1
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Figure 2.19. Jablonski diagram of a solvatochromic fluorophore (green oval) whose elec-
trons are first elevated from the ground state S0 to an excited electronic
state S1 by the absorption of light (hνA) leading to an altered dipole mo-
ment indicated by the black arrow in the green oval. Subsequently, the sur-
rounding solvent molecules reorient according to the changed fluorophore
dipole moment in a solvent relaxation process and the S1 energy level is
lowered resulting in a red shift of the emitted light (hνF). Reprinted from
Trends in biotechnology, 28, G. S. Loving, M. Sainlos, B. Imperiali, Moni-
toring protein interactions and dynamics with solvatochromic fluorophores.
73-83, Copyright (2010), with permission from Elsevier. [140]
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with R0 being the Förster radius defined as the distance between donor and acceptor
at which EFRET is 50 %. As illustrated in Figure 2.20(a), a steep decrease of EFRET occurs
with increasing distance and therefore, FRET intensity can be employed as a molecular
ruler for a distance range of (0.5–2)R0. The Förster radius in turn is dependent on
the overlap of donor emission and acceptor excitation spectra (Figure 2.20(b)). [142,143] Be-
cause the emission and excitation spectra are fluorophore-specific properties, R0 is a spe-
cific value for every donor-acceptor pair. For the donor-acceptor pairs 7-nitrobenz-2-oxa-
1,3-diazol-4-yl /5(6)-carboxytetramethylrhodamine (NBD/TAMRA) and NBD/lissamine
rhodamine B (NBD/Rhod), which are commmonly selected combinations for membrane








































Figure 2.20. Illustration of EFRET as a function of the distance r/R0 with the range of
(0.5–2)R0 marked in grey (a) as well as a schematic depiction of the spectral
overlap shaded in grey between donor emission and acceptor excitation
spectra required for FRET (b). [142]
With these tools in hand, the interactions that are required for the designed model
system, specifically the β-PNA/β-PNA interactions as well as β-peptide/membrane inter-
actions, can be investigated.
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3. Synthesis of β-Peptide Nucleic
Acids
In this chapter, the synthetic strategies for the building blocks, which are required for con-
structing β-peptide nucleic acids and are not commercially available, are elucidated. First,
the synthesis of the β-homologues of conventional Boc-β-amino acids will be presented,
followed by the preparation of alkyl- as well as cholesterol-modified amino acid building
blocks for the hydrophobic interaction sites. The synthesis of the different Boc-nucleo-β-
amino acids is explained before the SPPS strategy for the β-peptides is presented.
3.1. Boc-β3-D-Amino Acids
The synthesis of Boc-β-Ala-OH, which is identical to Boc-β-hglycine, was conducted under
aqueous conditions with sodium hydroxide as the base and di-tert-butyl dicarbonate (1)
starting from commercially available β-alanine (2) as shown in Figure 3.1. [147] With this

















Figure 3.1. Boc-protection of commercially available β-alanine. [147]
The other β3-amino acids were synthesized from the respective commercially avail-
able Boc-protected α-amino acids via an Arndt-Eistert homologation (Figure 3.2). [101]
First, the acid anhydride of the amino acid was formed using isobutyl chloroformate and
triethylamine. Then, it was converted into the diazoketone by acetylation of diazomethane
in a one-pot reaction. [102,135] The isolated diazoketone was used without further purifica-
tion for the next step of the homologation, which is the Wolff rearrangement. [103] This
is a crucial reaction step in the homologation, in which the diazoketone underwent a
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silver(I)-catalyzed rearrangement to a ketene and nitrogen gas was released. The ketene
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Figure 3.2. General synthesis of Boc-β3-d-amino acids via Arndt-Eistert homologa-
tion followed by Wolff rearrangement.
Table 3.1. Overview of the Boc-β3-d-amino acid synthesized via Arndt-Eistert ho-
mologation with their respective abbreviations and yields.
Boc-β3-d-amino acid Abbreviation Yield in %
Boc-β3-d-hlys(Cbz-Cl)-OH (5) hlys(CbzCl) 95
Boc-β3-d-hlys(Fmoc)-OH (7) hlys(Fmoc) 99
Boc-β3-d-hasp-OBzl (9) hasp-OBzl 80
Boc-β3-d-hglu(OAll)-OH (11) hglu(OAll) 58
An overview of the Boc-β3-d-amino acids synthesized via Arndt-Eistert homologa-
tion is shown in Table 3.1. Apart from Boc-β3-d-hlys(Cbz-Cl)-OH (5), which was needed
as a hydrophilic building block to ensure the solubility of the synthesized β-PNA, Boc-β3-
d-hlys(Fmoc)-OH (7) was synthesized. The Fmoc-protecting group is orthogonal to the
Boc- and Cbz-Cl-protecting groups and therefore allows the specific on-resin deprotection
and fluorophore-labelling of this lysine side chain. Boc-β3-d-hasp-OBzl (9) was synthe-
sized from Boc-l-Asp(OBzl)-OH as a component for the hydrophobic modification of the
β-PNA described in Section 3.2 and Section 3.3. Additionally, Boc-β3-d-hglu(OAll)-OH
11 was prepared for the β-PNA modification with cholesterol derivatives described in
Section 3.3. Apart from performing the Wolff rearrangement by sonication, microwave
irradiation with a domestic microwave was utilized for β-amino acid synthesis. Though
this procedure was faster, it resulted in lower yields, e.g. 46 % instead of 95 % for Boc-
β
3-d-hlys(Cbz-Cl)-OH (5). [148] Therefore, the synthesis was preferentially performed with
sonication.
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3.2. Alkyl-modified Boc-D-β3-Amino Acids
The synthesis of alkyl-modified β-amino acids as hydrophobic membrane interaction sites
was performed via Steglich esterification between the carboxylic group of an aspartic
acid side chain and a primary alkyl alcohol. This esterification reaction facilitates the
formation of esters under mild conditions and is also suitable for sterically demanding
as well as acid-labile educts. [149] First, the carboxylic acid forms an O-acylisourea inter-
mediate by addition of N,N’-dicyclohexylcarbodiimide (DCC). 4-Dimethylaminopyridine
(DMAP) then performs a nucleophilic attack on the carboxylic carbon atom resulting in
a reactive amide, which rapidly reacts with the alcohol forming the desired ester.
To ensure specific ester formation at the intended aspartic acid side chain, the α-
carboxylic group was protected by a benzyl group (Bzl). This protecting group was
removed by palladium-catalyzed hydrogenolysis afterwards. [150]
As a negative control for the hydrophobic membrane interaction, the unit Boc-β3-d-
hasp(OMe)-OH (12) was synthesized starting with the previously prepared Boc-β3-d-
hasp-OBzl (9, Figure 3.3). Steglich esterification was performed in methanol without
any additional solvent to yield the Bzl-protected intermediate 13 in a 85 % yield. After
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Figure 3.3. Synthesis of the methyl-modified β-amino acid via Steglich esterification
and subsequent hydrogenolytic benzyldeprotection.
The myristyl-modified hydrophobic membrane interaction building block was synthe-
sized from Boc-l-Asp(OBzl)-OH (Figure 3.4), which is homologous to Boc-β3-d-asp-OBzl
(14), since the synthesis performed with 9 was low in yield and the ester product could not
be separated from the educts. The esterification of 14 and myristyl alcohol was performed
in DCM, obtaining the Bzl-protected Boc-β3-d-asp(OC14)-OBzl (15) with 85 % yield. Af-
ter palladium-catalyzed hydrogenolysis, the building block Boc-β3-d-asp(OC14)-OH (16)
could be isolated with 98 % yield.
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Figure 3.4. Synthesis of the myristyl-modified β-amino acid via Steglich esterification
and subsequent hydrogenolytic benzyl deprotection.
3.3. Cholesterol-modified Boc-D-β3-Amino Acids
Insertion of cholesterol derivatives into β-PNA strands proved to be difficult because of
the sterol being sterically demanding and tending to aggregate. Therefore, three dif-
ferent strategies were designed and tested. For these incorporation strategies, different
cholesterol derivatives were synthesized.
The first strategy comprised of a cholesterol ester derivative analogous to the previously
described alkyl-modified building block (Section 3.2). Because cholesterol (17) is a ster-
ically demanding molecule, it was not directly connected to an aspartic acid side chain.
Instead, β-alanine was incorporated as a spacer between cholesterol (17) and Boc-β3-d-
asp-OBzl (14) to facilitate the synthesis of the building block and its incorporation into
β-PNA during solid-phase peptide synthesis (see Section 6.1). Additionally, the spacer was
supposed to ensure that the β-PNA is not pulled into the membrane by its hydrophobic
cholesterol modification. First, Boc-β-Ala-OH (3) and cholesterol (17) were converted to
the ester 18 via Steglich esterification with 72 % yield (figure 3.5). [151] Then, the Boc-
protecting group of 18 was removed by addition of trifluoroacetic acid (TFA), which
yielded the product H-β-Ala-OChol (19) quantitatively. Afterwards, an amide bond
was formed between the side chain carboxylic acid of Boc-β3-d-asp-OBzl (14) and the
amine of H-β-Ala-OChol (19) facilitated by 1-(bis(dimethylamino)methylene)-1H-1,2,3-
triazolo[4,5-b]-pyridinium 3-oxide hexafluorophosphate (HATU) andN,N -diisopropylethylamine
(DIPEA). The product Boc-β3-d-asp(OβAla-OChol)-OBzl (20) could be isolated with
80 % yield. The cholesterol ester building block 21 was obtained after palladium-catalyzed
hydrogenolysis of the Bzl-protecting group in a 98 % yield (Figure 3.5).
In a second strategy, cholesterol was linked to a spacer via an ether bond. Additionally,
based on a strategy devised by Wiegand1, it was planned to incorporate the cholesterol
1Markus Wiegand, Institute of Organic and Biomolecular Chemistry, University of Göttingen. Unpub-
lished results.
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Figure 3.5. Synthesis of the cholesterol ester building block Boc-β3-d-hasp(OβAla-
OChol)-OH (21) via Steglich esterification, amide bond formation and
palladium-catalyzed hydrogenolysis.
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moiety after β-peptide synthesis by specifically deprotecting a side chain carboxylic group
and attaching the cholesterol derivative via an amide bond in an on-resin modification
step (see Section 6.1). Therefore, a building block with a free amine group was synthesized
following the procedure described by Kim et al. [152] Synthesis of the ether intermediate
22 was performed in a base-catalyzed reaction (Figure 3.6). The hydroxyl group of
cholesterol (17) was deprotonated by potassium hydroxide to convert it into a reactive
alkoxide. This reactive species was able to perform a nucleophilic attack on the terminal
carbon atom of acrylonitrile (23), yielding the product 22 quantitatively. Then, the nitrile
was reduced via a nickel boride mediated reduction. The nickel boride, formed in situ
from nickel chloride and sodium borohydride, selectively reduced the nitrile group but
was mild enough to keep the cholesterol double bond intact and led to the Boc-protected
amine product 24 with 50 % yield. [153] Afterwards, the Boc-protecting group was cleaved































Figure 3.6. Synthesis of the cholesterol ether building block 3-aminopropyl-O-cholesterol
ether (25) started with a base-catalyzed ether synthesis between acrylonitrile
(23) and cholesterol (17), followed by nickel boride mediated nitrile reduc-
tion and Boc-protection resulting in 24, which is then Boc-deprotected to
yield 25.
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Figure 3.7. Synthesis of H-β-Ala-Chol (30) after conversion of cholesterol (17) to the re-
spective 3β-amino-5-cholestene (28) over three steps, amide bond formation
with Boc-β-alanine (3) and Boc-deprotection of the product 29.
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A third strategy was devised where cholesterol was incorporated via an amide bond.
Therefore, the hydroxyl group of cholesterol was converted into an amine group according
to Sun et al. [154] The hydroxyl group of cholesterol (17) was converted into a good leaving
group by base-catalyzed addition of mesyl chloride forming the cholesteryl mesylate 26
with 86 % yield (Figure 3.7). This intermediate was then treated with boron trifluoride
etherate, giving the azide product 27 with 78 % yield. The azide 27 was then reduced by
lithium aluminium hydride to form 3β-amino-5-cholestene (28) with 42 % yield. Analo-
gously to the previous strategies, β-alanine was introduced as a spacer by forming an amide
bond between the carboxylic acid of 3 and 28 using HATU and DIPEA. The product Boc-
β-Ala-NChol (29) was obtained with 72 % yield and was subsequently Boc-deprotected
using TFA to quantitatively yield H-β-Ala-NChol (30).
3.4. Boc-D-Nucleo-β3-Amino Acids
The syntheses of all the Boc-d-nucleo-β3-amino acids described in this chapter were con-
ducted by Worbs2. The nucleo-β3-amino acids were required as the molecular recognition
sites in β-PNA strands. In contrast to the β-amino acid building blocks described in Sec-
tion 3.1, these building blocks were not accessible by Arndt-Eistert homologation, due
to partial racemisation and the risk of nucleophilic attacks on the heterocyclic N - and
O-atoms by diazomethane. [155] Therefore, other synthetic routes starting with l-aspartic
acid derivatives were established in previous works. [117,121]
For the synthesis of the thymine and cytosine building blocks, the carboxylic group
of commercially available Boc-l-asp(OBzl)-OH (14) was reduced to obtain a Boc-β3-d-
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Figure 3.8. Synthesis of Boc-β3-d-hser-OBzl (31) as a precursor for the thymine building
block and Boc-β3-d-hser(OMs)-OBzl (32) as a precursor for the cytosine
building block starting from Boc-β3-d-asp-OBzl (14).
For the thymine building block, thymine (33) was protected with a benzoyl (Bz) pro-
tection group at its N 3-position to prevent N 3-alkylation in the following Mitsunobu
2Brigitte Worbs, Institute of Organic and Biomolecular Chemistry, University of Göttingen.
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reaction with Boc-β3-d-hserine (31) giving the N 1-alkylated product 34 (Figure 3.9). This
intermediate was then Bz-deprotected to give the desired nucleo-amino acid building block













































Figure 3.9. Synthesis of Boc-β3-d-hala(T)-OH (35) from 3-benzoyl-thymine (36) and
Boc-β3-d-hser-OH (31).
Regarding the cytosine building block, the exocyclic amine group of cytosine (37) was Z-
protected since the unprotected amino group would lead to side reactions in the following
reactions as well as in the β-PNA synthesis (Figure 3.10). Afterwards, the N 1-alkylated
product 39 from the Z-protected cytosine 38 and Boc-β3-d-hser(OMs)-OBzl (32) was
formed. Basic hydrolysis of the carboxylic benzyl ester in diluted sodium hydroxide
solution then gave the final nucleo-amino acid building block Boc-β3-d-hala(CZ)-OH (40).
For the preparation of adenine and guanine building blocks, previous works utilized Boc-
β
3-d-hserine (31) to perform an alkylation similar to the synthesis of Boc-β3-d-hala(T)-OH
(35). [116,128,156] However, a mixture of N 9 and N 7-alkylated products was obtained and
a lot of side products were detected, causing low yields. As a consequence, a different
synthetic route was devised, where the alkylation step was performed with a β-lactam
derivative of H-l-aspartic acid 41 (Figure 3.11). [116] Unprotected aspartic acid was con-
verted to the dibenzyl ester salt 42 and subsequent basic workup yielded the respective
amine 43. Preparation of the β-lactam mesylate 44 was accomplished following a protocol
according to Saltzmann et al., in which the amine was first silylated by trimethylsilyl
37















































Figure 3.10. Synthesis of Boc-β3-d-hala(CZ)-OH (40) from the Z-protected cytosine 38
and Boc-β3-d-hser(OMs)-OBzl (32) followed by Bzl-deprotection of the
carboxylic acid.
chloride (TMSCl) before cyclization was achieved with the Grignard reagent tert-butyl
magnesium chloride followed by acidic workup giving the β-lactam benzyl ester 45. [157,158]
The benzyl ester 45 was reduced to the corresponding alcohol 46 with sodium borohy-
dride, before the β-lactam mesylate 44 was formed with methanesulfonyl chloride.
Nucleophilic substitution catalyzed by 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) at 50 ℃
between commercially available adenine (47) and the prepared β-lactam mesylate 44
yielded the N 9-alkylated 4-adeninyl-methyl β-lactam intermediate 48 (Figure 3.12). The
β-lactam was then hydrolyzed with sodium hydroxide and Boc-protected in a one-pot
reaction to form the final nucleo-amino acid building block Boc-β3-d-hala(A)-OH (49).
For the guanine β-amino acid, commercially available 2-amino-6-chloropurine 50 was
deprotonated at the N 9-position by sodium hydride at room temperature, before it was
alkylated by the β-lactam mesylate 44 at 110 ℃ (Figure 3.13). The obtained product 4-(2-
amino-6-chloropurinyl)-methyl β-lactam (51) underwent acid-catalyzed hydrolysis of the
lactam ring with hydrochloric acid at elevated temperatures. Additionally, the 2-amino-
6-chloropurinyl group was converted into a guaninyl-moiety yielding the free guanine
β-amino acid 52. Afterwards, the β-amino group of 52 was Boc-protected to yield the














































Figure 3.11. Synthesis of the β-lactam mesylate 44 from H-l-aspartic acid (41) via the
dibenzyl-protected derivative 43 and subsequent cyclization reaction. The
benzyl ester of the β-lactam 45 was then reduced to give 46, which was


































Figure 3.12. Synthesis of the 4-adeninyl-methyl β-lactam intermediate 48 by alkylation
of adenine 47 with β-lactam mesylate 44 and subsequent hydrolysis of the
β-lactam ring and Boc-protection to give the adenine β-amino acid building
block 49.
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Figure 3.13. Synthesis of the 4-(2-amino-6-chloropurinyl)-methyl β-lactam 51 by alky-
lation of 2-amino-6-chloropurine (50) by β-lactam mesylate 44 followed
by β-lactam ring hydrolysis and simultaneous conversion of the 2-amino-6-
chloropurinyl to a guaninyl moiety yielding the guanine β-amino acid 52.
Boc-protection of the β-amino group gave the final Boc-β3-d-hala(G)-OH
(53).
3.5. Optimization of Solid-Phase Peptide Synthesis
for β-PNA Strands
Synthesis of the β-peptides was conducted via solid-phase peptide synthesis (SPPS) ac-
cording to Merrifield. [159] Though Fmoc-based SPPS has been established and suc-
cessfully employed for the synthesis of α-peptides as well as β-peptides, the Boc-protocol
was utilized due to better solubility of the Boc-β3-nucleo-amino acids in contrast to their
Fmoc-protected counterparts. [121] However, solubility of the Boc-β3-nucleo-amino acids
was still low in comparison to all other utilized amino acid derivatives so that sonification
was necessary to dissolve them. Additionally, the Boc-protocol is known to work bet-
ter for aggregation prone sequences, because hydrogen bonds are broken-up during the
acidic deprotection step. [160] SPPS was conducted manually in syringes equipped with a
polyethylene (PE) frit following a previously established synthesis protocol which is shown
in Figure 3.14 (see Section 8.4.1 for experimental details). [29]
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HOAt (5 eq), HATU (4.5 eq),
DIPEA (14 eq)

























1 h, 0 °C; 2 h, rt
Figure 3.14. Schematic cycle of the initial Boc-SPPS protocol performed to synthesize
the bifacial β-PNA strands.
Commercially available Boc-β-Ala-4-hydroxymethyl-phenylacetamidomethyl (PAM) resin
was applied to avoid partial racemization of the resin-bound amino acid. The dissolved
amino acid blocks were preactivated with HATU, HOAt and DIPEA. After acidic Boc-
deprotection with TFA at the N -terminus of the resin-bound nascent peptide chain, the
coupling solution was added and coupling was performed at 50 ℃. While single cou-
plings were performed for all non-nucleo-amino acid building blocks for 2 hours, double
couplings were conducted for the sterically demanding Boc-β3-nucleo-amino acids to en-
sure efficient coupling with each coupling step incubated for 1 h. To block potentially
unreacted N -termini, a capping step was subsequently carried out before a new SPPS
cycle commenced. Between every reaction step, the resin was washed with solvent. Af-
ter completion of the intended sequences, the peptide was cleaved from the resin using
the superacid trifluoromethanesulfonic acid (TFMSA) in TFA together with m-cresol,
thioanisole and 1,2-ethanedithiole (EDT) as scavengers, which simultaneously removed all
side chain protecting groups. The crude peptide could then be precipitated with icecold
ether and isolated. After synthesis of the first set of β-peptides with the established
Boc-protocol, mass spectrometric analysis of the crude peptides showed an abundance of
byproducts. Additionally, the high number of undesired byproducts impeded purification
via reverse-phase high performance liquid chromatography.
Therefore, the SPPS procedure was enhanced by altering various steps. The reaction
times for Boc-deprotection as well as capping were reduced by half since it has been de-
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DIPEA (0.2 M), 2,6-lutidine (0.3 M)

























1 h, 0 °C; 2 h, rt
Figure 3.15. Schematic cycle of the upgraded Boc-SPPS protocol performed to synthe-
size the monofacial β-PNA strands.
scribed in literature that shorter reaction times are sufficient. [161,162] Washing between
every SPPS step was expanded by a basic washing step with 5 % DIPEA in DMF. This
basic washing step was especially vital after Boc-deprotection as well as between capping
and Boc-deprotection. After Boc-deprotection, the basic washing step was supposed to
neutralize residual acid which would interfere in the following coupling step and reduce
coupling efficiency. During capping it has been found that acetic anhydride is reactive
enough to react with the exocyclic amino groups of the nucleobases. These acetylated
nucleobases not only constituted undesired byproducts by themselves because they are
stable against acetic conditions and thus are still present after cleavage, they are also able
to transfer the acetyl group to the N -terminus after it has been deprotected. [161,162] As
a result, the acetylated nucleobases as well as the “self-capped” truncated sequences re-
duce the yield and aggravate purification. The implementation of the basic washing step
after capping reverses the nucleo-acetylation, greatly reducing the occurrence of unidenti-
fiable byproducts. Regarding the coupling, double coupling was performed for all amino
acid building blocks. A definite advance of the SPPS protocol concerning efficiency and
speed could be made by introducing microwave-assisted coupling steps, which ensured
fast heating of the resin during synthesis. In combination with a higher coupling tem-
perature of 65 ℃, coupling times could be reduced from 1 h to 20 min. Moreover, the
addition of chaotropic LiCl salt was found to improve the coupling efficiency particularly
of the sterically demanding ACHC building block. [163] The improved coupling efficiency
42
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allowed for reduced amounts of amino acid building blocks and activators, making the
β-peptide synthesis more economic without sacrificing peptide yield. Including all de-
scribed improvements into the new SPPS protocol shown in Figure 3.15 led to an overall
improvement of β-peptide synthesis regarding reactant consumption, speed and yield.
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4. Bifacial β-Peptide Nucleic Acids
In this chapter the design, synthesis and characterization of the first β-PNA generation is
elucidated. These β-peptides contain two nucleobase motifs arranged in a way that they
are oriented in different directions as it is depicted in Figure 4.1. Due to the differently
oriented nucleobase motifs, the β-PNA strands display two interaction sites, which enable
them to form higher aggregates by specific interaction, and are denominated as bifacial
β-PNA.
Figure 4.1. Schematic illustration of the bifacial β-PNA model system interacting on
the lipid bilayer surface.
4.1. Design & Synthetic Strategy
Proceeding from previous, unpublished studies by Sitte1 β-peptide nucleic acids were
designed with two interaction sites as shown in Figure 4.2. Each interaction site was de-
vised to contain three nucleobases being solely composed of adenine 49 and thymine 35
β-amino acid building blocks. To ensure specific interaction and prevent self aggregation,
one β-peptide was designed to display the nucleobase motif TTA, while a complementary
β-peptide should possess the motif TAA. The weaker adenine-thymine nucleobase pairing
was chosen over the guanin-cytosine interaction since it was shown to be less susceptible
1Dr. Astrid Sitte, Institute of Organic and Biomolecular Chemistry, University of Göttingen. Unpub-
lished results.
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to unspecific aggregation (Section 2.4). [31] Additionally, the small number of three nucle-
obases should prevent unspecific interaction. Regarding sequence length, it was attempted
to keep the number of amino acids as low as possible while C - and N -termini should not
be on the same face as the membrane interaction sites to keep the number of charges and













Figure 4.2. Schematic depiction of the bifacial β-PNA system interacting in antiparal-
lel orientation with R denoting the positions of myristyl modifications for
membrane interaction.
Two sets of complementary β-PNA strands were synthesized to assess β-PNA interac-
tion in solution and on lipid bilayer surfaces. All designed sequences contained ACHC
because this conformationally constrained β-amino acid is known to promote 14-helix
formation. [19,106] As a hydrophilic component, β-homolysine was incorporated to ensure
solubility of the β-PNA strands in buffer as well as to hinder them from immersing into
the lipid bilayer but remaining above the lipid bilayer surface. Moreover, the incorporated
ACHC and β-homolysine were distributed on all three helix faces to prevent the forma-
tion of an amphiphilic helix since they are similar to antibiotic peptides which are known
to partially insert into membranes and disrupt the lipid bilayer by their detergent-like
behavior. [164,165]
The β-peptides 54 and 55, which were supposed to interact with membranes, were
devised to contain myristyl ester building block 16. Two sites instead of one site for
interaction were chosen because it was assumed that the hydrophobic effect of one myristyl
moiety might not be sufficient to anchor the β-PNA strands on the lipid bilayer. For the
β-peptides 56 and 57 which were supposed to be measured in solution, the hydrophobic
alkyl modification was replaced by ACHC. The sequences of the synthesized bifacial β-
PNA strands are shown in Figure 4.4 and Figure 4.3.
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Figure 4.3. Synthesized β-peptides with myristyl-modified building blocks for membrane
interaction.
To generate one nucleobase interaction site, every third β-amino acid was chosen as
a nucleo-β-amino acid building block so that the nucleobases of each binding site are
arranged at the same helix face and are placed directly next to each other. To make the
strands as short as possible, no building block was incorporated between the last nucleo-
β-amino acid building block of the first motif and the first nucleo-β-amino acid building
block of the second motif. For the investigation of interaction between the β-peptides and
lipid bilayers, the N -terminus was labelled with NBD which could easily be substituted
by other fluorophores. Nevertheless, with all prerequisites given a minimal length of 19


























































































































































Figure 4.4. Synthesized β-peptides without myristyl-modified building blocks to inves-
tigate the interaction in solution.
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4.2. Synthesis & Purification
Syntheses of the bifacial β-peptides were performed with SPPS based on a Boc-protocol
as described in Section 3.5. Double coupling steps and 1 h incubation for nucleo-β-
amino acid building blocks and single coupling steps with 2 h incubation for all other
building blocks were performed (see Section 8.4.1 for experimental details). Due to the
long coupling times, synthesis of a single β-PNA strand took several days. Analysis
by mass spectrometry of the β-peptides before labelling with NBD revealed side products
which could not be identified as capped truncation sequences. Interestingly, many of these
unidentifiable side products were of a higher mass than the target β-peptides. Especially
in the case of the myristyl modified β-PNA, side product signals outweighed the product
signal (Appendix A.1). Nevertheless, NBD labelling was conducted before the β-peptides
were cleaved and purified by RP-HPLC.
As already indicated by the mass spectra, chromatograms of all bifacial β-PNA showed
a mountain range of peaks revealing the low efficiency of the employed SPPS protocol.
Due to all the side products present, purification proved to be difficult. Peak separation
could not be accomplished because changing the gradient would broaden the peaks. Since
aggregation of the β-PNA strands was assumed, it was also attempted to break up hy-
drogen bonds by acidic or basic pH (1–9) before injection. However, no improvement was
observed. Therefore, heating of the sample prior to injection was tested which yielded no
enhancement of separation either. Then, heating of the stationary phase was assessed.
Unfortunately, also elevated temperatures during RP-HPLC did not improve peak shape
or separation. Therefore, the peak range was broadened over the gradient range and
fractionated. The composition of the fractions was then assessed by mass spectrometry.
Figure 4.5 shows the chromatograms for RP-HPLC with a C18 column of the soluble
β-peptides 56 (a) and 57 (b) with the retention times of the isolated product fractions.
In both cases the full-length β-PNA was distinguishable from the other peaks due to its
prominent NBD signal in the 464 nm trace, nucleobase signal at 254 nm and peptide bond
signal at 215 nm. However, it is notable that the 464 nm trace gave a signal throughout
the whole chromatogram, especially in the case of 57. This was surprising, because cap-
ping should prevent the formation of side products containing the N -terminal NBD label.
Nevertheless, the occurrence of the NBD signal throughout the chromatogram could be
attributed to unspecific side reactions during NBD labelling or to aggregation.
In Figure 4.6, chromatograms of 54 (a) and 55 (b) are displayed with the retention
times of the isolated product fractions. Whereas 54 could be purified using a C18 col-





























tR = 12.5-13.5 min
tR = 12.0-13.0 min
Figure 4.5. RP-HPLC chromatograms of crude 56 (a) and 57 (b) with the retention
time tR given for the purest isolated product fractions.
myristyl-modified β-peptides, a distinguishable peak could not be observed in any wave-
length trace and product fractions were only identified by mass spectrometry. Although
peak separation could not be achieved, fractionation yielded adequate purification for
all β-peptides since bulk impurities could be separated from the product peptides (Ap-






























tR = 16.5-17.0 min
Figure 4.6. RP-HPLC chromatogram of crude 54 (a) and 55 (b) with the retention time
tR given for the purest isolated product-fractions.
4.3. CD-Spectroscopic Characterisation
For secondary structure investigation of the β-peptides, CD spectroscopy was performed.
Measurements of 56 were first conducted in different solvents as shown in Figure 4.7(a).
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In all the employed solvents the formation of a right-handed 14-helix could be verified
by the signal maximum around 215 nm and a zero crossing between 200 nm and 205 nm
in the spectra. [23,129,135] Additionally, a second, weaker maximum was observable around
270 nm, which indicated a preferred conformational orientation of the nucleobases. [24,25]
Furthermore, stability of the 14-helix was assessed by measurements of the β-peptide
in 10 mM TRIS-HCl buffer (pH 7.5) at different temperatures (Figure 4.7(b)) which
revealed that although CD signal intensity decreased with increasing temperatures, signal
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Figure 4.7. CD spectra of 56 in different solvents (a) and at different temperatures
measured in 10 mM TRIS-HCl buffer at pH 7.5 (b).
Similar CD measurements were performed for 57. The spectra shown in Figure 4.8
gave similar results as for 56 in terms of stability of the formed 14-helix. Interestingly,
the nucleobase band appeared to be split in two maxima which is best observable for the
spectra measured in TFE (Figure 4.8(a)). With the higher maximum at 257 nm and the
lower maximum at 280 nm, this signal separation could indicate two different nucleobase
conformations.
β-peptides 54 and 55 were found to be nearly insoluble in water or buffer due to
their myristyl modification. Therefore, CD spectra were only recorded in methanol and
TFE (Figure 4.9). Formation of 14-helix for these β-peptides was indicated by the signal
maximum around 215 nm as well as the zero crossing between 200 nm and 205 nm.
When β-peptide samples were prepared in LUV suspensions to investigate their secondary
structure on lipid bilayer surfaces, neither 54 nor 55 could be attached to membranes
which will be further elucidated in Section 4.5. Therefore, no CD spectra were recorded
for bifacial β-peptides on lipid bilayers.
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Figure 4.8. CD spectra of 57 in different solvents (a) and at different temperatures

















































Figure 4.9. CD spectra of 54 (a) and 55 (b) in different solvents.
4.4. β-PNA Interaction in Solution
The interaction of the complementary β-PNA strands 56 and 57 was investigated in so-
lution by temperature-dependent UV spectroscopy in 10 mM TRIS-HCl buffer (pH 7.5).
Before measurement, equimolar amounts of the β-peptides were mixed and annealed.
Absorption of the β-peptide solutions at 260 nm was recorded between 0 ℃ to 80 ℃ ac-
cording to a protocol adapted from Chakraborty et al. (Section 8.3.6). [25] Additionally,
temperature-dependent UV spectra were recorded for 56 and 57 individually.
As it has already been outlined in Section 2.5, the UV absorption should increase with
rising temperature if the complementary strands have formed duplexes in the annealing
process. The increasing absorption is due to the destacking of nucleobases during ther-
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mal strand dissociation and indicates a cooperative dissociation of the double strands.
However, as shown in Figure 4.10, no sigmoid curve shape was observed for the combined



















Figure 4.10. Temperature-dependent UV spectra of 56 and 57 measured in 10 mM
TRIS-HCl buffer at pH 7.5.
In prrevious studies sigmoidally shaped thermal denaturing curves for nucleobase-
functionalized β-peptides have been observed. [24–28,31] However, these systems differed in
several aspects from the presented β-PNA strands. Most systems displayed four nucle-
obases for one interaction site, utilizing not only adenine and thymine but also guanine
and cytosine, and separated the hydrophilic homolysine and hydrophobic ACHC on dif-
ferent faces of the helix. [25,27,31] In some cases three nucleobases were employed for the
interaction sites, but also then the hydrophilic and hydrophobic amino acids were ar-
ranged on different helix faces. [24,28] Additionally, in most of these cases only guanine and
cytosine were incorporated into the interaction sites which are known to exhibit stronger
base pairing. [166] The system that is most similar to the presented one was designed by
Srivastava et al. with two interaction sites containing two or three nucleobases per β-
PNA strand to enable the formation of higher aggregates in solution. [26] The interaction
sites contain not only adenine and thymine but guanine and cytosine as well. Addition-
ally, the two interaction sites are directly adjacent to each other on the 14-helix, while
the interaction sites of the presented bifacial β-PNA strands are shifted. The immediate
proximity of the interaction sites could cause the adjacent nucleobases to interact and
thus reinforce stable duplex formation. These differences could explain why no sigmoid
curve was observed with the β-PNA system presented here.
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The absence of a sigmoidal melting curve indicates that no base stacking occurred
and it was concluded that no duplex formation in solution took place. However, it was
hypothesized that the interaction might be more favorable, when the β-PNA strands were
constrained in their spatial movement as it is the case when the β-peptides would be
attached to a lipid bilayer surface. Therefore, it was attempted to apply the myristyl-
modified β-PNA to LUV surfaces.
4.5. β-PNA Interaction with Bilayer Surfaces
For the attachment of 54 and 55 to lipid bilayer surfaces, DOPC-LUV suspensions were
prepared by MLV preparation and extrusion (see Section 8.4.2 for experimental details).
Because of their low solubility in aqueous media, the stock solutions of β-PNA needed
to be prepared in methanol, ethanol or DMSO. Reconstituting the β-PNA strands at the
lipid bilayer surface, however, turned out to be difficult. Upon addition of the β-peptides
to the aqueous vesicle suspension, a precipitate was formed rapidly. It was assumed that
due to their high hydrophobicity, the β-PNA strands aggregated without being attached
to the lipid bilayer. Therefore, the detergents 3-[(3-cholamidopropyl)dimethylammonio]-
1-propanesulfonate (CHAPS) or Tween® 20 were added as solubilizing agents to dissolve
β-PNA stock solutions in buffer. While the β-peptides could be solubilized in the stock
solutions, addition to the vesicle suspensions still resulted in precipitation. Using water
instead of buffer as the solvent yielded the same results.
As 54 and 55 could not be applied to lipid bilayer surfaces after preparation of the
vesicle suspensions, it was tested whether the β-PNA strands could be constituted on the
surface of lipid films before extrusion. [69,108] Therefore, stock solutions of the β-peptides
in methanol were added to the lipids dissolved in chloroform. After the solvent had been
evaporated by a nitrogen stream, the lipid-peptide film was dissolved in TFE which is
known to improve helical secondary structure formation. [167,168] The solvent was evapo-
rated by a nitrogen stream a second time. Afterwards, MLV preparation and extrusion
were conducted either with 10 mM TRIS-HCl buffer (pH 7.5) or water as the solvent.
However, several complications became apparent in the process. For example, prepara-
tion of the MLV suspensions was difficult since the β-PNA/lipid films were largely sticking
to the glass test tubes. Here, sonication facilitated detaching the lipid films. A more se-
rious problem was that MLV suspensions containing β-PNA quickly formed a precipitate
after sonication, leading to heavy loss of lipid and peptide material as well as clogging
of the polycarbonate membranes during extrusion. Therefore, the concentration of the
resulting vesicle solution was too low for CD or fluorescence spectroscopy.
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Another attempt consisted of a modified detergent-assisted reconstitution protocol orig-
inally intended to reconstitute SNARE model system components into membranes (Sec-
tion 8.4.2). [64] Lipid films and the β-PNA strands were solubilized with 100 mM n-octyl-
β-glucopyranoside (n-OG) in buffer. Then, the solubilized β-peptides were added to the
lipids and incubated for reconstitution. Afterwards, the detergent was removed by size
exclusion chromatography. However, also this procedure resulted in a heavy loss of lipid
and peptide material, so that CD or fluorescence spectroscopy could not be performed.
Since the β-PNA strands 54 and 55 did apparently not attach autonomously to lipid
bilayer surfaces as it was initially intended, a simplified system was designed to investigate
whether β-peptides interact with lipid bilayers (Chapter 5).
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In this chapter, a second β-PNA generation of shorter peptides designed to investigate
the factors and requirements for peptide-peptide as well as peptide-membrane interaction
is presented. These simplified β-peptides, which are schematically shown in Figure 5.1,
were designed with one nucleobase interaction site enabling the formation of antiparallel
dimers. Therefore, they are termed monofacial β-PNA. Moreover, the number of myristyl
modifications was reduced to improve solubility in aqueous media.
Figure 5.1. Schematic illustration of the monofacial β-PNA model system interacting on
the lipid bilayer surface.
5.1. Design & Synthetic Strategy
Based on the results of the precedent bifacial β-PNA generation, a simplified β-PNA de-
sign with one nucleobase interaction site was devised which is shown in Figure 5.2. Since
the anticipated interaction could not be verified with the nucleobase motifs composed
solely of adenine and thymine β-amino acid building blocks 49 and 35, the composition
of the nucleobase interaction sites was varied with an increasing amount of guanine and
cytosine 40 β-amino acid building blocks 53 and 40. Therefore, the three complemen-
tary sequence motifs TTA/TAA, GTA/TAC and GTC/GAC were devised to investigate
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sequence-dependent stability of duplex formation. Previous studies have shown that se-
quences composing only of guanine and cytosine are most frequently prone to self pairing
and unspecific interaction. Therefore, no sequence motif solely consisting of guanine and










Figure 5.2. Schematic depiction of the monofacial β-PNA system interacting in antipar-
allel orientation with R’ denoting the positions of myristyl modifications
for membrane interaction, Nb denoting the nucleobases at the interaction
sites and Fl denoting the fluorophore modification or acetylation at the
N -terminal homolysine.
The scaffold sequence of all synthesized monofacial β-PNA strands is shown in Figure 5.3
with Nb marking the position of the nucleobases. For the nucleobases to be arranged
at the same helix face, the nucleo-β-amino acid building blocks were incorporated at an
interval of three amino acids into the sequence. Similar to the bifacial β-PNA design,
ACHC was integrated to promote 14-helix formation and β-homolysine was incorporated
to ensure solubility of the β-peptides. Because the myristyl-modified bifacial β-PNA
strands turned out to be too hydrophobic, the monofacial β-peptides were designed with
higher β-homolysine content, which was estimated to enhance solubility in aqueous media
in the presence of a myristyl modification. Additionally, only one myristyl ester (OC14)
at position R’ was planned. The previous β-PNA generation exhibited a massive change
in solubility when two hydrophobic interaction sites were present, suggesting that one
hydrophobic interaction site would be enough for β-peptides of the current length. To
make the structure of soluble β-PNA units more comparable to that of their myristyl-
modified counterparts, a methyl ester (OMe) was integrated instead of ACHC. Labelling
with fluorophores or acetylation of the β-PNA strands was now planned to be located at
the side chain amine group of the N -terminal β-homolysine (position R) to add one more
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Figure 5.3. Sequence of the synthesized monofacial β-peptides with modifications at the
N -terminal hlysine side chain (R) and aspartic acid side chain (R’) as well
as Nb denoting the position of the nucleobases.
To investigate β-peptide/membrane interaction, the β-PNA strands were planned to be
labelled with NBD. For FRET measurements, β-peptides were designed with NBD- and
TAMRA-labels as a donor and acceptor pair, while acetylated versions were needed to
keep the total peptide concentration constant. Additionally, the acetylated β-peptides
were utilized for temperature-dependent measurements. For interaction analysis with
microscale thermophoresis (MST), β-peptides were labelled with FAM.
β-Peptides without nucleobases were designed as negative controls for the β-PNA inter-
action, which comprised of β-alanine building blocks instead of the nucleo-β-amino acid
building blocks (Figure 5.4).
Due to the increased β-homolysine content, the minimal length of the β-PNA was 16 β-
amino acids similar to the bifacial β-peptides 55 and 57, even though only one interaction
site for β-PNA interaction and for membrane interaction were implemented.
5.2. Synthesis & Purification
Syntheses of the monofacial β-peptides were performed following the revised Boc-protocol
SPPS described in Section 3.5 with double coupling steps and microwave-assisted coupling
(see Section 8.4.1 for experimental details). Due to the shorter coupling times, comple-
tion of the β-PNA strands was significantly quicker. Mass spectroscopic analysis of the
β-peptides still showed side products but in a smaller number and most signals could
be assigned to capped truncation signals (Appendix A.3). Additionally, the amount of
detected masses higher than the actual β-peptide mass was lower in comparison to the bi-
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Table 5.1. Overview of the synthesized monofacial β-peptides with their respective
nucleobase sequences as well as modifications at the N -terminal hlysine side
chain (R) and at the aspartic acid side chain (R’).
β-PNA Nucleobase sequence R R’


















76 GTA Ac OMe
77 TAMRA
78 TAC Ac OMe
79 NBD
80 GTC Ac OMe
81 NBD
82 TAMRA
83 GAC Ac OMe
84 NBD
85 GTC Ac OC14
86 NBD
87 TAMRA
88 GAC Ac OC14
89 NBD
90 none NBD OMe
91 none NBD OC14
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Figure 5.4. Synthesized β-peptides 90 and 91 without nucleobases as negative controls
for nucleobase interaction.
facial β-peptide mass spectroscopic analysis, indicating that the modified SPPS procedure
improved the efficiency of the synthesis.
After labelling with the respective fluorophores or acetylation, the peptides were puri-
fied by RP-HPLC. Chromatograms of the crude β-peptides showed better peak separation
in comparison to the bifacial β-PNA generation (Section 4.2). This is depicted in Fig-
ure 5.5 for 60 (a) and 62 (c) as an example for the soluble β-PNA strands with methyl
modifications.
Additionally, the myristyl-modified β-PNA strands showed a clearly improved peak
separation as it is exemplarily illustrated in Figure 5.6 for 73 (a) and 75 (c). In
contrast to the methyl-modified β-peptides, the peaks were a bit more broadened due
to the myristyl modification possibly because of stronger hydrophobic interactions be-
tween the myristyl-modified β-peptides and the stationary phase. In the case of the
TAMRA-labelled β-peptides, two product peaks occurred because the employed 5(6)-
carboxytetramethylrhodamine is a mixture of two isomers which could be separated by
the utilized flat gradient. Fractions were collected for both isomers which were combined.
Additionally, in all cases absorption signals for the fluorophores (in the 464 nm trace for
NBD and in the 540 nm trace in the case of TAMRA) were not only observed for the
product peaks but for other peaks as well. These additional fluorophore absorption sig-
nals indicate that labelling did not only take place on the targeted homolysine side chain
but also at other positions. Nevertheless, the occurrence of these fluorophore-labelled side
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tR1 = 23.0 min
tR2 = 25.4 min
a)
c)
Figure 5.5. Chromatogram of crude 60 (a) and 62 (c) from semi-preparative RP-HPLC
runs as well as the respective isolated product of 60 (b) and 62 (d) from
analytical RP-HPLC runs. For the chromatograms of the crude β-PNA
strands, the retention times tR of the product peaks are given.
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products was much lower than compared to the bifacial β-PNA strands and the monofacial



















































tR1 = 23.0 min
tR2 = 25.4 min
a)
c)
Figure 5.6. Chromatogram of crude 73 (a) and 75 (c) from semi-preparative RP-HPLC
runs as well as the respective isolated product of 73 (b) and 75 (d) from
analytical RP-HPLC runs. For the chromatograms of the crude β-PNA
strands, the retention times tR of the product peaks are given.
Due to the enhanced peak separation, the β-PNA strands could be purified successfully
in a quick and simple fashion which was validated by analytic RP-HPLC. The chro-
matograms of purified β-PNA strands 60 and 62 are depicted in Figure 5.5(b) and (d)
respectively, showing that side products could be separated effectively. Also in case of
the myristyl-modified β-peptides, exemplarily illustrated for 73 and 75 in Figure 5.6(b)
and (d) respectively, the chromatograms showed effective purification. Additionally, mass
spectroscopic analysis of the purified β-peptides confirmed the successful purification (Ap-
pendix A.3).
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5.3. CD-Spectroscopic Characterization
CD spectroscopy was performed to investigate the secondary structure of the β-peptides.
As for the bifacial β-PNA strands, measurements were conducted in 10 mM TRIS-HCl
buffer (pH 7.5) at different temperatures to assess 14-helix formation and its thermal
stability. β-Peptides with both methyl and myristyl modification were soluble in buffer,
which was attributed to the higher β-homolysine content in contrast to the bifacial β-
peptides described in Chapter 4. As it is exemplarily shown in Figure 5.7 for 59 (a), 60
(b), 61 (c) and 62 (d), all measurements verified the formation of a right-handed 14-helix
because the CD spectra showed a global maximum of around 215 nm, a global minimum
of around 195 nm as well as a zero crossing between 200 nm and 205 nm. [23,129,135] More-
over, CD spectra of all β-peptides functionalized with nucleobases exhibited an additional
signal maximum of around 270 nm which is indicative for a conformational preorgani-
zation of the nucleobases. [24,25] Furthermore, in all cases the amplitude of the CD signal
was only slightly diminished by the elevated temperatures. Therefore, it was concluded
that 14-helix formation is highly stable and pronounced. It should be noted that the
signal amplitude varied between the different β-PNA samples which could be due to con-
centration variations but could also be attributed to the modification of the N -terminal
homolysine side chain. Since the fluorophores are substantially larger than the acetyl
group, they might also influence the helix formation. Additionally, interactions between
the fluorophores and β-amino acid side chains in close proximity could be possible. Par-
ticularly, the FAM label led to a more pronounced minimum at 243 nm additionally to
the signal bands typical for 14-helix formation as it is apparent in Figure 5.7(c), which
might be due to a preferential orientation of the fluorophore itself.
While most β-PNA strands showed the anticipated distinct signal amplitude, CD spec-
tra of the β-peptides 90 and 91 without nucleobases featured a lower signal amplitude
(Figure 5.8). Though the signals still indicate a 14-helix, the low intensity suggests that
the propensity to form a 14-helix is much lower, when no nucleobases are present in the
sequence but α-alanine is introduced instead. In the case of α-peptides, it is known that
glycine destabilizes helical structures due to its high conformational freedom and is there-
fore also called a α-breaking residue. [169,170] The introduced β-alanine which has no side
chain is the β-homologue of glycine and possibly exhibits high conformational freedom as
well, which leads to a higher flexibility of the 14-helix. [171]
CD measurements of 90 in different solvents showed that the effect of β-alanine is ob-
servable in aqueous solvents and in methanol (Figure 5.9). In TFE, however, this effect

























































































































Figure 5.7. CD spectra recorded at different temperatures and pH 7.5 in 10 mM TRIS-




















































Figure 5.8. CD spectra recorded at different temperatures and pH 7.5 in 10 mM TRIS-
HCl buffer of 90 (a) and 91 (b).
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amplitude. TFE is able to compensate the higher flexibility since this solvent is known
to stabilize helical conformations by clustering around the peptide, locally creating a hy-
drophobic environment in which the intermolecular hydrogen bonds are strengthened. [168]
Although the CD signal was low, the spectra showed the characteristic 14-helix pattern,
which is why the β-peptides without nucleobases could be used as negative controls.
However, for future systems β-homoalanine should be preferred over β-alanine because it
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Figure 5.9. CD spectra of 90 recorded in different solvents.
Since the myristyl-modified β-PNAs were supposed to attach to lipid bilayers, their
secondary structure was also investigated in vesicle suspensions to ensure that the 14-
helix formation is not negatively affected by the presence of membranes. Therefore, the
respective β-peptides were added to DOPC-LUV suspensions in 10 mM TRIS-HCl buffer
(pH 7.5), which were prepared according to SOP10 and SOP12 (Section 8.4.2), and CD
spectra were recorded at 20 ℃. In Figure 5.10, exemplary CD spectra for myristyl-modified
β-PNA strands with different fluorophore labels (75, 74, 73) as well as acetylation (72)
in vesicle suspensions are shown. All spectra show the characteristic pattern for a right-
handed 14-helix with a global maximum of around 215 nm, a global minimum of around
195 nm as well as a zero crossing between 200 nm and 205 nm which indicates that
14-helix formation is still distinct. Additionally, the values for the maxima and minima
of the β-peptides in presence of vesicles coincide with the values measured of β-peptides
in solution. These results show that the β-PNA strands are not submerged into the
membrane, since previous studies detected shifting of the minima and maxima values to
shorter wavelengths for membrane-constituted β-peptides. [107,109,145]
Apart from the characteristic pattern of the CD spectra for 14-helix formation, the
local maximum of around 270 nm is still observable indicating that the conformational
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preorganization of the nucleobases is not disrupted by the presence of lipid bilayers. Fur-
thermore, the spectral pattern for 74 shows the additional minimum at 243 nm possibly
caused by preferential conformational orientation of the FAM label. These results showed

























Figure 5.10. CD spectra of the indicated myristyl-modified β-PNA strands recorded in
DOPC-LUV suspensions with 10 mM TRIS-HCl buffer (pH 7.5) at 20 ℃.
In summary, the CD measurements of all synthesized monofacial β-peptides indicate
14-helix formation which is stable in different environments, pronounced when nucleo-β-
amino acids are incorporated and less pronounced when β-alanine is present instead.
5.4. β-PNA Interaction in Solution
Interaction of the monofacial β-PNA strands was investigated in solution by different
spectroscopic methods to assess how the variation of the nucleobase sequence influences
the dimer formation of complementary β-PNA monomers.
5.4.1. Temperature-Dependent UV Spectroscopy
Interaction of the β-PNA strand combinations 59+64 (TTA/TAA), 76+78 (GTA/TAC)
and 80+83 (GTC/GAC) was investigated by temperature-dependent UV spectroscopy in
10 mM TRIS-HCl buffer (pH 7.5). The complementary β-peptides were mixed in equimo-
lar concentrations and annealed before the absorption of the samples was recorded at
260 nm during heating and cooling cycles according to the protocol described in Sec-
tion 8.3.6. Afterwards, the hyperchromicity Arel was calculated from the measured values
and plotted as a function of temperature in a range from 0 ℃ to 80 ℃. The resultant
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UV curves are shown in Figure 5.11. A sigmoid curve shape characteristic for cooperative
strand dissociation during melting was not observed. Instead, an exponential curve shape
was recorded from which a melting temperature could no be derived. Based on the high
hyperchromicity values detected in the melting curves and compared to previous studies,




















Figure 5.11. Temperature-dependent UV spectra of the complementary β-PNA combi-
nations 59+64 (TTA/TAA, black), 76+78 (GTA/TAC, red) and 80+83
(GTC/GAC, green) with a concentration of 8 µM each, measured at pH 7.5
in 10 mM TRIS-HCl buffer.
In all preceding studies with β-PNA strands, the measured changes in hyperchromic-
ity were much lower even though in most cases a higher number of base pairings were
possible. [25,26] Furthermore, the melting temperatures which were determined for these
preceding systems were much lower than the results of the current system would imply
which is contradictory to the preliminary findings that a higher number of base pairs lead
to a more stable duplex formation. [24,28] Additionally, all three complementary β-PNA
strands show very similar curve shapes which as well indicate that the absorption changes
are unlikely caused by base destacking since it has been shown that the thermal stability
of β-PNA duplexes is highly influenced by its content of guanine (G) and cytosine (C)
in such way that β-PNA strands with a low GC content exhibit a much lower Tm than
β-PNA strands with a high GC content. [25] Therefore, it was assumed that other effects
apart from base destacking are causing the immense change in absorption masking any
possible changes of absorption caused by thermal strand dissociation. As a consequence,
a different approach to investigate β-PNA strand dimerization was chosen.
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5.4.2. Fluorescence-Spectroscopic Analysis of β-PNA
Interaction
Since the results of temperature-dependent UV spectroscopy were inconclusive regarding
β-PNA dimerization, Förster resonance energy transfer (FRET) measurements were
conducted to investigate if β-PNA strands with complementary nucleobase motifs in-
teract in solution. The fluorophores 7-nitrobenz-2-oxa-1,3-diazol-4-yl (NBD) and 5(6)-
carboxytetramethylrhodamine (TAMRA) were chosen as a FRET donor-acceptor-pair
since they have successfully been employed in FRET analysis of aggregating β-peptides
before. [145] As it has been described in Section 2.5, FRET can take place when the emission
spectrum of the donor overlaps with the absorption spectrum of the acceptor. As illus-
trated in Figure 5.12, this condition is met by the chosen fluorophores since the emission


















Figure 5.12. Normalized excitation and emission spectra of NBD and TAMRAmeasured
at pH 7.5 in 10 mM TRIS-HCl buffer.
Fluorescence measurements of the β-PNA were conducted as described in Sec-
tion 8.3.7. While the concentration of the NBD-labelled donor β-peptide was kept
constant at 4 µM, the mole fraction χA of the TAMRA-labelled acceptor β-peptide
was varied from 0.0 to 0.5. To keep the total peptide concentration constant
at 8 µM, the corresponding acetylated β-peptide was added. In addition to the
complementary β-PNA strands 59/62+65 (TTA/TAA), 76/77+79 (GTA/TAC) and
80/82+84 (GTC/GAC), every possible mismatch combination 59/62+79 (TTA/TAC),
59/62+84 (TTA/GAC), 76/77+65 (GTA/TAA), 76/77+84 (GTA/GAC), 80/82+65
(GTC/TAA) and 80/82+79 (GTC/TAC) was tested to investigate the sequence speci-
ficity of the system. Furthermore, all TAMRA-labelled and acetylated β-PNA strands
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were combined with the negative control 90 (no Nb). Before measurements, the required
amounts of β-peptides were mixed in 10 mM TRIS-HCl buffer (pH 7.5) and annealed
by incubation at 80 ℃ for 5 min followed by slow cooling to room temperature. Then,
emission spectra were recorded in a wavelength range of 470 nm to 650 nm.
Since initial FRET measurements at room temperature utilizing a plate reader showed
high variations of the spectra and did not indicate β-peptide interactions, further measure-
ments were performed at a lower temperature of 10 ℃ with a fluorescence spectrometer
and a quartz cuvette (complete data sets are shown in Appendix A.6). The results for
the complementary combinations 59/62+65 (TTA/TAA), 76/77+79 (GTA/TAC) and
80/82+84 (GTC/GAC) as well as one negative control 80/82+90 (GTC/no Nb) are
shown in Figure 5.13. All complementary combinations show a more pronounced FRET
with increasing χA of the TAMRA-labelled β-PNA strand than the negative control mea-
surements indicating that at 10 ℃ all complementary nucleobase motifs exhibit inter-
action. Additionally, the higher the GC content in the sequences the more pronounced
interaction could be observed, which was expected.
Since the fluorescence measurements at 10 ℃ showed promising results, they were
repeated at 20 ℃. As it is illustrated in Figure 5.14, also at elevated temperature FRET
was more pronounced for the complementary β-peptide combinations in comparison to
the negative control, even though overall intensity was reduced. Therefore, it can be
concluded that β-PNA strand dimerization still occured at 20 ℃ but was less stable than
at 10 ℃.
All measurements were conducted in triplicates and the relative change of NBD fluores-
cence intensity of the β-peptide combinations at 530 nm (F/F 0) was then plotted against
the increasing mole fraction of the TAMRA-labelled β-peptide species. In Figure 5.15
the results of the complementary β-PNA strands are shown. At 10 ℃ (Figure 5.15(a)), a
decrease of the NBD fluorescence for all three complementary nucleobase motifs is observ-
able with 80/82+84 (GTC/GAC) exhibiting the strongest decrease, while the decrease
of fluorescence intensity is lower for 76/77+79 (GTA/TAC) and lowest for 59/62+65
(TTA/TAA). For the measurements at 20 ℃ (Figure 5.15(b)), the β-PNA strands show a
similar behavior albeit less pronounced. These findings indicate that the stability of the
β-PNA dimerization is highly affected by sequence composition and temperature.
Moreover, when the matching β-PNA combinations were compared to mismatching
combinations, it became apparent that the mismatched β-peptides showed significantly
reduced changes of NBD fluorescence intensity just like the negative control in contrast
to the matching β-peptides. This is especially notable in case of 80/82+84 indicating
that the mismatch combinations do not interact whereas the matching combination does
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Figure 5.13. Emission spectra at 10 ℃ of the complementary β-PNA strands 59/62+65
(TTA/TAA) (a), 76/77+79 (GTA/TAC) (b), 80/82+84 (GTC/GAC) (c)
as well as a negative control measurement 80/82+90 (GTC/no Nb) (d)
measured with the indicated χA of the TAMRA-labelled β-PNA strand at
pH 7.5 in 10 mM TRIS-HCl buffer.
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Figure 5.14. Emission spectra at 20 ℃ of the complementary β-PNA strands 59/62+65
(TTA/TAA) (a), 76/77+79 (GTA/TAC) (b), 80/82+84 (GTC/GAC) (c)
as well as a negative control measurement 80/82+90 (GTC/no Nb) (d)
measured with the indicated χA of the TAMRA-labelled β-PNA strand at
pH 7.5 in 10 mM TRIS-HCl buffer.
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Figure 5.15. Relative change of NBD fluorescence intensity (F/F0) at 530 nm of the β-
PNA combinations 59/62+65 (TTA/TAA), 76/77+79 (GTA/TAC) and
80/82+84 (GTC/GAC) at 10 ℃ (a) and 20 ℃ (b) as a function of in-
creasing χA of the TAMRA-labelled β-PNA strand measured at pH 7.5 in
10 mM TRIS-HCl buffer.
(Figure 5.16). These results show that the nucleobase interaction is highly specific and





























Figure 5.16. Relative change of NBD fluorescence intensity (F/F0) at 530 nm of the
matching and mismatching β-PNA combinations 80/82+84 (GTC/GAC),
80/82+90 (GTC/no Nb), 80/82+65 (GTC/TAA) and 80/82+79
(GTC/TAC) at 10 ℃ (a) and 20 ℃ (b) as a function of increasing χA of the
TAMRA-labelled β-PNA strand measured at pH 7.5 in 10 mM TRIS-HCl
buffer.
In an attempt to quantify the stability of dimer formation, MST measurements were
conducted to determine a kD value for the matching β-PNA strands 58+66 (see Sec-
tion 8.3.8 for experimental details). However, the FAM fluorophore showed unexpected
variation in fluorescence, the results varied widely and no sigmoidal curve shape could
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be obtained from the data. Therefore, no kD value could be determined. Repeating the
MST assay with a different fluorophore, however, could give better results.
5.4.3. CD-Spectroscopic Analysis of β-PNA Interaction
Dimerization of the complementary β-PNA strands was additionally investigated by CD
spectroscopy. First, CD spectra were recorded for the complementary combinations
59+64 (TTA/TAA), 76+78 (GTA/TAC) and 80+83 (GTC/GAC) and compared to
the spectra of the individual β-peptides as well as the calculated average from the single
strands. Furthermore, temperature-dependent CD measurements were performed with all
complementary combinations as well as the individual β-PNA strands between 5 ℃ and
95 ℃ (see Section 8.3.4 for experimental details).
For the β-PNA combination with the weakest interaction motif 59+64 (TTA/TAA),
only minor differences between the CD spectra of the combined β-PNA strands and the
calculated average were observable, which could be attributed to interactions between the
β-PNA strands but could also be caused by variations in concentration (Figure 5.17(a)).
Temperature-dependent CD measurements showed minimal interaction of the β-peptides
as well because the temperature-dependent signal intensity of the combined sample was


















































Figure 5.17. Combined, single and calculated average CD spectra at 20 ℃ (a) as well
as temperature-dependent CD measurements at 273 nm (b) of 59 and 64
(TTA/TAA) measured at pH 7.5 in 10 mM TRIS-HCl buffer.
For the β-PNA combination 76+78 (GTA/TAC), CD spectra of the combined β-PNA
strands differed slightly more from the calculated average than the previously described
combination. The signal maximum at around 270 nm attributed to nucleobase confor-
mation was not only larger than the calculated average but was also shifted to a shorter
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wavelength indicating interaction between the β-PNA strands (Figure 5.18(a)). Addi-
tionally, the temperature-dependent CD measurements showed a higher intensity for the
combined β-PNA strands compared to the individual β-peptides at low temperatures
which decreased with increasing temperatures. The increased signal intensity at low tem-
peratures suggests that a dimer of 76+78 is formed at low temperatures which dissociates


















































Figure 5.18. Combined, single and calculated average CD spectra at 20 ℃ (a) as well
as temperature-dependent CD measurements at 273 nm (b) of 76 and 78
(GTA/TAC) measured at pH 7.5 in 10 mM TRIS-HCl buffer.
The trend prevailed with the CD spectra of β-PNA combination 80+83 (GTC/GAC).
Compared to the calculated average, the CD spectrum of the compared β-PNA strands
showed a significantly higher maximum at around 270 nm indicating that the β-peptides
are interacting (Figure 5.19(a)). Furthermore, the interaction appeared to stabilize the
14-helix as well since the signal intensities at around 215 nm and 195 nm were more
distinct. When the temperature-dependent CD signals at 273 nm were recorded, the CD
measurement of the combined sample exhibited a sigmoidal curve shape confirming that
duplex formation occurs with this nucleobase motif and that the thermal dissociation is
a cooperative process (Figure 5.19(b)).
Moreover, the annealing procedure, in which samples were incubated at 80 ℃ for 5 min
and slowly cooled to rt, was not necessary for the presented system to achieve dimer
formation. CD spectra of the combined β-peptides with and without annealing were
equal but it is particularly apparent for 80+83 (Figure 5.19(a)).
The results of the CD spectroscopic analyses were in good agreement with the FRET
measurements (Section 5.4.2) showing that the binding motif TTA/TAA exhibits very low
interaction. With increasing GC content, the interaction is enhanced, which is confirmed
by the comparison of the temperature-dependent CD spectra of the β-PNA combinations
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Figure 5.19. Combined, single and calculated average CD spectra at 20 ℃ (a) as well
as temperature-dependent CD measurements at 273 nm (b) of 80 and 83
(GTC/GAC) measured at pH 7.5 in 10 mM TRIS-HCl buffer.
(Figure 5.20). Therefore, the incorporation of guanine and cytosine is needed for dimer
formation with the presented system because of the small number of nucleobase pairings.
Consequently, melting temperatures could only be determined for 76+78 (GTA/TAC)
























Figure 5.20. Overview of the temperature-dependent CDmeasurements at 273 nm of the
complementary β-PNA strands 59+64 (TTA/TAA), 76+78 (GTA/TAC)
and 80+83 (GTC/GAC) measured at pH 7.5 in 10 mM TRIS-HCl buffer.
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5.5. β-PNA Interaction on Bilayer Surfaces
β-PNA/lipid bilayer interaction as well as β-PNA/β-PNA dimer formation on lipid bilayer
surfaces were investigated by fluorescnce- and CD-spectroscopic methods to assess if the
combination of these two modes of interaction is feasible.
5.5.1. Fluorescence-Spectroscopic Analysis of Membrane
Interaction
To investigate if the myristyl-modified β-peptides interact with lipid bilayers, different
fluorescence spectroscopic methods were applied. For initial studies, the change in NBD
fluorescence was monitored in different solvents since NBD is known to be environment-
sensitive. [172,173] In organic solvents or in close proximity to lipid bilayers, NBD fluores-
cence is increased in comparison to aqueous solvents. Therefore, the NBD fluorescence
intensity of myristyl-modified 73 and of the respective methyl-modified 65 was measured
in methanol, 10 mM TRIS-HCl buffer (pH 7.5) and DOPC-LUV suspensions in a wave-
length range of 475–650 nm (see Section 8.3.7 for experimental details). The DOPC vesicle
suspensions were prepared from MLV solutions with 10 mM TRIS-HCl buffer (pH 7.5) by
extrusion as described in Section 8.4.2. The methyl-modified 65 showed increased fluo-
rescence emission when measured in methanol while measurements in 10 mM TRIS-HCl
buffer (pH 7.5) and DOPC-LUV suspensions showed equally low fluorescence intensities
which indicate that the methyl modification does not lead to attachment of the β-peptide
to the lipid bilayer (Figure 5.21(a)). In case of 73, the NBD fluorescence intensity re-
mained high in methanol and low in buffer but the measurement in vesicle suspension
revealed an increase of emission intensity, demonstrating that the myristyl modification
leads to an autonomous attachment of the β-PNA to the lipid bilayer surface.
Additionally, the results were validated by a FRET assay with NBD and lissamine
rhodamine B (Rhod) as a FRET pair which are a convenient donor-acceptor-pair due to
their overlap of donor emission and acceptor excitation spectra as shown in Figure 5.22.
In this case, FRET between the donor, which was an NBD-labelled β-peptide, and the
acceptor, which was a Rhod-labelled lipid incorporated into a vesicle, was recorded.
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Figure 5.21. NBD emission spectra of 65 (a) and 73 (b) at 2.5 µM measured in the





















Figure 5.22. Normalized excitation and emission spectra of NBD and Rhod measured
with DOPC-LUV suspensions (0.75 % Rhod-DOPE) at rt.
Therefore, DOPC-LUV suspensions containing 0.75 mol% of Rhod-DOPE were mixed
with 5 µM NBD-labelled β-PNA to achieve a P/L ratio of 1:150 before the fluorescence
emission was detected in a wavelength range of 480–660 nm. As shown in Figure 5.23, in
case of myristyl-modified β-peptides 69 and 73 (a) as well as 86 and 88 (b), an intense
increase of the Rhod fluorescence signal in comparison to the measurement without β-
peptide is apparent. These findings indicate that the myristyl-modified β-PNA units are
attached to the lipid bilayer surface. In contrast, the methyl-modified counterparts 60 and
65 (a) as well as 81 and 83 (b) show no substantial increase of the Rhod fluorescence signal
which is an indication that no β-PNA/lipid bilayer interaction occurs when the myristyl
modification is omitted. The same results were found for the β-peptides without nucle-
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obases. While an increase of Rhod fluorescence occurs in presence of myristyl-modified
91, in presence of methyl-modified 90 no increase can be observed which substantiates
that the myristyl modification self-reliantly inserts into preformed lipid bilayers attaching

















































Figure 5.23. Emission spectra of the indicated β-PNA strands with the nucleobase mo-
tifs TTA/TAA (a) or GTC/GAC (b) and without nucleobases (c) at a
concentration of 5 µM measured in DOPC-LUV suspensions (0.75 mol%
Rhod-DOPE) in 10 mM TRIS-HCl buffer at pH 7.5 and rt.
During the fluorescence spectroscopic analyses it was found that the monofacial β-
peptides showed improved solubility in aqueous media even with the myristyl modifi-
cation in contrast to the bifacial β-PNA generation (Chapter 4). Due to the enhanced
hydrophilicity and the arrangement of homolysines on all three helical faces, it was deemed
unlikely that the β-PNA strands would completely immerse into the lipid bilayer. How-
ever, with the fluorescence spectroscopic results presented here it could not be ruled out.
Therefore, further studies were necessary to fully disclose the extent of interaction between
β-PNA strands and lipid bilayers (Section 5.5.3).
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5.5.2. Fluorescence Spectroscopic Analysis of β-PNA
Interaction on Bilayer Surfaces
Since the complementary nucleobase interaction motif GTC/GAC showed the most pro-
nounced interaction in solution, dimerization of β-PNA strands on lipid bilayers were
investigated with the corresponding myristyl-modified β-PNA strands 85/87+89. Anal-
ysis was performed via FRET with the same donor-acceptor-pair used in solution, NBD
and TAMRA, which only showed slight shifts in presence of lipid bilayers compared to
the excitation and emission spectra in solution(Figure 5.24). First, time-resolved emis-
sion spectra were recorded to assess how fast the β-PNA interaction occurs. For that, the
NBD-labelled and the TAMRA-labelled β-peptides were sequentially added to previously


















Figure 5.24. Normalized excitation and emission spectra of NBD and TAMRAmeasured
at pH 7.5 in vesicle suspensions with 10 mM TRIS-HCl buffer.
When the complementary β-PNA strands were mixed in DOPC vesicle suspensions, a
precipitate was formed rapidly even when the β-peptide and lipid concentrations were
highly diluted. It was assumed that the precipitate was formed due to β-PNA dimer
formation between β-PNA strands located on different vesicles surfaces (Figure 5.25(a)).
Therefore, the negatively charged lipid DOPS was added (20 mol%) to hinder the dimer-
ization between different vesicles by electrostatic repulsion. Although the measurements
with DOPC/DOPS vesicles showed no precipitation, there was also no detectable FRET
(Figure 5.26). This could be attributed to the electrostatic repulsion also inhibiting nucle-
obase pairing. These findings also imply that interaction between β-PNA strands located
on different membranes might be favored over interaction between β-PNA strands located
on the same lipid bilayer due to the trilateral structure of the 14-helix. In combination
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with the membrane curvature of the vesicle, the trilateral geometry might impede dimer
formation of β-PNA strands located on the same bilayer surface because the nucleobases
are misaligned to form the required hydrogen bonds (Figure 5.25(b)). Another expla-
nation could be that the β-PNA strands are able to interact while located on the same
vesicle, even though the curvature is unfavorable for the interaction, rupturing the vesicle
membrane in the process due to tensions resulting from bending the membrane. However,
further studies are required to substantiate the described hypotheses.
Figure 5.25. Schematic illustration of the proposed favored interaction between β-PNA
units located on different vesicles (a) and the angular constraints impeding
interaction between β-PNA units located on the same vesicle (b).
Bicelles were chosen for further measurements because they offer a planar membrane
model system due to their disk-like shape. [61,76] Bicelles with a qDMPC/DHPC-ratio of 2
were prepared from the long-chain phospholipid DMPC and the short-chain phospholipid
DHPC with 5 mM TRIS-HCl buffer (pH 7.5) according to a protocol described in Sec-
tion 8.4.2. [78] To keep the bicelles stable, they were stored on ice prior to measurements
and diluted shortly before to yield a bicelle concentration of 10 mM. Then the labelled β-
peptides were added to yield a concentration of 0.5 µM respectively. Time-resolved NBD
emission measurements revealed that for the complementary β-PNA strands 87+89, the
NBD fluorescence of 89 decreased quickly upon addition of the TAMRA-labelled 87 (Fig-
ure 5.27(a)). In contrast, the same measurements with 91 showed a lower decrease of NBD
fluorescence intensity after 87 addition (Figure 5.27(b)). These findings indicate that the
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Figure 5.26. Time-resolved NBD emission of 89 (GAC) and 91 (no Nb) (added at point
A) with or without 87 (GTC) (added at point B) with a concentration of
0.5 µM each, measured in DOPC-LUV suspensions (20 mol% DOPS) with
10 mM TRIS-HCl buffer at pH 7.5.
myristyl-modified β-PNA strands interact while bound to lipid bilayers and that the dimer
formation is a rapid process. Additionally, measurements of the NBD-labelled β-peptides
89 and 91 with and without bicelles showed an increase of NBD fluorescence when they
were added to bicelles in contrast to buffer or DHPC alone demonstrating rapid binding







































Figure 5.27. Time-resolved NBD emission of 89 (a) and 91 (b) (added at point A) with
or without 87 (added at point B) with a concentration of 0.5 µM each,
measured in DMPC/DHPC bicelle solutions with 5 mM TRIS-HCl buffer
(pH 7.5) at 20 ℃.
Comparing the emission spectra of 89 before and after addition of the TAMRA-labelled
87 also showed that the decrease of NBD fluorescence intensity was the result of FRET
and not any other effect, since it was associated with increased TAMRA fluorescence
80
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(Figure 5.28(a)). As expected, for the negative control 91 no significant FRET was
observable because neither a significant decrease of NBD fluorescence nor increase of
































Figure 5.28. Emission spectra of 89 (a, GAC) and 91 (b, no Nb) with or without 87
(GTC) with a concentration of 0.5 µM each, measured in DMPC/DHPC
bicelle solutions with 5 mM TRIS-HCl buffer (pH 7.5) at 20 ℃.
Moreover, time-resolved NBD emission measurements were repeated with TAMRA-
labelled 82, which is the methyl-modified soluble counterpart to 87, to investigate whether
myristyl-modified 85 attached to lipid bilayers would interact with 83 in solution. The
decrease of NBD fluorescence upon addition of the TAMRA-labelled β-peptide occurred
at a much slower rate for 89 (Figure 5.29(a)). In the case of 91 even no statistical FRET
was observed, since the NBD fluorescence intensity showed no significant difference to the
measurement without addition of 82 (Figure 5.29(b)).
Consequently, also the emission spectra of 89 and 91 showed a much lower influence of
82 on the NBD fluorescence intensity as well as a reduced TAMRA fluorescence intensity
(Figure 5.30). While residual FRET can be observed for 89+82, no FRET occurs in case
of 91+82
Apparently, the attachment of both interaction partners to the lipid bilayer and the
resulting alignment on a two-dimensional plane seems to greatly facilitate duplex forma-
tion. In contrast, the interaction is greatly diminished when the preorganization on the
membrane surface is omitted for one interaction partner because the chance of the solu-
ble β-peptide 82 approaching lipid-bound β-peptide 91 in the right orientation is much
lower. Also these findings contradict the previously described hypothesis that preferen-
tial binding occurs between β-PNA strands located on different lipid bilayer surfaces and
corroborates that duplex formation mainly occurs between β-PNA strands located on the
81































Figure 5.29. Time-resolved NBD emission of 89 (a) and 91 (b) (added at point A) with
or without 82 (added at point B) with a concentration of 0.5 µM each,
measured in DMPC/DHPC bicelle solutions with 5 mM TRIS-HCl buffer
(pH 7.5) at 20 ℃.
same lipid bilayer surface. Nonetheless, FRET could be detected between 89 and 82
indicating that dimer formation also occurs when one β-PNA strand is attached to lipid

































Figure 5.30. Emission spectra of 89 (a, GAC) and 91 (b, no Nb) with or without 92
(GTC) with a concentration of 0.5 µM each, measured in DMPC/DHPC
bicelle solutions with 5 mM TRIS-HCl buffer (pH 7.5) at 20 ℃.
5.5.3. CD-Spectroscopic Analysis of β-PNA Interaction on
Bilayer Surfaces
To further validate β-PNA dimer formation on lipid bilayers, CD spectroscopy was per-
formed with the myristyl-modified β-peptides in DMPC/DHPC bicelle solutions with
5 mM TRIS-HCl buffer (pH 7.5) at 20 ℃. Annealing of the samples was omitted because
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the preceding CD spectroscopic analysis of β-PNA interaction in solution showed that an
annealing procedure was not necessary for dimer formation. CD spectra were recorded for
85+88 and compared to the spectra of the individual β-peptides as well as the calculated
average from the single strands (Figure 5.31). Just as the CD spectrum of the combined
β-PNA strands 80+83 measured in solution, the CD spectrum of 85+88 showed a signif-
icantly higher maximum of around 273 nm in comparison to the individual measurements
or the calculated average demonstrating that β-PNA dimerization apparently occurs in a
lipid-bilayer-bound state (Figure 5.31(a)).
Additionally, CD spectra were recorded for 85+83 to substantiate the results of the
interaction between myristyl-modified 85 attached to lipid bilayers and 83 in solution.
Comparing the CD spectra of 85+83 to the calculated average showed an increase of the
maximum of around 273 nm although the increase was not as distinct as compared to the
measurement with both β-PNA strands attached to lipid bilayer surfaces. These findings
demonstrate that β-peptide interaction also occurred if only one interaction partner is


















































Figure 5.31. Combined, individual and calculated average CD spectra at 20 ℃ of 85+88
(a, GTC/GAC) and 85+83 (b, GTC/GAC) measured in DMPC/DHPC
bicelle solutions with 5 mM TRIS-HCl buffer (pH 7.5).
The CD spectra also revealed that the signal minima and maxima characteristic for
the 14-helix correspond to the minima and maxima found for the β-peptides in solution,
indicating that the β-PNA strands are not immersed into the lipid bilayer themselves but
are still in the aqueous phase as intended. In the case of membrane constituted β-peptides,
it has been found that the CD signals were shifted to shorter wavelengths. [107,109,145]
Temperature-dependent CD spectroscopy was not possible for the samples because a
precipitate was formed upon heating. Therefore, no melting curves could be determined
for the β-PNA/β-PNA dimer formation on lipid bilayer surfaces.
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5.6. Lessons learned from the Monofacial β-PNA
System
The monofacial β-PNA model system described in this chapter gave an idea of the factors
required for β-PNA/β-PNA interaction as well as β-PNA/membrane interaction. Dimer
formation with the reduced minimal nucleobase interaction site could successfully be
detected by fluorescence and CD spectroscopy showing the influence of sequence variety
on the stability of duplex formation. Moreover, it was demonstrated that dimer formation
is highly selective not tolerating any mismatched nucleobases in the sequences.
The interaction of β-PNA strands and lipid bilayers was shown by fluorescence spec-
troscopy as well. The attachment of the β-peptides to the membrane surface appears to
occur rapidly which is mediated by the hydrophobic myristyl modification. It was also
shown by CD spectroscopic analysis that the myristyl-modified β-PNA strands are lo-
cated above the lipid bilayer surface and not immersed into the membrane. Preliminary
results of leakage assays with sulforhodamine B (SRB) and DLS measurements indicated
that attachment of individual myristyl-modified β-peptides to DOPC-LUVs might cause






































Figure 5.32. Time-resolved SRB emission measurements (a) in vesicle leakage assays of
the indicated β-peptides added after 300 s (ex=583 nm, em=583 nm) with
DOPC-LUVs containing 20 mM SRB and DLS measurements (b) of the
same β-peptides measured with DOPC-LUVs in 10 mM TRIS-HCl buffer
(pH 7.5).
After demonstrating that the interaction of the β-peptides with lipid bilayer surfaces
is feasible, duplex formation on bicelles could also be detected by fluorescence and CD
spectroscopy when both β-PNA strands are attached to the lipid bilayer or when only one
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β-peptide is located at the membrane surface. Additionally, because precipitate formation
occured when complementary β-PNA strands were added, the reasons for this observa-
tion should be investigated further being possibly caused by omnidirectional aggregation
of vesicles or fusion. Preliminary fluorescence microscopic studies of immobilized vesicles
validated dimer formation on lipid bilayer surfaces because FRET between the donor-
acceptor pair NBD and TAMRA could be detected (Figure 5.33). Moreover, the results
indicated that DOPC-LUV coated with 89 tend to form aggregates which might be am-
plified when the complementary β-PNA strand is present. However, further studies have
















Figure 5.33. Composite fluorescence micrographs of immobilized DOPC-LUV coated
with 89 before (a) and after (b) addition of 87 as well as representative
fluorescence emission spectra of the two conditions (c). Measurements were
performed in collaboration with the Steinem group in 10 mM TRIS-HCl
buffer (pH 7.5).
The findings described in this chapter reveal the prerequisites for for expanding the
design and establishing a β-PNA model system with multiple nucleobase interaction sites
85
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as well as myristyl modifications for an aggregational network on lipid bilayer surfaces
which mimics the membrane skeleton.
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Cholesterol Modification
In addition to the monofacial myristyl-modified β-PNA strands discussed in Chapter 5,
cholesterol-modified β-peptides were designed as well, since cholesterol is known to accu-
mulate in lipid rafts. With these cholesterol-modified β-peptides it was investigated how
the sterol would perform in comparison to the saturated alkyl chain as a modification
for membrane-interaction. The anticipated β-PNA/β-PNA as well as β-PNA/membrane
interactions of the model system are schematically shown in Figure 6.1.
Figure 6.1. Schematic illustration of the monofacial β-PNA model system modified with
cholesterol derivatives interacting on the lipid bilayer surface.
6.1. Design & Synthetic Strategy
Parallel to the monofacial β-peptides with myristyl modification, β-PNA strands were
designed with one nucleobase interaction site and one cholesterol modification as a mem-
brane interaction site (Figure 6.2). Since cholesterol is a polycyclic alcohol which is bulkier
than the myristyl alcohol, it was not directly linked to the β-peptides but connected via a
linker unit in order to evade possible steric problems. In addition, it was suspected that
the cholesterol derivative might pull the β-strands into the membrane if it was directly
connected to it.
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Figure 6.2. Schematic depiction of the monofacial cholesterol-modified β-PNA system
interacting in antiparallel orientation with nucleobases at the interaction
sites and NBD modification at the N -terminal homolysine.
For the introduction of cholesterol derivatives, three different strategies were devised
and tested. First, cholesterol was linked to a β-amino acid building block via an ester
bond analogous to the myristyl-modified β-amino acid building block. This cholesterol
ester derivative 21 was planned to be incorporated into the β-peptide directly during
SPPS (Figure 6.3, Strategy A). In a second strategy, the cholesterol was connected via
an ether bond to the β-PNA strand after completion of SPPS.1 Therefore, the cholesterol
ester derivative was replaced with a homoglutamic acid, which was side chain protected
with an allyl ester. After completion of the β-peptide sequence, the allyl ester was cleaved
off to enable amide bond formation between the cholesterol ether derivative 25 and the
carboxyl group of the aspartic acid side chain (Figure 6.3, Strategy B). A third strategy
analogous to the second one was devised with the difference that a cholesterol amide
derivative 30 was incorporated (Figure 6.3, Strategy C).
Initially, cholesterol-modified β-PNA strands with the complementary sequence motif
TTA/TAA were devised. The scaffold sequence is illustrated in Figure 6.4, which is anal-
ogous to the sequence shown in the previous Chapter 5, except for the cholesterol modifi-
1This synthetic strategy was based on a strategy devised by Markus Wiegand, Institute of Organic and
Biomolecular Chemistry, University of Göttingen (unpublished results).
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Figure 6.3. Synthetic strategies for the modification of β-PNA with cholesterol deriva-
tives. While strategy A employs ester derivative 21 to introduce cholesterol
during SPPS, strategy B and C incorporate cholesterol building blocks via
on-resin modification after SPPS which either contain an ether (25) or an
amide bond (30).
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cation. While ACHC was incorporated to promote 14-helix formation, β-homolysine was
integrated to prevent the β-peptides from immersing themselves into the lipid bilayer. For
the nucleobase interaction site, the nucleo-β-amino acid building blocks were incorporated
at every third position in the sequence so that they were arranged at the same helix face.
The complementary β-PNA strands were labelled with NBD to assess the interaction be-
tween the β-peptides and lipid bilayers mediated by cholesterol. For further studies, NBD





























































































































Figure 6.4. Synthesized monofacial β-peptides with incorporated nucleo-β-amino acid
building blocks and cholesterol modification connected via an amide bond
for membrane interaction.
Additionally, β-peptide strand 95 without nucleobases was devised as a negative control
for which the nucleo-β-amino acid building blocks were replaced by β-alanine building
blocks analogous to 91 (Figure 6.5).
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Figure 6.5. Synthesized β-peptide 95 with the cholesterol modification and without nu-
cleobases as a negative control for nucleobase interaction.
6.2. Synthesis & Purification
The cholesterol-modified β-peptides were synthesized via SPPS based on the revised Boc-
protocol described in Section 3.5 with microwave-assisted coupling steps. As already
illustrated in Section 6.1, different synthetic strategies were applied to achieve cholesterol
modification. First, a cholesterol-modified β-PNA strand with the TAA-motif was at-
tempted to be synthesized on commercially available β-ala-PAM resin (0.8 mmol/g) with
double coupling for the nucleo-β-amino acid building blocks. Then strategy A was ap-
plied (Figure 6.3), directly incorporating cholesterol connected to a β-amino acid building
block via an ester bond (21) during SPPS in a double coupling step. After coupling
of 21, a test cleavage was performed to investigate if the coupling was successful and if
the expected product 96a had been formed (Figure 6.6). However, only the hydrolyzed
product 96b could be identified by mass spectroscopic analysis of the crude peptide. It
was concluded that the ester bond of the cholesterol derivative appears to be more acid
labile than the ester bond of the myristyl-modified building block. As a consequence,
the coupling appeared to be successful during SPPS but the ester bond might have been
hydrolyzed during acid-catalyzed cleavage. Therefore, strategy A was not suitable for the
incorporation of cholesterol and other strategies were tested.
To survey the coupling conditions to incorporate cholesterol, a test peptide without
nucleobases was utilized (Figure 6.7, 97a). Test peptide 97a was synthesized on Boc-
β-ala-PAM resin with double coupling steps before it was attempted to incorporate dif-
ferent cholesterol derivatives. Initial modifications were unsuccessful with 97a synthe-
sized on resin with a loading density of 0.8 mmol/g. It was assumed that due to the
high loading density, the β-peptide strands are too crowded on the surface of the resin
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beads for the cholesterol moieties to diffuse to the modification sites. Therefore, the
resin was downloaded following Section 8.4.1 yielding a resin with a reduced loading
density of 0.25 mmol/g. For strategy B with the ether derivative 25, cleavage of the
allyl protecting group was performed with tetrakis(triphenylphosphane)palladium(0) in
dry DCM under argon atmosphere followed by amide bond formation between the free
carboxyl group and 25 with (1-cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylamino-
morpholino-carbenium hexafluorophosphate (COMU) as the coupling reagent (see Sec-
tion 8.4.1 for experimental details). [174] Afterwards, a test cleavage was performed and
the isolated crude peptide was analyzed by mass spectroscopy. However, neither product
97b, nor the educt could be detected. Instead only unidentifiable side products were





































































Figure 6.6. Synthesized monofacial β-peptides 96a and 96b with nucleobases and the
cholesterol modification connected via an ether bond for membrane interac-
tion.
In strategy C, 97a was allyl-deprotected after SPPS as described above for strategy B
but additionally a microwave-assisted procedure was applied which did not require dry
conditions and protective argon atmosphere (see Section 8.4.1 for experimental details).
Then, the cholesterol amide derivative 30 was coupled with COMU in a double coupling
step. [175] After coupling, a test cleavage was performed and the crude peptide was ana-
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lyzed. Since the formation of the product 97c could be verified by mass spectroscopic
analysis, strategy C proved to be successful and it was employed for the synthesis of the











































































































































Figure 6.7. Synthesized test-β-peptides without nucleobases and the cholesterol modifi-
cation connected via an ether or amide bond for membrane interaction.
For the β-PNA strands 93 and 94, microwave-assisted SPPS was halted before the last
β-amino acid building block Boc-β3-d-hlys(Fmoc)-OH (7) was incorporated to prevent po-
tential interference of the Fmoc-protecting group during cleavage of the allyl-protecting
group as well as during subsequent cholesterol modification with the cholesterol-amide
building block 30 and COMU. Afterwards, the last β-amino acid building block was
coupled, Fmoc-deprotected and labelled with NBD (see Section 8.4.1 for experimental
93
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details). For the negative control 95, SPPS of the whole sequence was completed be-
fore cholesterol modification was performed. After complete synthesis of the cholesterol-
modified β-peptides, analytical U-HPLC as well as mass spectroscopic analysis showed
that product formation was successful. However, a lot of side products were present (Fig-
ure 6.8(a), Figure 6.9(a) and Appendix A.7). Purification of the crude β-peptides via
RP-HPLC turned out to be problematic. Since the β-PNA strands became so hydropho-
bic due to the cholesterol modification, semi-preparative RP-HPLC was conducted with
a C8 column to adjust the stationary phase to the higher hydrophobicity of the product.
However, the β-PNA strands apparently aggregated and interacted strongly with the sta-
tionary phase, resulting in peak broadening especially in the case of 93, where the product
peak was overlaid by other peaks as well. For 94, peak broadening was also observed but
































Figure 6.8. Chromatograms of analytical U-HPLC runs with a C8 column of β-peptide
94 before (a) and after (b) purification.
In the case of the negative control 95, purification was performed with a C18 column
and a more hydrophobic eluent system (A: H2O + 0.1 % TFA, B: MeCN + 20 % 1-PrOH
+ 0.1 % TFA) to overcome aggregation and interaction with the stationary phase because
the chromatogram of the analytical U-HPLC run indicated even higher hydrophobicity
of this β-peptide (Figure 6.9(a)). Additionally, the crude β-peptide was dissolved in hex-
afluoroisopropanol (HFIP) which is known to exceptionally solubilize aggregation-prone
apolar peptides, even dissolving amyloid fibers. [176,177] However, peak broadening was still
observed and after purification the formation of new peaks was observed which might be
attributed to the formation of new aggregates forming (Figure 6.9(b)). Nevertheless, the





























Figure 6.9. Chromatograms of analytical U-HPLC runs with a C8 column of β-peptide
95 before (a) and after (b) purification.
6.3. CD-Spectroscopic Characterization
When the secondary structure of the β-peptides was analyzed by CD spectroscopy, the
cholesterol-modified β-peptides could be dissolved at low concentrations in 10 mM TRIS-
HCl buffer (pH 7.5) and were measured at different temperatures. The spectra of the
β-PNA strands 93 and 94 verified 14-helix formation, since a global maximum of around
215 nm, a global minimum of around 195 nm and a zero crossing between 200 nm and
205 nm could be detected (Figure 6.10). [23,129,135] Additionally, a local maximum was
recorded of around 270 nm which indicates a conformational preorganization of the nu-
cleobases. [24,25] It could also be revealed that the 14-helix formation is highly stable and
























































Figure 6.10. CD spectra of 93 (a), 94 (b) recorded at different temperatures in 10 mM
TRIS-HCl buffer (pH 7.5).
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6. Monofacial β-PNA with Cholesterol Modification
CD spectra of the negative control 95 without nucleobases showed the characteristic
pattern of a 14-helix as well, although signal amplitude was decreased in comparison
to the β-PNA strands 93 and 94 (Figure 6.11). Additionally, the 14-helix of 95 seems
to exhibit a lower stability at increased temperatures. Apparently, the exchange of the
nucleo-β-amino acids for β-alanine leads to a higher flexibility of the 14-helix. β-Alanine
is homologous to glycine which exhibits a high conformational freedom because it has no
side chain and is known to destabilize helical structures. [169,170] Therefore, it is likely, that

























Figure 6.11. CD spectra of 95 recorded at different temperatures in 10 mM TRIS-HCl
buffer (pH 7.5).
Since the cholesterol-modified β-peptides were planned to be attached to lipid bilayers,
the influence of membranes on the secondary structure was assessed in vesicle suspensions.
DOPC-LUV suspensions were prepared in 10 mM TRIS-HCl buffer (pH 7.5), and the
cholesterol-modified β-peptides were added before CD spectra were recorded at 20 ℃
(see Section 8.4.2 for experimental details). As Figure 6.12 illustrates, the CD spectra
of 93, 94 and 95 exhibit the characteristic pattern for a right-handed 14-helix with a
global maximum of around 215 nm, a global minimum of around 195 nm as well as a
zero crossing between 200 nm and 205 nm. Moreover, the additional local maximum of
around 270 nm, likely cause by preorganization of the nucleobases, was observed. Apart
from the finding that 14-helix formation is still distinct in presence of lipid bilayers, the
results also indicate that the β-peptides are not submerged into the lipid bilayer, since
the signal maxima and minima of the CD spectra recorded in vesicle suspensions coincide
with the signal minima and maxima observed in solution. Previous studies have revealed
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6.4. Fluorescence Spectroscopic Analysis of Bilayer Interaction
a shifting of the signals to shorter wavelengths for β-peptides constituted into membranes


























Figure 6.12. CD spectra of the indicated cholesterol-modified β-PNA strands recorded
in DOPC-LUV suspensions with 10 mM TRIS-HCl buffer (pH 7.5) at 20 ℃.
Overall, the recorded CD spectra of the β-peptides in solution and in vesicle suspensions
indicate that 14-helix formation is not negatively affected by the cholesterol modification
and stable in aqueous solution as well as in presence of lipid baylers. Additionally, when
the nucleo-β-amino acids are replaced by β-alanine, 14-helix formation is less distinct.
6.4. Fluorescence Spectroscopic Analysis of Bilayer
Interaction
To investigate the capability of cholesterol-modified β-peptides to autonomously attach
to lipid bilayer surfaces, a FRET assay was performed which has already been utilized
for the previously described myristyl-modified β-pepides with NBD and Rhod B as a
donor-acceptor-pair (Section 5.5.1). Therefore, DOPC-LUV suspensions with 0.75 mol%
Rhod-DOPE were prepared and mixed with the NBD-labelled β-peptides to achieve a
P/L ratio of 1:150 and a peptide concentration of 5 µM. The excitation wavelength was
set to 460 nm and fluorescence emission of the samples was detected in a wavelength
range of 480–660 nm. Comparing 93 and 94 to their methyl-modified counterparts 60
and 65, showed that Rhod B fluorescence was increased in the presence of cholesterol-
modified β-PNA strands (Figure 6.13(a)). These results demonstrate that the cholesterol
modification self-reliantly inserts into the preformed lipid bilayer, thereby attaching the
β-peptides to the surface.
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Furthermore, 95 was compared to its methyl-modified counterpart 90 as well as the
myristyl-modified 91. As illustrated in Figure 6.13(b), 95 and 91 show a similar propen-
sity to be attached to the lipid bilayer surface via their respective hydrophobic modifi-
cation because the detected Rhod B fluorescence intensity caused by FRET is similar.

































Figure 6.13. Emission spectra of the indicated β-PNA strands with the nucleobase mo-
tifs TTA/TAA (a) and without nucleobases (b) at a concentration of 5 µM
measured in DOPC-LUV suspensions (0.75 mol% Rhod-DOPE) in 10 mM
TRIS-HCl buffer at pH 7.5 and rt.
After the interaction of the cholesterol-modified β-peptides was successfully verified,
further analysis of the interaction between the β-PNA strands on lipid bilayer surfaces
will be necessary like it has been performed for the myristyl-modified β-PNA counterparts
(Section 5.5.2). Therefore, cholesterol-modified β-PNA strands should be prepared with
the nucleobase motifs CTG and CAG and labelled with the required fluorophores.
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7. Conclusions
The vast interactions between the membrane and cytoskeleton components forming the
so called membrane skeleton are known to shape and stabilize the lipid bilayer. [3,4] This
extended protein network lines the inner side of the plasma membrane and either in-
teracts with the membrane directly or via adaptor proteins. [2] The membrane skeleton
is not only essential for stability, it has also been shown to form a mesh like structure
which influences the lipid phase separation by changing the diffusion rate of lipids and
consequently altering the local lipid composition. [6,7] Moreover, the membrane skeleton
has been shown to apparently alter membrane heterogeneity through its mesh size which
also might be the driving force behind local membrane protein domains. [8] Therefore,
it has been hypothesized that the membrane skeleton is required to fine-tune the local
membrane morphology and domain composition by cytoskeletal pinning. [6,10] To gain in-
sight into the interactions between the lipid bilayer and the protein network, different in
vitro model systems and approaches have been employed. While recombinant variants of
eukaryotic cytoskeletal components, which have to be expressed and isolated first, have
been utilized to examine the interactions in most studies, also prokaryotic homologues or
polymers have been utilized in an attempt to reduce complexity. [6,12,13,16]
In this thesis, an artificial model system was developed to form a peptide network
on lipid bilayer surfaces in order to further investigate the membrane-skeletal interde-
pendency regarding influence on membrane shape and stability or on the local lipid
composition. This system should aggregate through specific interaction mimicking the
cytoskeletal interaction with membranes but should be less complex than the eukaryotic
system. Therefore, β-peptide nucleic acids (β-PNA) were selected to establish the model
system in a bottom-up approach because the protease-stable, rigid 14-helical topology
of the β-peptide is an eminently suited scaffold for the membrane-associated peptide
network. [19,129] Moreover, the nucleobase functionalization of β-peptides resulting in the
aforementioned β-PNA has been shown to mediate oligomer formation through specific
molecular interaction. [25–28] This specific interaction has already been employed in a model
system investigating SNARE-mediated membrane fusion and offers the possibility to as-
semble higher-organized super structures. [29]
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In the beginning, SPPS of the model β-peptides showed low yields and efficiency. There-
fore, the β-PNA synthesis procedure was altered and vastly improved by a microwave-
assisted SPPS strategy in terms of coupling times as well as reagent equivalents and con-
sumption. [163] Nevertheless, β-PNA synthesis might still be enhanced by switching from
Boc- to Fmoc-protocol since the Fmoc-protected amino acid building blocks require even
shorter coupling times, and “self-capping”, which can be problematic during Boc-protocol
SPPS, is not observed here. However, Fmoc-protocol SPPS might have to be optimized
regarding utilized solvents because the solubility of Fmoc-protected nucleo-β-amino acid
building blocks in DMF is even lower than that of the Boc-protected units. Moreover,
the acid-catalyzed cleavage of the Boc-protecting group during SPPS might be important
as well since the acid is known to break-up hydrogen bonds of aggregates formed dur-
ing synthesis. In total, 45 β-peptides were synthesized for different model systems, using
the initial Boc-strategy for the preparation of the first generation of β-peptides and an
upgraded Boc-strategy for the following SPPS.
The first generation of bifacial β-PNA strands equipped with two nucleobase interaction
sites and two myristyl modifications as hydrophobic membrane interaction sites was syn-
thesized by the initial SPPS protocol (Figure 7.1). Due to a high occurrence of side prod-
ucts and peak broadening, especially in the case of the myristyl-modified β-PNA strands,
purification was challenging. Nevertheless, the desired β-peptides could be obtained and
analyzed. These bifacial β-PNA strands were supposed to form oligomers, however, inter-
action between the peptides 56 and 57 via the nucleobase motifs TTA-TAA insolution
could not be adequately verified. Moreover, handling of the bifacial β-PNA with myristyl
modifications 54 and 55 was not trivial since they turned out to be too hydrophobic to
autonomously attach onto preformed membranes. Therefore, the bifacial β-PNA strands
were not applicable for the desired model system and the design had to be revised.
A second generation of monofacial β-PNA strands was designed comprising of one nu-
cleobase interaction site and one hydrophobic membrane interaction site per β-peptide
(Figure 7.1). The new β-PNA strands were supposed to form dimers and, based on the
experiences from the bifacial system, were designed to be less hydrophobic for a better
handling. SPPS with the improved synthesis protocol resulted in reduced occurrence of
side products, thereby facilitating purification. Initially, duplex formation of the β-PNA
units without the myristyl modification were analyzed in solution in order to investi-
gate, how dimer stability is influenced by nucleobase sequence composition. FRET assays
revealed that three nucleobases are already sufficient for duplex formation if the motif
contains guanine and cytosine. Furthermore, the results demonstrated that sequence
specificity is high since duplex formation with mismatching sequences could not be ob-
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served. In subsequent fluorescence and CD spectroscopic analyses, the propensity of the
myristyl modification to insert into the membrane and attaching the β-peptides to the
membrane surface in the process could be demonstrated. Lastly, β-PNA/β-PNA duplex
formation could also be detected in combination with membrane association either with
both interaction partners located on the lipid bilayer surface or with one attached to
the lipid bilayer surface while the other one was in solution. Duplex formation could be
demonstrated to occur swiftly at room temperature making annealing obsolete.
Additionally to the myristyl modification, a cholesterol modification was connected to
the monofacial β-PNA strands because this sterol is presumed to promote the formation
of lipid rafts. Initially, it was attempted to incorporate cholesterol as an alcohol either
linked via an ester or an ether bond. However, these strategies did not succeed because
the ester and ether bonds proved to be unstable during acid-catalyzed cleavage. There-
fore, the amine derivative of cholesterol was generated and linked to the β-peptides via an
amide bond. Even though the desired cholesterol-modified β-peptides could be generated,
the coupling conditions of the cholesterol-derivate should be improved because an increase
in side product formation was observed after cholesterol modification. Purification again
proved to be challenging because of the hydrophobic and aggregation-prone nature of
the cholesterol-modified β-peptides. Nevertheless, autonomous insertion of the choles-
terol into preformed lipid bilayers and consequently attachment of the peptides could be
demonstrated successfully paving the way for further necessary studies regarding dimer
formation of the β-PNA strands on lipid bilayer surfaces.
Figure 7.1. Overview of the initial bifacial and refined monofacial model systems as well




CD spectroscopic analysis indicated pronounced 14-helix formation for the β-peptides
of the first and second generation demonstrating that the different modifications such
as the hydrophobic membrane interaction sites or the fluorophore labels did not disturb
the desired secondary structure. In addition, the β-peptides proved to be highly stable
even at elevated temperatures. The β-peptides without nucleobases represented the only
exception because the conformational freedom of the introduced β-alanine resulted in
β-peptides exhibiting a more flexible and less stable 14-helix.
Since in some cases formation of precipitate was observed, the influence of lipid bilayer
composition and vesicle size could be further assessed to investigate potential causes
e.g. by aggregation or rupture of the vesicles during DLS and vesicle leakage assays.
Additionally, fluorescence microscopy might give further insight into the β-PNA/β-PNA
interactions on membrane surfaces and their influence on local membrane curvature as
well as composition by employing planar membrane models. Moreover, the analysis of
geometry of β-PNA/membrane interaction with individual β-peptides as well as higher
ordered structures by AFM might give more information about the distance between
β-PNA strands and the lipid bilayer.
Many prerequisites regarding β-PNA/β-PNA and β-PNA/membrane interactions could
be defined in this thesis rendering the design of higher aggregate systems possible. As a
next step, the extension of the monofacial model system with multiple nucleobase motifs
on one β-PNA strand for trimer and fibril formation should be conducted, stepwise ap-
proaching the targeted membrane skeleton network model. Additionally, the nucleobase-
mediated specific interaction of the β-PNA also holds the potential to form other higher-






PAM-resins for solid-phase peptide synthesis were purchased from Iris Biotech (Mark-
tredwitz, Germany) and Fluka (Taufkirchen, Germany). Amino acid derivatives were
obtained from GL Biochem (Shanghai, China), Novabiochem (Darmstadt, Germany),
PolyPeptide Group (Strasbourg, France), Fluorochem (Hadfield, UK) and Oxchem (Wood
Dale, USA), whereas coupling reagents were obtained from Fluorochem (Hadfield, UK),
GL Biochem (Shanghai, China), Iris Biotech (Marktredwitz, Germany) and Roth (Karl-
sruhe, Germany). Lipids were acquired from Avanti (Alabaster, USA). All other chem-
icals were purchased from Acros Organics (Geel, Belgium), Alfa Aesar (Karlsruhe, Ger-
many), Applichem (Darmstadt, Germany), Fisher Scientific (Schwerte, Germany), Fluka
(Taufkirchen, Germany), Fluorochem (Hadfield, UK), Glentham Life Science (Corsham,
UK), Grüssing (Filsum, Germany), Iris Biotech (Marktredwitz, Germany), Merck KGaA
(Darmstadt, Germany), Roth (Karlsruhe, Germany), Sigma Aldrich (St. Louis, USA) and
VWR Chemicals (Fontenay-sous-Bois, France) in analytical grade and used as supplied.
8.1.2. Solvents
Technical solvents were used for flash column chromatography. All other solvents were
purchased from Applichem (Darmstadt, Germany), Grüssing (Filsum, Germany), Merck
KGaA (Darmstadt, Germany), Roth (Karlsruhe, Germany), Sigma Aldrich (St. Louis,
USA) and VWR Chemicals (Fontenay-sous-Bois, France) with the highest grade available.
Dry solvents stored over molecular sieve and under inert argon atmosphere were purchased
from Acros Organics (Geel, Belgium) and Sigma Aldrich (St. Louis, USA). Triethylamine
and allyl alcohol were dried by addition of molecular sieves (3 Å) which were previously
heat dried at 100 ℃ over night.
Ultra-pure water was obtained from either a Millipore Simplicity (Burlington, USA) or




Moisture and air sensitive reactions were carried out under inert argon or nitrogen atmo-
sphere in dry solvents. Glassware was heat dried under reduced pressure beforehand and
flushed with inert gas prior to use.
8.1.4. Lyophilisation
Freeze-drying of peptides and synthesized molecules was performed by using a Christ
Alpha 2-4 LD plus lyophilizer (Osterode am Harz, Germany) connected to a Vacuubrand
chemistry hybrid pump RC5 high vacuum pump (Wertheim, Germany). Beforehand, the
samples were dissolved in water or mixtures of water and dioxane and frozen in liquid
nitrogen. Fractions collected from the HPLC device containing a low concentration of
methanol or acetonitrile were also frozen in liquid nitrogen before lyophilization.
For freeze-drying of small amounts in 1.5 mL or 2.0 mL sample tubes a Christ RVC 2-18





8.2.1. Thin Layer Chromatography (TLC)
Analytical TLC was performed on TLC 60 F254 silica gel coated aluminum sheets from
Merck KGaA (Darmstadt, Germany). Detection of compounds was either performed by
fluorescence quenching at 254 nm or 366 nm or by different TLC stains. The stains
used were ninhydrin solution (1.5 g ninhydrin and 3 mL acetic acid in 100 mL n-butanol,
detects amino groups), potassium permanganate (1.5 g KMnO4, 10 g K2CO3 and 1.25 mL
10 % NaOH in 200 mL water, detects alkenes and other oxidizable groups) or cerium
ammonium molybdate (CAM) stain (2 g Cer(IV)SO4 and 5 g (NH4)2MoO4 in 200 mL
10 % aq. H2SO4 solution, universal stain) and subsequent heating with a heat gun.
8.2.2. Flash Column Chromatography
Flash column chromatography was performed using silica gel (grain size 40–63 µm) from
Merck KGaA (Darmstadt, Germany). The column was packed with silica gel suspended
in the required solvent (50–150-fold weight excess). Samples were either loaded onto the
silica gel column as a concentrated solution or adsorbed to silica gel or celite. Elution was
conducted with 0.5–1.0 bar and product fractions were identified by TLC.
8.2.3. Dry Column Vakuum Chromatography
Dry column vacuum chromatography was performed according to Pedersen [178] by filling
a cylindrical sintered glass funnel with dry silica gel (grain size 15–40 µm) which was
then repeatedly tapped onto a cork ring until the silica was tightly packed appearing
to be “solid”. The silica gel was further compressed by applying vacuum via a vacuum
adapter. After the successful packing was confirmed by addition of a fraction of the
required apolar eluent, which should pass the column in a straight horizontal line when
vacuum was applied, the sample adsorbed on celite was applied onto the column. Elution
was conducted by stepwise addition of a gradient of eluent and product fractions were
identified by TLC.
8.2.4. High Performance Liquid Chromatography (HPLC)
Reversed-phase HPLC (RP-HPLC) for the analysis and purification of samples was
performed using mainly an HPLC system from JASCO, (Tokyo, Japan) consisting
of a diode array MD-2010plus, degasser DG-2080-53 and two PU-2080plus pumps.
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Optionally, a fraction collector CHF122SC from Advantec (Milpitas, USA) was coupled
to the HPLC system. Alternatively, an Äkta basic 10 system from Amersham Pharmacia
Biotech (Little Chalfont, UK) was used, equipped with a P-900 pump module. The
following columns from Macherey-Nagel (Düren, Germany) and Hichrom (Theale, UK)
were used:
Analytical: MN Nucleodur® RP-C18-ec 100-5-C18, 250 mm × 4.6 mm, 5 µm
Semi-prep. (C18): MN Nucleodur® RP-C18-ec 100-5-C18, 250 mm × 10 mm, 5 µm
Semi-prep. (C8): Vydac 208TP C8, 350 × 10 mm, 5 µm
Semi-prep. (C4) MN Nucleosil® RP-C4 120-5-C4, 250 mm × 10 mm, 5 µm
While a flow of 1 mL/min for analytical columns and a flow of 3 mL/min for
semi-preparative columns was adjusted, a linear gradient of solvent B was used with the
following solvent compositions:
Solvent A Solvent B
Standard-System: H2O + 0.1 % TFA MeCN + 0.1 % TFA
HFIP-System: H2O + 0.1 % HFIP MeCN + 0.1 % HFIP
1-PrOH-System: H2O + 0.1 % TFA MeCN + 20 % 1-PrOH + 0.1 % TFA
UV-detection was performed at 215 nm, 254 nm and 280 nm for non-labelled peptides.
In case of labelled peptides, UV-absorption was recorded at 464 nm for the NBD-label,
540 nm for the TAMRA-label and 470 nm for the FAM-label instead of 280 nm. Prior
to purification or analysis, samples were dissolved in H2O/MeCN or HFIP and filtered.
Collected fractions which contained product were lyophilized (see subsection 8.1.4).
8.2.5. Ultra-High Performance Liquid Chromatography
(U-HPLC)
For analytic RP-HPLC, a U-HPLC system UltiMate 3000 from Thermo Fisher Scienific
(Waltham, USA) was used as an alternative to the JASCO systemt, consisting of pumps-,
detector-, autosampler-, column oven- and diode array-modules. A linear gradient of A
(H2O + 0.1 % TFA) to B (MeCN + 0.085 % TFA) with a flow rate of 0.3 mL/min was
utilized with either of the following columns:
Thermo Fisher Scientific (Waltham, USA) Hypersil Gold C8 100 mm × 2.1 mm
ACE Excel (Aberdeen, Scotland) ACE Excel 2 C18 100 mm × 2.1 mm
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Prior to analysis, samples were dissolved in H2O/MeCN and filtered. UV-absorption




8.3.1. Nuclear Magnetic Resonance Spectroscopy (NMR)
1H-NMR spectroscopy was performed at 300 MHz on a Mercury-VX 300 or an VNMRS-
300 spectrometer from Varian (Palo Alto, USA). 13C-NMR spectroscopy was performed
at 126 MHz on an INOVA-500 from Varian (Palo Alto, USA). The sample temperature
was 27 ℃ for CDCl3 and 30 ℃ for DMSO-d6. The chemical shifts denoted in ppm
(parts per million) were given in relation to the standard TMS (δTMS = 0 ppm). The
chemical shifts of the residual protons of the deuterated solvents were used as an internal
standard (for CDCl3 δ(1H-NMR) = 7.26 ppm and δ(13C-NMR) = 77.16 ppm; for DMSO-
d6 δ(1H-NMR) = 2.50 ppm and δ(13C-NMR) = 39.52 ppm). [179] Coupling constants nJX,Y
were given in Hertz (Hz), where X and Y were the coupling partners and n was the order
of coupling. The following abbreviations for the multiplicities were used: s (singlet), d
(doublet), t (triplet), q (quartet), m (multiplet), br (broad).
8.3.2. Mass Spectrometry (MS)
Electrospray ionization (ESI-MS) and high resolution ESI (HR-MS) spectra were recorded
with a maXis or MicroTOF spectrometer from Bruker Daltonik GmbH (Bremen, Ger-
many). The values are given in m/z.
8.3.3. Circular Dichroism Spectroscopy (CD)
CD spectroscopy was performed using a J-1500 CD spectrometer from Jasco (Tokyo,
Japan) and an F250 recirculation cooler from Julabo (Seelbach, Germany). Measurements
were performed with a Quartz SUPRASIL QS cuvette of 0.1 cm path length from Hellma
Analytics (Müllheim, Germany) while the device and sample cell were continuously flushed
with nitrogen. The spectra were recorded in a wavelength range from 180–350 nm with a
bandwidth of 1.0 nm, a response time of 1.0 s, a data pitch of 0.5 nm, a scanning speed
of 100 nm/min and CD scale of 200 meg/1.0 dOD in ‘continuous mode’. Measurements
were performed with the indicated temperatures (ranging from 10 ℃ to 80 ℃) and in
the indicated solvents and buffer systems. An average of five spectra were recorded
per sample and background-corrected against pure solvent without peptide. Afterwards,
the spectra were expressed as molar ellipticity [θ] (deg × cm2 × dmol−1) according to
Greenfield [180] with the following formula:
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[θ] (deg × cm2 × dmol−1) = CD
c× d×NAA
(8.1)
with CD being the measured ellipticity (mdeg), c the concentration of the peptide
(mol× L−1), d the path length (cm) and NAA the number of residues.
8.3.4. Temperature Dependent CD Spectroscopy
Temperature dependent CD-measurements were performed with a J-1500 CD spectrom-
eter from Jasco (Tokyo, Japan) and an F250 recirculation cooler from Julabo (Seelbach,
Germany) with a Quartz SUPRASIL QS cuvette of 0.1 cm path length from Hellma An-
alytics (Müllheim, Germany) while the device and sample cell were continuosly flushed
with nitrogen. Samples were heated with a heating rate of 1 ℃/min from 5 ℃ to 95 ℃.
Data points for heating and cooling cycles were recorded with a sampling rate of 0.5 ℃,
1 s wait time, CD scale of 200 mdeg/1.0 dOD, D.I.T. of 2 s and a bandwidth of 1.0 nm at
a wavelength of 273 nm. Melting temperatures for the oligomerizing peptides were deter-
mined by the peak maximum of the first derivation of the melting curves. Additionally,
spectra scans were performed during heating at 5 ℃, 20 ℃, 40 ℃, 60 ℃, 80 ℃ and 95 ℃ in
a wavelength range from 180–320 nm with a bandwidth of 1.0 nm, a data pitch of 0.5 nm,
a scanning speed of 100 nm/min, a D.I.T. of 2 s and CD scale of 200 meg/1.0 dOD in
‘continuous mode’. An average of five spectra were recorded per sample and background-
corrected against pure solvent without peptide. Afterwards, the spectra were expressed
as molar ellipticity (see equation (8.1)).
8.3.5. UV/Vis-Spectroscopy
Peptide concentrations were determined using a nanodrop ND-2000c spectrophotometer
from Thermo Scientific (Waltham, USA) with either a Quartz SUPRASIL QS cuvette of
1.0 cm path length from Hellma Analytics (Müllheim, Germany) or by using the imple-





with c being the peptide concentration (mol× L−1), A the measured absorption, ε the
molar extinction coefficient (L× cm−1 ×mol−1) and d the sample path length (cm). The
molar extinction coefficients and corresponding wavelengths as well as solvents are shown
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in Table 8.1. The coefficients of the nucleobase motifs were calculated by summation of
the single nucleobase coefficients at 260 nm.
Table 8.1. Extinction coefficients for nucleobases, TAMRA, NBD and FAM. [161,181,182]
Absorption wavelength Exctinction coefficient Solvent
[nm] [L× cm−1 ×mol−1]
A 260 13 700 H2O
T 260 8600 H2O
G 260 11 700 H2O
C 260 6600 H2O
TAMRA 548 85 500 H2O
NBD 466 2200 MeOH
FAM 496 80 000 0.1 N NaOH
8.3.6. Temperature Dependent UV-Spectroscopy
Temperature dependent UV-measurements were performed with a V-650 spectrometer
from Jasco (Tokyo, Japan), with a black Quartz SUPRASIL QS cuvette of 1.0 cm path
length from Hellma Analytics (Müllheim, Germany) and continuous nitrogen flushing of
the sample cell during measurements. The temperature was controlled utilizing an ETCS-
761 temperature controller from Jasco (Tokyo, Japan) with a F250 recirculation cooler
from Julabo (Seelbach, Germany). Samples were measured at 260 nm with a bandwidth
of 2 nm, a sampling rate of 0.4 ℃, response time set to ‘fast’ and the following heating
protocol was applied:
Annealing
6.0 ◦C/min → 80.0 ◦C → 2 min hold time
3.0 ◦C/min → −2.1 ◦C → 3 min hold time
Data recording
0.4 ◦C/min → 85.0 ◦C → 5 min hold time
 3 cycles0.4 ◦C/min → 0.0 ◦C → 5 min hold time
Alternatively, temperature dependent UV-spectra were recorded with a V-550 with an
ETC-505T temperature controller from Jasco (Tokyo, Japan) and aWKL26 recirculation
cooler from HAAKE (Karlsruhe, Germany). Here, the annealing was performed manually
by incubating the sample at 80.0 ℃ for 5 min followed by slow cooling to rt. Measurements
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were performed at 260 nm with 2 nm bandwidth, 5 s wait time, a sampling rate of 0.4 ℃,
response time set to ‘fast’ and the following heating protocol was applied:
Data recording
1.0 ◦C/min → 80.0 ◦C → 10 s hold time
 2–3 cycles1.0 ◦C/min → 4.0 ◦C → 10 s hold time
Data points for heating and cooling cycles were recorded. The hyperchromicity Arel
was then calculated with the following equation:
Arel(T ) =
(A(T )− A0)× 100
A0
(8.3)
with A(T ) being the absorbance for every temperature T and A0 being the total mini-
mum absorbance for the cycle. Melting temperatures for the oligomerizing peptides were
determined by the peak maximum of the first derivation of the melting curves.
8.3.7. Fluorescence Spectroscopy
NBD Fluorescence
Fluorescence spectra for the analysis of the NBD fluorescence shifting were recorded on a
FP-6200 spectrometer from Jasco (Tokyo, Japan) at room temperature. Measurements
were performed with the indicated solvents in a Quartz SUPRASIL QS fluorescence cu-
vette of 1.0 cm path length from Hellma Analytics (Müllheim, Germany) and continuous
nitrogen flushing of the sample cell. The excitation wavelength was set to 464 nm and
emission was detected between 475–650 nm with both bandwidths set to 5 nm, response
set to ‘fast’, scanning speed set to 125 nm/min, data pitch set to 1.0 nm and sensitivity
set to ‘low’.
Membrane Interaction FRET Assay
Membrane interaction FRET assays were performed with a Clariostar plate reader from
BMG Labtech (Ortenberg, Germany) at room temperature in a black pp 96-well F-bottom
plate from Greiner Bio-One (Kremsmünster, Austria) with a total sample volume of
200 µL. NBD-labelled peptides and Rhodamine-labelled LUVs (0.75 % Rhod-DOPE)
were mixed right before measurement to yield a P/L ratio of 1:150 in TRIS-HCl buffer
(10 mM, pH 7.5). After focal and gain adjustment, emission spectra were recorded with
an excitation wavelength of 460 nm in a range of 480–660 nm while the bandwidth was
set to 10 nm.
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Peptide Interaction FRET Assay
Peptide interaction FRET assays were performed on a FP-6200 spectrometer from Jasco
(Tokyo, Japan) with an ETC-272T temperature controller from Jasco (Tokyo, Japan) and
a WKL26 recirculation cooler from HAAKE (Karlsruhe, Germany). Measurements were
conducted at the indicated temperatures and solvents and with a Quartz SUPRASIL QS
fluorescence cuvette of 1.0 cm path length from Hellma Analytics (Müllheim, Germany).
While the TAMRA-labelled peptide concentration was varied with the mole fraction χA
ranging from 0.0 to 0.5, the NBD-labelled peptide concentration with 4 µM as well as the
total peptide concentration with 8 µMwere kept constant by addition of the corresponding
acetylated peptide. Emission spectra were recorded in a wavelength range from 470–
650 nm with excitation at 460 nm, bandwidth set to 5 nm, response set to ‘fast’, scanning
speed of 125 nm/min, data pitch of 1.0 nm and sensitivity set to ‘medium’.
Time-resolved FRET Assay
Time-resolved FRET assays for peptide interaction were started with TRIS-HCl buffer
(5 mM, pH 7.5) which either contained 1 mM DMPC/DHPC (q=2) or 0.3 mM DHPC or
no lipids at all in a Quartz SUPRASIL QS fluorescence cuvette of 1.0 cm path length from
Hellma Analytics (Müllheim, Germany) equipped with a stirrer at 20 ℃. After 120 s the
NBD-labelled peptide was added to yield a concentration of 0.5 µM. The NBD fluorescence
emission was recorded for 180 s before the TAMRA-labelled peptide (0.5 µM) or buffer
was added and the fluorescence emission was recorded for another 600 s. Excitation was
set to 460 nm and the fluorescence intensity was detected at 530 nm with a bandwidth of
5 nm, data pitch of 10 s, response set to ‘fast’, measure time set to 900 s and sensitivity
set to ‘high’.
Vesicle Leakage Assay [183,184]
Vesicle leakage assays were performed on a FP-6200 spectrometer from Jasco (Tokyo,
Japan) with an ETC-272T temperature controller from Jasco (Tokyo, Japan) and a
WKL26 recirculation cooler from HAAKE (Karlsruhe, Germany). Measurements were
performed with a Quartz SUPRASIL QS fluorescence cuvette of 1.0 cm path length from
Hellma Analytics (Müllheim, Germany) at 20 ℃. The excitation wavelength was set to
567 nm and the fluorescence intensity was detected at 583 nm with a data pitch of 10 s,




The time course measurement was started with a 1.5 µM solution of LUVs which con-
tained sulforhodamine B (20 mM) in TRIS-HCl buffer (10 mM, pH 7.5) before a peptide
solution (2.5 µM) in H2O was added after 300 s to yield a P/L ratio of 1:300. The
measurement was continued for another 1200 s to record the fluorescence emission Ft.
Afterwards, a solution of Triton-X was added to an end concentration of 0.5 % (v/v)
to achieve end point fluorescence intensity F100%. The fluorescence intensity was then
normalized to F100% with the following equation:
F (%) = 100× (Ft − F0)(F100% − F0)
(8.4)
with F (%) being the normalized fluorescence, Ft the fluorescence intensity for every
point of time t, F0 the fluorescence intensity measured at t = 0 and F100% being the
maximal fluorescence intensity after addition of Triton-X.
8.3.8. Microscale Thermophoresis (MST)
Thermophoresis measurements were performed with a Monolith NT.115 from Nano-
Temper Technologies (Munich, Germany). For the samples, hydrophilic capillaries and
the provided MST buffer (1x MST Buffer: 50 mM TRIS-HCl pH 7.4, 150 mM NaCl,
10 mM MgCl2, 0.05 % Tween-20). FAM-labelled and acetylated peptides were chosen to
investigate the nucleobase-pairing mediated interaction. A dilution series of the acetylated
peptides was prepared to which the FAM-labelled peptides were added and measurements
were started after 5 minutes incubation at 20 ℃. Measurements were also performed at
20 ℃with varying LED power and sequential IR Laser Power of 20 %, 40 % and 80 %.
8.3.9. Dynamic Light Scattering (DLS)
Vesicle size and size changes were measured with a Zetasizer Nano S particle characteriza-
tion system from Malvern Instruments (Malvern, UK) at 25 ℃. Measurements were per-
formed in disposable semi-micro cuvettes from Brand (Wertheim, Germany) and 500 µL of
the vesicle samples with or without peptides were measured. For each sample, three mea-
surements with a delay of 0 s were performed. Number of runs, measurement position and




8.4. Standard Operating Protocols (SOPs)
8.4.1. SOPs for Peptide Synthesis
SOP1: Down-Loading of Boc-β-Ala-PAM Resin
To reduce the loading density of commercially available Boc-β-Ala-PAM resin
(0.8 mmol/g), a second amino acid building block was coupled sub-stoichiometrically.
The Boc-β-Ala-PAM resin (1.00 eq) was dried overnight in a Becton-Dickinson (BD) dis-
cardit II 10 mL syringe with a PE-frit under reduced pressure and weighed afterwards.
The Boc-protecting group was cleaved using TFA with 5 % m-cresol (v/v, 2 × 4.0 mL,
1 min). Afterwards, the syringe was thoroughly washed with DMF/DCM (1:1 v/v, 5 ×
4.0 ml), DMF/DIPEA (95:5 v/v, 5 × 4.0 mL) and DMF (5 × 4.0 mL). After the re-
quired N -Boc-β-amino acid (0.25 eq), HOAt (0.25 eq) and HATU (0.23 eq) were dissolved
in 4.0 mL DMF, DIPEA and 2,6-lutidine were added to yield an end concentration of
200 mM and 300 mM respectively right before the coupling solution was added to the
resin. The resin was then incubated for 1 h at room temperature on a shaker. After
washing the resin with DMF (5 × 4.0 mL), a second coupling was performed with 0.12 eq
amino acid building block, 0.12 eq HOAt, 0.11 eq HATU, 200 mM DIPEA and 300 mM
2,6-lutidine in DMF for 1 h at room temperature. Afterwards, the resin was thoroughly
washed with DMF/DCM (1:1 v/v, 5 × 4.0 ml), DIPEA in DMF (5 % v/v, 5 × 4.0 mL),
DMF (5 × 4.0 mL), MeOH (5 × 4.0 mL) and dried overnight under reduced pressure.
After weighing the down-loaded resin, the new loading density was calculated after the
following equation: [185]
n = mges −mresin(MXAA −MH2O −MBoc)×mresin
× 1000 (8.5)
with n being the loading density of the resin after down-loading (mmol/g), mges the
resin mass after down-loading (g), mresin the resin mass before the procedure (g), MXAA
the molar mass of the coupled N -Boc-β-amino acid (g/mol), MH2O the molar mass of
water (g/mol) and MBoc the molar mass of the cleaved Boc-protecting group (g/mol).
SOP2: Manual SPPS
Manual SPPS was performed in a PE-frit equipped BD discardit II syringe on a 20 µmol
scale using an oven and stirrer for the coupling steps. Commercially available Boc-β-Ala-
PAM resin was swollen in DMF overnight. The Boc-protecting group was cleaved using
TFA with 5 % m-cresol (v/v, 2 × 2.0 mL, 2 min), before the resin was washed thoroughly
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with DMF/DCM (1:1 v/v, 5 × 2.0 ml) and DMF (5 × 2.0 mL). For single coupling
steps, the required N -Boc-β-amino acid (5.0 eq), HOAt (5.0 eq) and HATU (4.5 eq)
were dissolved in 500 µL DMF. Due to low solubility, nucleobase containing amino acid
building blocks were dissolved by sonication. Then, the activated Boc-β-amino acid was
mixed with DIPEA (14.0 eq) and added immediately to the resin. The resin was incubated
and mixed at 50 ℃ for 2 h. When double coupling was performed, the incubation time
was reduced to 1 h for the separate coupling steps and the second reaction was performed
with fewer equivalents (3.0 eq N -Boc-β-amino acid, 3.0 eq HOAt, 2.7 eq HATU, 14 eq
DIPEA in 500 µL DMF). After coupling, the resin was washed with DMF/DCM (1:1
v/v, 5 × 2.0 ml) and DMF (5 × 2.0 mL). Capping was performed by adding a solution
of DMF/DIPEA/Ac2O (8:1:1 v/v, 1 × 2.0 mL, 10 min) and the resin was washed again
with DMF/DCM (1:1 v/v, 5 × 2.0 ml) and DMF (5 × 2.0 mL). If synthesis was paused,
the resin was suspended in DMF and stored overnight on a shaker or at -20 ℃ for longer
periods. After completion of the peptide synthesis, the resin was washed with DMF/DCM
(1:1 v/v, 5 × 2.0 ml), DMF (5 × 2.0 mL) and MeOH (5 × 2.0 mL), dried under reduced
pressure and stored in a desiccator.
SOP3: Manual Microwave-Assisted SPPS
Manual microwave assisted SPPS was performed in a PE-frit equipped BD discardit II
syringe on a 20 µmol scale using a Discover microwave (MW) reaction cavity from CEM
(Kamp-Lintfort, Germany) for the coupling steps. Commercially available or down-loaded
Boc-β-Ala-PAM resin was swollen in DMF overnight. The Boc-protecting group was
cleaved using TFA with 5 % m-cresol (v/v, 2 × 2.0 mL, 1 min), before the resin was
washed thoroughly with DMF/DCM (1:1 v/v, 3 × 2.0 mL), DMF/DIPEA (95:5 v/v, 3 ×
2.0 mL) and DMF (3 × 2.0 mL). Afterwards, double coupling was performed (2 × 20 W,
65 ℃, 20 min). For each coupling reaction, the required Boc-β-amino acid (3.0 eq), HOAt
(3.0 eq) and HATU (2.8 eq) were dissolved in 500 µL 0.8 M LiCl in DMF/DMSO (4:1 v/v).
For nucleobase containing amino acid building blocks, fewer equivalents were used (Boc-β-
amino acid (2.0 eq), HOAt (2.0 eq) and HATU (1.9 eq)) and were dissolved by sonication
due to low solubility. DIPEA and 2,6-lutidine were added to the activated amino acid
building block to yield an end concentration of 200 mM and 300 mM respectively before
addition to the resin. After the second coupling step, the resin was washed with NMP (5
× 5.0 mL). Remaining free amine groups were capped with DMF/DIPEA/Ac2O (8:1:1
v/v, 1 × 2.0 mL, 5 min) and the resin was washed again with DMF/DCM (1:1 v/v, 3 ×
2.0 mL), DMF/DIPEA (95:5 v/v, 3 × 2.0 mL) and DMF (3 × 2.0 mL). If synthesis was
paused, the resin was suspended in DMF and stored overnight on a shaker or at -20 ℃
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for longer periods. After the peptide sequence was completed, the resin was thoroughly
washed with DMF/DCM (1:1 v/v, 3 × 2.0 mL), DMF/DIPEA (95:5 v/v, 3 × 2.0 mL),
DMF (3 × 2.0 mL) and MeOH (3 × 2.0 mL), dried under reduced pressure and stored in
a desiccator.
SOP4: On-Resin Fmoc-Deprotection
On-resin Fmoc-deprotection of β3-hlysine side chains was performed in a PE-frit equipped
BD discardit II syringe. The required quantity of resin-bound peptide was swollen in
DMF for at least 1 h. Deprotection was conducted by addition of piperidine in DMF
(20 %, v/v) and shaking of the syringe for 10 min at rt. This procedure was repeated and
the resin was washed thoroughly with DMF/DCM (1:1 v/v, 3 × 2.0 mL), DMF/DIPEA
(95:5 v/v, 3 × 2.0 mL) and DMF (3 × 2.0 mL) before further modifications were made.
SOP5: On-Resin Allyl-Deprotection [175]
On-resin allyl-deprotection of β3-hglutamic acid side chains was performed in a PE-frit
equipped BD discardit II syringe using a Discover MW reaction cavity from CEM (Kamp-
Lintfort, Germany). The required quantity of resin-bound peptide was swollen in DCM
for at least 1 h. First, phenylsilane (15 eq) in 500 µL DCM was added to the resin
and incubated at rt for 1 min. Then, Pd(PPh3)4 (0,25 eq) was added and the reaction
mixture was incubated at 38 ℃ for 5 min under microwave irradiation (25 W). Afterwards,
the resin was washed thoroughly with DCM (5 × 5.0 mL). The deprotection reaction was
performed a second time and the resin was washed with DMF/DCM (1:1 v/v, 3× 2.0 mL),
DMF/DIPEA (95:5 v/v, 3 × 2.0 mL) and DMF (3 × 2.0 mL) before further modifications
were made.
SOP6: On-Resin Fmoc-Protection [186]
On-resin Fmoc-protection of amino groups was performed in a PE-frit equipped BD dis-
cardit II syringe. Fmoc-Osu (5 eq) and DIPEA (5 eq) were dissolved in 500 µL THF/DMF
(1:1 v/v), immediately transferred to the resin and incubated for 16 h on a shaker. The
resin was washed with DMF/DCM (1:1 v/v, 3 × 2.0 mL), DMF/DIPEA (95:5 v/v, 3 ×
2.0 mL) and DMF (3 × 2.0 mL) before further modifications were made.
SOP7: Cholesterol-Modification
Cholesterol derivatives were coupled to resin-bound peptides via a β3-hglutamic acid side
chain previously allyl-deprotected (see section 8.4.1) in a PE-frit equipped BD discardit
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II syringe. First, COMU (4 eq) was dissolved on 300 µL DMF. After addition of DIPEA
and 2,6-lutidine, to yield an end concentration of 200 mM and 300 mM respectively, the
solution was immediately transferred to the resin and incubated on a shaker for 2 min.
Then, the cholesterol derivative (4 eq) dissolved in 300 µL DCM/DMF (1:1 v/v) was
added to the resin and shaken for 1 h. Coupling was conducted a second time and the
resin was washed thoroughly with DMF/DCM (1:1 v/v, 3 × 2.0 mL), DMF/DIPEA (95:5
v/v, 3 × 2.0 mL) and DMF (3 × 2.0 mL) before further modifications were made.
SOP8: Fluorophore-Labelling
Fluorophores were coupled as a last step to resin-bound peptides via a β3-hlysine side
chain previously Fmoc-deprotected (see section 8.4.1) in a PE-frit equipped BD discardit
II syringe.









Fluorophor-labelling was achieved by addition of the required fluorophore derivatives
and activators dissolved in 500 µL DMF to the resin and incubation at rt overnight on
a shaker. Afterwards, the resin was washed with DMF/DCM (1:1 v/v, 3 × 2.0 mL),
DMF/DIPEA (95:5 v/v, 3 × 2.0 mL), DMF (3 × 2.0 mL) and MeOH (3 × 2.0 mL)
before it was transferred to screw top glass vials for cleavage. For NBD-, TAMRA-





Peptide-cleavage from the resin with simultaneous removal of all side chain protect-
ing groups was performed in screw top glass vials. A cleavage mixture of TFA/m-
cresol/thioanisole/EDT/TFMSA (10:1:1:0.5:1 v/v) was used. First, the cleavage solution
was added without TFMSA to the resin and incubated for 5 min on ice before TFMSA
was added drop-wise to the icecold mixture. The resin was shaken on ice for 1 h and at
least 2 h at rt. After incubation, the cleavage solution was filtered from the resin and
collected. The resin was washed several times with TFA, the filtrate was added to the
cleavage solution and concentrated in a nitrogen stream. The crude peptide was precipi-
tated with icecold diethyl or methyl tert-butyl ether and centrifuged (9000 rpm, 20 min,
-15 ℃). After the supernatant was discarded, the pellet was washed three times with
icecold ether subsequent followed by centrifugation. The dried pellet was dissolved in
H2O (or H2O/MeCN, 9:1 v/v, if necessary) and lyophilized (see subsection 8.1.4).
8.4.2. SOPs for Vesicle Preparation
SOP10: Multilamellar Vesicles (MLVs) [187]
On ice, lipids were dissolved in CHCl3 and the required amount was transferred to small
glass test tubes. The solvent was removed in a nitrogen stream leaving behind a clear
lipid film on the inner test tube walls. The lipid films were further dried overnight under
reduced pressure at 50 ℃. Afterwards, the lipid film was rehydrated in up to 1 ml filtrated
buffer by 1 h incubation either at rt for DOPC lipids or at 40 ℃ for DMPC lipids and
subsequent vortexing for 30 s, followed by 5 min incubation in three cycles. The resulting
milky MLV suspension was then used to prepare SUVs (see section 8.4.2) or LUVs (see
section 8.4.2).
For vesicle leakage assays (see section 8.3.7) lipid films were hydrated with buffer con-
taining 20 mM SRB.
SOP11: Small Unilamellar Vesicles (SUVs) [187]
MLV suspensions were transferred to 1.5 mL sample tubes which were placed in a sonicator
and sonicated for 30 min with 60 % power to yield clear SUV suspensions.
SOP12: Large Unilamellar Vesicles (LUVs) [58,69]
MLV suspensions were loaded into a LiposoFast extruder with gas-tight syringes from
Avestin (Ottawa, Kanada). Beforehand, the extruder was assembled tightly and filled
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with the required buffer without any air bubbles inside. The vesicle suspensions were
extruded 31 times through polycarbonate membranes with the indicated pore size to
yield a clear LUV suspension.
For vesicle leakage assays (see section 8.3.7), LUVs containing 20 mM SRB were pre-
pared from MLV suspensions containing 20 mM SRB. After extrusion, free SRB was
removed by size exclusion chromatography through a column filled with Sephadex™ G-
50 Fine (from Amersham Pharmacia Biotech AB, Amersham, UK ) with the respective
buffer without fluorophore as the eluent.
SOP13: Bicelles [78]
DMPC was dissolved in CHCl3 on ice and the required amount was transferred to small
glass test tubes. The solvent was removed in a nitrogen stream leaving behind a clear lipid
film on the inner test tube walls. Then, the lipid films were dried overnight under reduced
pressure at 50 ℃. Afterwards, the lipid films were dissolved in 20 mM DHPC in TRIS-
HCl buffer (5 mM, pH 7.5) yielding a DMPC concentration of 40 mM and a qDMPC/DHPC
of 2. To accelerate bicelle formation, the solutions were vortexed for 30 s, followed by
incubation on ice for 5 min and heated to 42 ℃ for 10 min. The resulting clear bicelle
solution was stored on ice to keep it stable and diluted shortly before measurements.
SOP14: Detergent-assisted Reconstitution [64]
Adapted from a SNARE reconstitution protocol, it was attempted to attach hydrophobic
β-peptides onto DOPC-bilayer surfaces. After lipid films with 0.5 mg DOPC were prepared
following SOP10, they were solubilized with 50 µL 100 mM n-octyl-β-glucopyranoside (n-
OG) in buffer and thrice incubated on ice for 20 min followed by vortexing for 30 s.
Afterwards, the peptide dissolved in 100 mM n-OG in buffer was added to yield a P/L
ratio of 1:300. After 30 min incubation on ice, the detergent was removed by size ex-
clusion chromatography using a NAP™-10 column from GE Healthcare (Little Chalfont,
UK) equilibrated with buffer without detergent. The lipid-containing fractions were con-
centrated in a vacuum centrifuge (see subsection 8.1.4) for 1 h and a second size exclusion
chromatography was performed. After concentrating of the lipid-containing fractions was
repeated, the samples were transferred to small glass test tubes and dried overnight un-
der reduced pressure and over saturated NaCl-solution resulting in clear lipid films which





8.5.1. Syntheses of β3-Amino Acids








Commercially available β-alanine (5.53 g, 60.0 mmol, 1.00 eq) was dissolved in
dioxane/H2O (2:1 v/v, 180 mL) and 1 M aq. NaOH-solution (60 mL) was added. The
solution was cooled to 0 ℃ before Boc2O (14.12 mL, 66.0 mmol, 1.10 eq) was added
dropwise and the reaction was stirred overnight at rt. Afterwards, the volume was
reduced to approximately 100 mL under reduced pressure and EtOAc (60 mL) was
added. The solution was adjusted to pH=2 with 1 M aqueous (aq.) KHSO4 solution.
The organic phase was separated from the aqueous phase and the aqueous phase was
extracted with EtOAc (3 × 50 mL). All organic phases were combined, dried over MgSO4
and the solvent was removed under reduced pressure. The oily residue was dried under
reduced pressure and the product Boc-β-Ala-OH (11.1 g, 58.7 mmol, 98 %) was obtained
as a colourless crystalline solid.
1H-NMR (300 MHz, DMSO-d6 ): δ (ppm) = 1.37 (s, 9H, Boc-CH3), 2.34 (t,
3JH,H = 7.1 Hz, 2H, α-CH2), 3.12 (td, 3JH,H = 7.1, 5.6 Hz, 2H, β-CH2), 6.71 (s, 1H,
Boc-NH), 12.05 (sbr, 1H, COOH).
13C-NMR (126 MHz, DMSO-d6 ): δ (ppm) = 28.19, 34.24, 36.14, 77.61, 155.42, 172.76.
ESI-MS (m/z): 212.1 [M+Na]+.


















Under nitrogen atmosphere, Boc-d-lys(Cbz-Cl)-OH (5.45 g, 13.1 mmol, 1.00 eq) was
dissolved in dry THF (55 mL) and cooled to -10 ℃. NEt3 (2.00 mL, 14.5 mmol,
1.10 eq) and isobutylchloroformate (1.88 mL, 14.5 mmol, 1.10 eq) were added before
the mixture was stirred for 1 h at -10 ℃. The solution was allowed to warm up to
0 ℃ before diazomethane (0.7 M in ether, 37.43 mL, 26.2 mmol, 2.00 eq) was added
under light exclusion and the solution was stirred for 3 h at rt. Afterwards, the
excess diazomethane was quenched with acetic acid (3 mL) and Et2O (80 mL) was
added. The solution was washed with saturated (sat.) aq. solutions of NaHCO3 (3
× 50 mL), NH4Cl (2 × 50 mL) and NaCl (1 × 50 mL), dried over MgSO4 and the
solvent was removed under reduced pressure. The product Boc-d-lys(Cbz-Cl)-N2 (4) was
obtained as a yellow oil (5.75 g, 13.1 mmol, quant.) and used without further purification.
ESI-MS (m/z): 439.2 [M+H]+, 456.2 [M+NH4]+, 461.2 [M+Na]+.
HR-MS (ESI): calc. for [C20H28N4O5Cl] ([M+H]+): 439.1743, found: 439.1735; calc. for
[C20H31N5O5Cl] ([M+NH4]+): 456.2008, found: 256.1994; calc. for [C20H27N4O5ClNa]

















Method A) Boc-d-lys(Cbz-Cl)-N2 (5.60 g, 12.76 mmol, 1.00 eq) was dissolved in
THF/H2O (9:1 v/v, 60 mL). Under light exclusion, silver benzoate (0.29 g, 1.28 mmol,
0.10 eq) was added and the solution was incubated in a sonicator for 3 h. Afterwards,
EtOAc (100 mL) was added and the pH was adjusted to pH = 2–3 with 1 M aqueous
HCl. The organic phase was washed with sat. aq. NaCl-solution (3 × 50 mL), dried over
MgSO4 and the solvent was removed under reduced pressure. The crude residue was
dissolved in DCM (10 mL) and added dropwise to an excess of cold pentane (-22 ℃).
The obtained precipitate was filtered, washed with cold pentane (3 × 50 mL) and
dried overnight under reduced pressure. After drying, Boc-β3-d-hlys(Cbz-Cl)-OH (5.2 g,
12.12 mmol, 95 %) was obtained as a colourless solid.
Method B) Boc-d-lys(Cbz-Cl)-N2 (5.75 g, 13.1 mmol, 1.00 eq) was dissolved in
THF/H2O (7:3 v/v, 60 mL). Silver benzoate (0.30 g, 1.4 mmol, 0.10 eq) was added and
the reaction solution was immediately irradiated by microwave irradiation (55 s, 460 W).
Afterwards, EtOAc (100 mL) was added and the pH was adjusted to pH = 2–3 with 1 M
aqueous HCl. The organic phase was washed with sat. aq. NaCl-solution (3 × 50 mL),
dried over MgSO4 and the solvent was removed under reduced pressure. The crude
residue was dissolved in DCM (10 mL) and added dropwise to an excess of cold pentane
(-22 ℃). The obtained precipitate was filtered, washed with cold pentane (3 x 50 mL)
and dried overnight under reduced pressure. After drying, Boc-β3-d-hlys(Cbz-Cl)-OH
(2.60 g, 6.06 mmol, 46 %) was obtained as a colourless solid.
1H-NMR (300 MHz, DMSO-d6 ): δ (ppm) = 1.55–1.05 (m, 15H, Boc-CH3, γ-
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CH2, δ-CH2, ε-CH2), 2.39–2.18 (m, 2H, α-CH2), 3.09–2.84 (m, 2H, ζ-CH2), 3.80–3.59
(m, 1H, β-CH), 5.08 (s, 2H, Cbz-Cl-CH2), 6.65 (d, 3JH,H = 8.7 Hz, 1H, Cbz-Cl-NH),
7.26–7.41 (m, 3H, Cbz-Cl-CHar), 7.42–7.52 (m, 2H, Boc-NH, Cbz-Cl-CHar), 12.09 (sbr,
1H, COOH).
13C-NMR (126 MHz, DMSO-d6 ): δ (ppm) = 22.77, 28.16, 29.18, 34.00, 39.08, 40.28,
47.31, 62.53, 77.44, 127.30, 129.26, 129.67, 132.29, 134.64, 155.08, 155.78, 172.63.
ESI-MS (m/z): 429.2 [M+H]+, 451,2 [M+Na]+, 427.2 [M-H]-.
HR-MS (ESI): calc. for [C20H30N2O6Cl] ([M+H]+): 429.1787, found: 429.1786; calc.
for [C20H29N2O6ClNa] ([M+Na]+): 451.1606, found: 451.1610; calc. for [C20H29N2O6Cl]
([M-H]-): 427.1641, found: 427.1635.
(R)-3-(tert-Butoxycarbonyl-amino)-7-(9-fluorenylmethyloxycarbonyl)-amino-













Under nitrogen atmosphere, Boc-d-lys(Fmoc)-OH (6.13 g, 13.1 mmol, 1.00 eq) was
dissolved in dry THF (55 mL) and cooled to -10 ℃. NEt3 (2.00 mL, 14.5 mmol, 1.10 eq)
and isobutylchloroformate (1.88 mL, 14.5 mmol, 1.10 eq) were added before the mixture
was stirred for 1 h at -10 ℃. The solution was allowed to warm up to 0 ℃ before
diazomethane (0.7 M in ether, 37.43 mL, 26.2 mmol, 2.00 eq) was added under light
exclusion and the solution was stirred for 3 h at rt. Afterwards, the excess diazomethane
was quenched with acetic acid (3 mL) and Et2O (80 mL) was added. The solution was
washed with sat. aq. solutions of NaHCO3 (3 × 50 mL), NH4Cl (2 × 50 mL) and NaCl
(1 × 50 mL), dried over MgSO4 and the solvent was removed under reduced pressure.
The product Boc-d-lys(Cbz-Cl)-N2 (6) was obtained as a yellow oil (6.45 g, 13.1 mmol,
















Boc-d-lys(Fmoc)-N2 (6.45 g, 13.1 mmol, 1.00 eq) was dissolved in THF/H2O (9:1 v/v,
60 mL) and silver benzoate (0.30 g, 1.3 mmol, 0.10 eq) was added under light exclusion.
The reaction mixture was then sonicated for 3 h at rt. Afterwards, EtOAc (100 mL)
was added and the pH of the solution was adjusted to pH=2–3 with 1 M aqueous HCl.
Then, the organic phase was washed with sat. aq. NaCl-solution (3 × 50 mL), dried over
MgSO4 and the solvent was removed under reduced pressure. The crude product was
dissolved in DCM (10 mL) and added dropwise to cold pentane (-22 ℃). The precipitate
was subsequently filtered, washed with cold pentane (3 × 50 mL) and dried overnight
under reduced pressure. The product Boc-β3-d-hlys(Fmoc-OH) (6.27 g, 13.0 mmol, 99 %)
was acquired as a light yellowish solid.
1H-NMR (300 MHz, DMSO-d6 ): δ (ppm) = 1.77–1.00 (m, 15H, Boc-CH3, γ-
CH2, δ-CH2, ε-CH2), 2.44–2.18 (m, 2H, α-CH2), 2.98 (t, 3JH,H = 6.4 Hz, 2H, ζ-CH2),
3.83–3.66 (m, 1H, β-CH), 4.20 (t, 3JH,H = 6.9 Hz, 1H, Fmoc-CH), 4.29 (d, 3JH,H =
6.8 Hz, 2H, Fmoc-CH2), 6.60 (d, 3JH,H = 8.7 Hz, 1H, Fmoc-NH), 7.21 (t, 3JH,H = 5.7 Hz,
1H, Boc-NH), 7.46–7.27 (m, 4H, Fmoc-CHar), 7.68 (d, 3JH,H = 7.4 Hz, 2H, Fmoc-CHar),
7.87 (d, 3JH,H = 6.8 Hz, 2H, Fmoc-CHar), 12.06 (sbr, 1H, COOH).
13C-NMR (126 MHz, DMSO-d6 ): δ (ppm) = 22.75, 28.21, 29.16, 33.96, 40.17, 46.80,
47.32, 65.17, 77.39, 120.01, 125.07, 126.97, 127.51, 140.70, 143.91, 155.03, 156.03, 172.53.
ESI-MS (m/z): 505.2 [M+Na]+, 481.2 [M-H]-.
HR-MS (ESI): calc. for [C27H34N2O6Na] ([M+Na]+): 505.2309, found: 505.2301; calc.
















Commercially available Boc-l-Asp(OBzl)-OH (8.80 g, 25.0 mmol, 1.00 eq) was dissolved
in dry THF (55 mL) under nitrogen atmosphere and cooled to -10 ℃. NEt3 (3.81 mL,
27.5 mmol, 1.10 eq) was added followed by isobutylchloroformate (3.57 mL, 27.5 mmol,
1.10 eq). The reaction mixture was stirred for 1 h at -10 ℃. Then, it was allowed to
come to 0 ℃ before diazomethane (0.6 M in ether, 83.00 mL, 50.0 mmol, 2.00 eq) was
added under light exclusion and the solution was stirred for 4 h at rt. Afterwards, excess
diazomethane was quenched with acetic acid (3 mL) and Et2O (100 mL) was added.
The solution was washed with sat. aq. solutions of NaHCO3 (3 × 50 mL), NH4Cl (2 ×
50 mL) and NaCl (1 × 50 mL), dried over MgSO4 and the solvent was removed under
reduced pressure. The product Boc-l-Asp(OBzl)-N2 (8.68 g, 25.0 mmol, quant.) was













Boc-l-Asp(OBzl)-N2 (8.68 g, 25.0 mmol, 1.00 eq) was dissolved in dioxane/H2O (7:3 v/v,
100 mL). Silver benzoate (0.57 g, 2.5 mmol, 0.10 eq) was added right before the solution
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was irradiated by microwave irradiation (55 s, 460 W). Subsequently, EtOAc (100 mL)
was added and the pH of the mixture was adjusted to pH = 2 with 1 M aq. HCl-solution.
The organic phase was washed with sat. aq. NaCl-solution (3 × 50 mL), dried over
MgSO4 and the solvent was removed under reduced pressure. The residue was dissolved
in DCM (10 mL) and the product was precipitated by dropwise addition to cold pentane
(-20 ℃). The obtained precipitate was filtered, washed three times with cold pentane and
dried overnight under reduced pressure. The dried product Boc-β3-d-hasp-OBzl (6.71 g,
19.9 mmol, 80 %) was obtained as a colourless solid.
1H-NMR (500 MHz, DMSO-d6 ): δ (ppm) = 1.36 (s, 9H, Boc-CH3), 2.60–2.34
(m, signal overlayed with solvent signal, α-CH2, γ-CH2), 4.23–4.03 (m, 1H, β-CH), 5.06
(s, 2H, Bzl-CH2), 6.83 (d, 3JH,H = 8.5 Hz, 1H, NH), 7.46–7.24 (m, 5H, Bzl-CHar), 12.19
(sbr, 1H, COOH).
13C-NMR (126 MHz, DMSO-d6 ): δ (ppm) = 28.14, 38.81, 38.87, 44.79, 65.50, 77.73,
127.78, 127.87, 128.30, 136.06, 154.63, 170.39, 172.00.
ESI-MS (m/z): 360.1 [M+Na]+, 336.1 [M-H]-.
HR-MS (ESI): calc. for [C17H23NO6Na] ([M+Na]+): 360.1418, found: 360.1422; calc for













Under nitrogen atmosphere, Boc-β3-d-hasp-OBzl (1.69 g, 5.0 mmol, 1.00 eq) was dissolved
in dry MeOH (20 mL). DMAP (61 mg, 0.5 mmol, 0.10 eq) and DCC (1.13 g, 5.5 mmol,
1.1 eq) were seperately dissolved in dry MeOH (20 mL) and subsequently added
dropwise to the reaction mixture. The solution was stirred for 2 d at rt under nitrogen
atmosphere before the white precipitate, which had formed, was filtered of and washed
with DCM (3 × 20 mL). The solvent was then removed under reduced pressure and the
residue was purified via flash column chromatography (pentane/EtOAc = 1:10 v/v) to ob-
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tain the product Boc-β3-d-hasp(OMe)-OBzl (1.38 g, 3.9 mmol, 78 %) as a colourless solid.
TLC (pentane/EtOAc = 1:10 v/v): Rf=0.36.
1H-NMR (300 MHz, DMSO-d6 ): δ (ppm) = 1.36 (s, 9H, Boc-CH3), 2.60–2.44 (m,
signal overlayed with solvent signal, α-CH2, γ-CH2), 3.57 (s, 3H, Me-CH3), 4.28–4.09 (m,
1H, β-CH), 5.07 (s, 2H, Bzl-CH2), 6.86 (d, 3JH,H = 8.5 Hz, 1H, NH), 7.41–7.27 (m, 5H,
Bzl-CH).
13C-NMR (151 MHz, DMSO-d6 ): δ (ppm) = 28.10, 38.77, 38.83, 44.84, 51.28, 65.54,
77.82, 127.77, 127.88, 128.30, 136.03, 154.66, 170.29, 170.85.
ESI-MS (m/z): 352.2 [M+H]+, 374.2 [M+Na]+, 350.2 [M-H]-
HR-MS (ESI): calc. for [C18H26NO6] ([M+H]+,): 352.1755, found: 352.1748; calc. for














Pd/C (10 wt.%, cat.) was suspended in MeOH (15 mL) and Boc-β3-d-hasp(OMe)-OBzl
(1,38 g, 3.9 mmol, 1.00 eq) dissolved in MeOH (15 mL) was added. The mixture was
degassed by alternatingly placing it under reduced pressure and passing nitrogen gas
into the flask several times. Then, the solution was placed under hydrogen atmosphere
and stirred for 3 d at rt. Afterwards, Pd/C was filtered off via celite and washed with
MeOH (3 × 5 mL). The solvent was removed under reduced pressure and the prod-
uct Boc-β3-d-hasp(OMe)-OH (1.00 g, 3.8 mmol, 98 %) was acquired as a light yellow solid.
1H-NMR (300 MHz, CDCl3): δ (ppm) = 1.42 (s, 9H, Boc-CH3), 2.82–2.50 (m,
4H, α-CH2), 3.83 (γ-CH2), 3.67 (s, 3H, Me-CH3), 4.39–4.16 (m, 1H, β-CH), 5.41 (d, 3JH,H
= 9.1 Hz, 1H, NH), 9.70 (sbr, 1H, COOH).




ESI-MS (m/z): 284.1 [M+Na]+, 260.1 [M-H]-.
HR-MS (ESI): calc. for [C11H19NO6Na] ([M+Na]+): 284.1105, found: 284.1107; calc.




















Under argon atmosphere, Boc-l-Asp(OBzl)-OH (1.78 g, 5.5 mmol, 1.10 eq) and tetrade-
canol (1.07 g, 5.0 mmol, 1.00 eq) were dissolved in dry DCM (20 mL). DMAP (61 mg,
0.5 mmol, 0.10 eq) dissolved in dry DCM (20 mL) was added to the reaction mixture.
Then, DCC (1.13 g, 5.5 mmol, 1.10 eq) dissolved in dry DCM (20 mL) was added dropwise
and the solution was stirred for 3 d at rt. Afterwards, the formed precipitate was filtered
off and washed with DCM (2 × 20 mL). The solvent was removed under reduced pressure
and the residue was directly adsorbed on to silica gel for a subsequent purification
via flash column chromatography (pentane/EtOAc = 10:1 v/v). The product Boc-
β
3-d-asp(OC14)-OBzl (2.21 g, 4.25 mmol, 85 %) could be obtained as a yellow waxy solid.
TLC (pentane/EtOAc = 10:1 v/v): Rf=0.47.
1H-NMR (300 MHz, DMSO-d6 ): δ (ppm) = 0.91–0.80 (m, 3H, 14-CH3), 1.33–1.13
(m, 22H, 3–13-CH2), 1.38 (s, 9H, Boc-CH3), 1.57–1.44 (m, 2H, 2-CH2), 2.88–2.68 (m,
2H, α-CH2), 4.00 (t, 3JH,H = 6.4 Hz, 2H, 1-CH2), 4.47–4.32 (m, 1H, β-CH), 5.10 (s, 2H,
Bzl-CH2), 7.24 (d, 3JH,H = 8.3 Hz, 1H, NH), 7.41–7.28 (m, 5H, Bzl-CH).
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13C-NMR (126 MHz, DMSO-d6 ): δ (ppm) = 13.80, 22.00, 25.18, 27.89, 28.56, 28.62,
28.83, 28.86, 28.93, 28.93, 28.96, 31.21, 35.83, 50.06, 64.57, 65.62, 78.20, 127.53, 127.70,
128.08, 135.68, 154.85, 169.54, 170.73.
ESI-MS (m/z): 542.3 [M+Na]+, 518.3 [M-H]-.
HR-MS (ESI): calc. for [C30H49NO6Na] ([M+Na]+): 542.3452, found: 542.3454; calc.












Pd/C (10 wt.%, cat.) was suspended in MeOH (25 mL) and Boc-β3-d-asp(OC14)-OBzl
(2.21 g, 4.29 mmol, 1.00 eq) dissolved in MeOH (50 mL) was added. The mixture was
degassed by subsequently applying reduced pressure and nitrogen gas several times.
Afterwards, the solution was placed under hydrogen atmosphere and stirred overnight
at rt. The Pd/C was filtered off via celite which was subsequently washed with MeOH
(3 × 10 mL). The solvent was removed under reduced pressure to yield the product
Boc-β3-d-asp(OC14)-OH (1.80 g, 4.2 mmol, 98 %) as a yellow waxy solid.
1H-NMR (300 MHz, DMSO-d6 ): δ (ppm) = 0.93–0.78 (m, 3H, 14-CH3), 1.33–
1.15 (m, 22H, 3–13-CH2), 1.38 (s, 9H, Boc-CH3), 1.60–1.48 (m, 2H, 2-CH2), 2.73–2.52
(m, 2H, α-CH2), 4.02 (t, 3JH,H = 6.4 Hz, 2H, 1-CH2), 4.36–4.25 (m, 1H, β-CH), 7.13 (d,
3JH,H = 8.3 Hz, 1H, NH), 12.33 (sbr, 1H, COOH).
13C-NMR (126 MHz, DMSO-d6 ): δ (ppm) = 13.82, 21.98, 25.17, 28.01, 28.54, 28.58,
28.81, 28.85, 28.89, 28.91, 28.93, 31.18, 35.83, 50.13, 64.45, 78.12, 154.86, 171.01, 171.20.
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ESI-MS (m/z): 452.3 [M+Na]+, 428.3 [M-H]-.
HR-MS (ESI): calc. for [C23H43NO6Na] ([M+Na]+): 452.2983, found: 452.2984; calco
for [C23H42NO6] ([M-H]-): 428.3018, found: 428.3021.
(R)-4-(tert-Butoxycarbonyl-amino)-6-diazo-5-oxohexanoic allyl










Under argon atmosphere, Boc-D-glu(OAll)-OH (3.76 g, 13.1 mmol, 1.00 eq) was dissolved
in dry THF (40 mL) and cooled to -10 ℃. NEt3 (2.00 mL, 14.5 mmol, 1.10 eq) and
isobutylchloroformiate (1.88 mL, 14.5 mmol, 1.10 eq) were consecutively added before
the solution was stirred for 1 h at -10 ℃. Then, the solution was allowed to warm up to
0 ℃ and diazomethane (0.85 M in ether, 31.00 mL, 26.2 mmol, 2.00 eq) was added under
light exclusion. After the reaction mixture was stirred for 3 h at rt, excess diazomethane
was quenched with acetic acid (3 mL) and Et2O (80 mL) was added. The solution was
washed with sat. aq. solutions of NaHCO3 (3 × 50 mL), NH4Cl (2 × 50 mL) and NaCl
(1 × 50 mL), dried over MgSO4 and the solvent was removed under reduced pressure.
The product Boc-d-glu(OAll)-N2 (4.08 g, 13.1 mmol, quant.) was obtained as a yellow
oil and used without further purification.
ESI-MS (m/z): 312.2 [M+H]+, 334.1 [M+Na]+.
HR-MS (ESI): calc. for [C14H22N3O5] ([M+H]+): 312.1554, found: 312.1551; calc. for

















Boc-d-glu(OAll)-N2 (4.08 g, 13.1 mmol, 1.00 eq) was dissolved in THF/H2O (7:3 v/v,
60 mL). Silver benzoate (0.30 g, 1.3 mmol, 0.10 eq) was added before the reaction was
irradiated by microwave irradiation (55 s, 460 W). Afterwards, EtOAc (100 mL) and
H2O (50 mL) were added and the pH of the solution was adjusted to pH = 2 with 2 M
HCl. The organic phase was washed with sat. aq. NaCl-solution (3 × 50 mL), dried
over MgSO4 and the solvent was removed under reduced pressure. The residue was
dissolved in DCM (5 mL) and added dropwise to cold pentane (-20 ℃). The resulting
precipitate was filtered off, washed with cold pentane (3 × 50 mL) and dried overnight
under reduced pressure yielding the product Boc-d-glu(OAll)-OH (2.30 g, 7.6 mmol,
58 %) as a colourless solid.
1H-NMR (300 MHz, DMSO-d6 ): δ (ppm) = 1.37 (s, 9H, Boc-CH3), 1.81–1.52
(m, 2H, γ-CH2), 2.42–2.22 (m, 4H, α-CH2, δ-CH2), 3.74 (dt, 3JH,H = 12.6, 9.0 Hz, 1H,
β-CH2), 4.53 (dt, 3JH,H = 5.4, 1.5 Hz, 2H, 1-CH2), 5.34–5.15 (m, 2H, 3-CH2), 5.99–5.82
(m, 1H, 2-CH), 6.66 (d, 3JH,H = 8.8 Hz, 1H, NH), 12.10 (sbr, 1H, COOH).
13C-NMR (126 MHz, DMSO-d6 ): δ (ppm) = 28.14, 29.40, 30.10, 46.75, 64.14, 77.45,
117.32, 132.54, 154.80, 171.89, 171.99.
ESI-MS (m/z): 324.1 [M+Na]+, 300.1 [M-H]-.
HR-MS (ESI): calc. for [C14H23NO6Na] ([M+Na]+): 324.1418, found: 324.1418; calc.
for [C14H22NO6] ([M-H]-): 300.1453, found: 300.1455.
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Under argon atmosphere, Boc-β-Ala-OH (2.08 g, 11.0 mmol, 1.10 eq) and cholesterol
(3.87 g, 10.0 mmol, 1.00 eq) were dissolved in dry DCM (40 mL). DMAP (0.12 g,
1.0 mmol, 0.10 eq) was separately dissolved in dry DCM (40 mL) and added to the
reaction mixture. Afterwards, DCC (2.27 g, 11.0 mmol, 1.10 eq) was also separately
dissolved in dry DCM (40 mL) and added dropwise to the reaction mixture. The
solution was stirred for 3 d at rt, before the formed precipitate was filtered of, washed
with DCM (2 × 20 mL) and discarded. The solvent of the filtrate was removed under
reduced pressure and the residue was directly adsorbed on to silica gel for a subsequent
purification via flash column chromatography (pentane/EtOAc = 10:1 v/v). The product
Boc-β-Ala-OChol (3.55 g, 6.4 mmol, 64 %) was acquired as a yellow waxy solid.
TLC (pentane/EtOAc = 10:1 v/v): Rf=0.46.
1H-NMR (300 MHz, CDCl3): δ (ppm) = 0.67 (s, 3H, 18-CH3), 0.85 (dd, 3JH,H = 6.6,
1.3 Hz, 6H, 26-CH3, 27-CH3), 0.90 (d, 3JH,H = 6.5 Hz, 3H, 21-CH3), 1.69–0.93 (m, 32H,
Boc-CH3, 19-CH3, 1-CH2, 2-CH2, 8-CH, 9-CH, 11-CH2, 12-CH2, 14-CH, Chol-17-CH,
20-CH, 22–25-CH2), 2.07–1.75 (m, 6H, 7-CH2, 15-CH2, 16-CH2), 2.35–2.25 (m, 2H,
4-CH2), 2.48 (t, 3JH,H = 6.1 Hz, 2H, α-CH2), 3.37 (q, 3JH,H = 6.1 Hz, 2H, β-CH2),
4.69–4.54 (m, 1H, 3-CH), 5.08–4.96 (m, 1H, NH), 5.40–5.32 (m, 1H, 6-CH).
13C-NMR (126 MHz, CDCl3): δ (ppm) = 12.09, 18.94, 19.51, 21.25, 22.77, 23.02, 24.05,
24.49, 27.99, 28.20, 28.42, 28.60, 32.06, 32.10, 35.10, 35.98, 36.38, 36.78, 37.16, 38.31,
39.71, 39.92, 42.50, 50.21, 56.32, 56.86, 74.45, 79.38, 122.79, 139.56, 155.76, 171.82.
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ESI-MS (m/z): 580.4 [M+Na]+.










Boc-β-Ala-OChol (3.55 g, 6.4 mmol, 1.00 eq) was dissolved in DCM (50 mL) and TFA
(10 mL, 130.7 mmol, 1.49 eq) was added dropwise. The solution was stirred for 1 h at
rt. Afterwards, the solution was concentrated under a nitrogen stream and coevaporated
with toluene (3 × 40 mL). The residue was dissolved in dioxane (80 mL), frozen in liquid
nitrogen and lyophilized to yield the product H-β-Ala-OChol (2.91 g, 6.4 mmol, quant.)
as a colourless solid.
1H-NMR (300 MHz, CDCl3): δ (ppm) = 0.68 (s, 3H, 18-CH3), 0.87 (dd, 3JH,H
= 6.6, 1.3 Hz, 6H, 26-CH3, 27-CH3), 0.92 (d, 3JH,H = 6.4 Hz, 3H, 21-CH3), 1.73–0.95
(m, 23H, 19-CH3, 1-CH2, 2-CH2, 8-CH, 9-CH, 11-CH2, 12-CH2, 14-CH, 17-CH, 20-CH,
22–25-CH2), 2.17–1.73 (m, 6H, 7-CH2, 15-CH2, 16-CH2), 2.37–2.25 (m, 2H, 4-CH2), 2.73
(t, 3JH,H = 6.1 Hz, 2H, α-CH2), 3.29–3.16 (m, 2H, β-CH2), 4.70–4.54 (m, 1H, 3-CH), 5.36
(d, 3JH,H = 4.9 Hz, 1H, 6-CH), 8.13 (s, 2H, NH2).
13C-NMR (126 MHz, CDCl3): δ (ppm) = 12.12, 18.99, 19.50, 21.30, 22.80, 23.05, 24.18,
24.54, 27.77, 28.24, 28.48, 31.31, 32.09, 32.15, 35.81, 36.06, 36.45, 36.78, 37.12, 38.06,
39.74, 39.98, 42.55, 50.22, 56.46, 56.91, 75.61, 122.99, 139.36, 171.06.
ESI-MS (m/z): 458.4 [M+H]+.



















Under nitrogen atmosphere, Boc-β3-d-asp-OBzl (1.54 g, 4.8 mmol, 1.50 eq) was dissolved
in dry DCM (20 mL) and cooled to 0 ℃. HATU (1.81 g, 4.8 mmol, 1.50 eq) and DIPEA
(1.94 mL, 11.2 mmol, 3.50 eq) were added and the reaction mixture was stirred for
30 min at 0 ℃. Afterwards, H-β-Ala-OChol (1.45 g, 3.2 mmol, 1.00 eq) dissolved in dry
DCM (20 mL) was added dropwise and the solution was stirred for 1 h at 0 ℃. Then, the
solution was allowed to come to rt and stirred for 24 h. The solvent was removed under
reduced pressure, the residue was dissolved in EtOAc (50 mL) and washed with a 1 M
aq. KHSO4-solution (2 × 30 mL), sat. aq. solutions of NaHCO3 (2 × 20 mL) and NaCl
(2 × 20 mL). The organic phase was then dried over MgSO4, the solvent was removed
under reduced pressure and the residue was purified via flash column chromatography
(pentane/EtOAc = 1:10 v/v). The product Boc-β3-d-asp(OβAla-OChol)-OBzl (2.29 g,
3.0 mmol, 95 %) was obtained as a yellow solid.
TLC (pentane/EtOAc = 1:1 v/v): Rf=0.78.
1H-NMR (300 MHz, CDCl3): δ (ppm) = 0.67 (s, 3H, 18-CH3), 0.86 (dd, 3JH,H = 6.6,
1.3 Hz, 6H, 26-CH3, 27-CH3), 0.91 (d, 3JH,H = 6.5 Hz, 3H, 21-CH3), 1.66–0.94 (m, 32H,
Boc-CH3, 19-CH3, 1-CH2, 2-CH2, 8-CH, 9-CH, 11-CH2, 12-CH2, 14-CH, 17-CH, 20-CH,
22–25-CH2), 2.07–1.73 (m, 6H, 7-CH2, 15-CH2, 16-CH2), 2.32 (d, 3JH,H = 8.1 Hz, 2H,
4-CH2), 2.47 (t, 3JH,H = 6.1 Hz, 2H, Alaα-CH2), 3.12–2.63 (m, 2H, Aspα-CH2), 3.49 (q,
3JH,H = 6.1 Hz, 2H, Alaβ-CH2), 4.48 (s, 1H, Aspβ-CH2), 4.69–4.56 (m, 1H, 3-CH), 5.12
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(d, 3JH,H = 3.0 Hz, 2H, Bzl-CH2), 5.40–5.33 (m, 1H, 6-CH), 5.62 (d, 3JH,H = 8.8 Hz, 1H,
Asp-NH), 6.94 (t, 3JH,H = 6.2 Hz, 1H, Ala-NH), 7.40–7.27 (m, 4H, Bzl-CHar).
13C-NMR (126 MHz, CDCl3): δ (ppm) = 12.07, 18.92, 19.50, 21.23, 22.76, 23.01, 24.02,
24.47, 27.94, 28.19, 28.41, 28.47, 32.03, 32.08, 34.39, 35.28, 35.96, 36.36, 36.76, 37.13,
38.25, 39.69, 39.91, 42.48, 50.18, 50.83, 56.30, 56.84, 66.91, 74.56, 80.56, 122.79, 128.26,
128.39, 128.62, 135.43, 139.54, 155.41, 170.55, 171.45, 171.62.
ESI-MS (m/z): 763.5 [M+H]+, 785.5 [M+Na]+.
HR-MS (ESI): calc. for [C46H71N2O7] ([M+H]+): 763.5256, found: 763.5243; calc. for

















Pd/C (10 wt.%, cat.) was suspended in MeOH (15 mL). Boc-β3-d-asp(OβAla-OChol)-
OBzl (2.29 g, 3.0 mmol, 1.00 eq) dissolved in MeOH (35 mL) was added. The solution
was degassed by alternatingly putting it under reduced pressure and passing nitrogen
gas into the flask several times, before it was placed under hydrogen atmosphere stirred
for 20 min at rt. Afterwards, Pd/C was filtered off with a syringe filter and washed
with MeOH (3 × 5 mL). The solvent was removed under reduced pressure, yielding the
product Boc-β3-d-asp(OβAla-OChol)-OH (1.98 g, 2.9 mmol, 98 %) as a yellow waxy solid.
1H-NMR (300 MHz, CDCl3): δ (ppm) = 0.67 (s, 3H, 18-CH3), 0.85 (dd, 3JH,H
= 6.6, 1.4 Hz, 6H,26-CH3, 27-CH3), 0.90 (d, 3JH,H = 6.4 Hz, 3H, 21-CH3), 2.05–0.93
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(m, 38H, Boc-CH3, 19-CH3,1-CH2, 2-CH2, 7–9-CH, 11-CH2, 12-CH2, 14–17-CH, 20-CH,
22–25-CH2), 2.30 (d, 3JH,H = 8.1 Hz, 2H, 4-CH2), 2.51 (t, 3JH,H = 6.2 Hz, 2H, Alaα-CH2),
3.007–2.652 (m, 2H, Aspα-CH2), 3.57–3.45 (m, 2H, Alaβ-CH2), 4.50 (s, 1H, Aspβ-CH2),
4.68–4.54 (m, 1H, 3-CH), 5.40–5.30 (m, 1H, 6-CH), 5.79 (d, 3JH,H = 8.9 Hz, 1H, Asp-NH),
7.24–7.12 (m, 1H, Ala-NH), 7.82 (sbr, 1H, COOH).
13C-NMR (126 MHz, CDCl3): δ (ppm) = 12.08, 18.94, 19.50, 21.25, 22.77, 23.02, 24.07,
24.49, 27.90, 28.20, 28.42, 28.47, 32.04, 32.10, 34.30, 35.48, 35.98, 36.39, 36.47, 36.76,
37.14, 38.20, 39.70, 39.92, 42.50, 50.19, 50.77, 56.34, 56.86, 74.79, 80.84, 122.83, 139.51,
155.71, 171.39, 171.76, 174.61.
ESI-MS (m/z): 673.5 [M+H]+, 695.5 [M+Na]+, 671.5 [M-H]-.
HR-MS (ESI): calc. for [C39H65N2O7] ([M+H]+): 673.4786, found: 673.4781; calc.
for [C39H64N2O7Na] ([M+Na]+): 695.4606, found: 695.4605; calc. for [C39H63N2O7]
([M-H]-): 671.4641, found: 671.4642.








Cholesterol (9.70 g, 25.0 mmol, 1.00 eq) was dissolved in DCM (150 mL). 18-Crown-6
(0.70 g, 2.5 mmol, 0.10 eq) was added, followed by KOH solution (40 % w/w in H2O,
10 mL). The solution was cooled down to 0 ℃ and acrylonitrile (8.2 mL, 125 mmol,
5.00 eq) was added dropwise. The reaction mixture was stirred overnight at rt. After-
wards, the solvent was removed under reduced pressure. The residue was taken up in
hexane (150 mL) and washed with H2O (2 × 50 mL) as well as sat. aq. NaCl-solution (1
× 50 mL). The organic phase was dried over MgSO4 and the solvent was removed under
reduced pressure. The product cyanoethyl-O-cholesteryl ether (10.99 g, 25.0 mmol,
quant.) was obtained as a light yellow waxy solid.
TLC (CHCl3): Rf=0.39.
1H-NMR (400 MHz, CDCl3): δ (ppm) = 0.67 (s, 3H, 18-CH3), 0.86 (dd, 3JH,H =
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6.6, 1.8 Hz, 6H, 26-CH3, 27-CH3), 0.91 (d, 3JH,H = 6.6 Hz, 3H, 21-CH3), 2.04–0.94 (m,
29H, 19-CH3, 1-CH2, 2-CH2, 7–9-CH, 11-CH2, 12-CH2, 14–17-CH, 20-CH, 22–25-CH2),
2.40–2.13 (m, 2H, 4-CH2), 2.57 (t, 3JH,H = 6.5 Hz, 2H, Acryl2-CH2), 3.28–3.14 (m, 1H,
3-CH), 3.73–3.64 (m, 2H, Acryl3-CH2), 5.41–5.29 (m, 1H, 6-CH).
13C-NMR (100 MHz, CDCl3): δ (ppm) = 12.00, 18.86, 19.47, 19.49, 21.21, 22.70, 22.96,
23.97, 24.43, 28.15, 28.37, 28.39, 32.02, 32.07, 35.92, 36.33, 36.97, 37.23, 39.04, 39.66,
39.92, 42.46, 50.30, 56.31, 56.90, 62.81, 79.91, 118.10, 122.12, 140.54.
ESI-MS (m/z): 462.4 [M+Na]+.
HR-MS (ESI): calc. for [C30H49NONa] ([M+Na]+): 462.3706, found: 462.3694.











Under argon atmosphere, NiCl2·6H2O (11.90 g, 50.0 mmol, 2.00 eq) was dissolved in
dry MeOH (100 mL). Cyanoethyl-O-cholesteryl ether (10.99 g, 25.0 mmol, 1.00 eq)
was dissolved in dry DCM (50 mL) and added with Boc2O (16.05 mL, 75.0 mmol,
3.00 eq) to the reaction solution. The solution was stirred for 10 min at rt before NaBH4
(9.50 g, 250.0 mmol, 10.00 eq) was added in small portions within 30 min. Then, the
reaction mixture was stirred for 3 h at rt. Afterwards, the black sludge was filtered off
and washed with MeOH (3 × 10 mL). Hexane (50 mL) was added for and the hexane
phase was isolated. Extraction with hexane (50 mL) was repeated three more times.
Then, the combined hexane phases were dried over MgSO4, silica gel was added and the
solvent was removed under reduced pressure adsorbing the residue directly on silica gel
for purification via flash column chromatography (pentane:EtOAc = 10:1 v/v). Due to
mixed fractions, a second flash column chromatography (pentane:EtOAc = 10:1 v/v) was
performed yielding the product 3-tert-butoxycarbonyl-aminopropyl-O-cholesteryl ether
(6.80 g, 12.5 mmol, 50 %) as a colourless solid.
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TLC (pentane/EtOAc = 10:1 v/v): Rf=0.31.
1H-NMR (300 MHz, CDCl3): δ (ppm) = 0.67 (s, 3H, 18-CH3), 0.86 (dd, 3JH,H = 6.6,
1.3 Hz, 6H, 26-CH3, 27-CH3), 0.91 (d, 3JH,H = 6.5 Hz, 3H, 21-CH3), 2.08–0.94 (m, 40H,
Boc-CH3, 19-CH3, 1-CH2, 2-CH2, 7–9-CH, 11-CH2, 12-CH2, 14–17-CH, 20-CH, 22–25-
CH2, Alkyl2-CH2), 2.39–2.12 (m, 2H, 4-CH2), 3.27–3.06 (m, 3H, 3-CH, Alkyl3-CH2),
3.53 (t, 3JH,H = 6.0 Hz, 2H, Alkyl1-CH2), 4.91 (sbr, 1H, NH), 5.38–5.29 (m, 1H, 6-CH).
13C-NMR (126 MHz, CDCl3): δ (ppm) = 12.11, 18.96, 19.61, 21.31, 22.79, 23.04, 24.07,
24.52, 28.23, 28.45, 28.62, 28.67, 30.27, 32.13, 32.17, 36.00, 36.41, 37.10, 37.44, 39.12,
39.31, 39.73, 40.01, 42.53, 50.41, 56.36, 56.97, 66.47, 79.04, 79.31, 121.66, 140.94, 156.02.
ESI-MS (m/z): 544.5 [M+H]+, 566.5 [M+Na]+.
HR-MS (ESI): calc. for [C35H62NO3] ([M+H]+): 544.4724, found: 544.4723; calc. for
[C35H61NO3Na] ([M+Na]+): 566.4544, found: 566.4540.








3-tert-butoxycarbonyl-aminopropyl-O-cholesteryl ether (6.80 g, 12.5 mmol, 1.00 eq)
was dissolved in DCM (40 mL). TFA (10.50 mL, 136.0 mmol, 20.00 eq) was added
dropwise and the reaction mixture was stirred for 2 h at rt. Afterwards, the solution
was concentrated under a nitrogen stream and coevaporated with toluene (3 × 30 mL).
The residue was dissolved in dioxane (120 mL), frozen in liquid nitrogen and lyophilized
to obtain the product 3-aminopropyl-O-cholesterol ether (3.10 g, 7.0 mmol, 56 %) as a
colourless solid.
1H-NMR (300 MHz, CDCl3): δ (ppm) = 0.67 (s, 3H, 18-CH3), 0.86 (dd, 3JH,H
= 6.6, 1.3 Hz, 6H, 26-CH3, 27-CH3), 0.91 (d, 3JH,H = 6.5 Hz, 3H, 21-CH3), 1.69–0.95
(m, 23H, 19-CH3, 1-CH2, 2-CH2, 8-CH, 9-CH, 11-CH2, 12-CH2, 14-CH, 17-CH, 20-CH,
22–25-CH2), 2.13–1.69 (m, 8H, 7-CH2, 15-CH2, 16-CH2, Alkyl2-CH2), 2.38–2.13 (m, 2H,
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4-CH2), 3.24–3.03 (m, 3H, 3-CH, Alkyl3-CH2), 3.72–3.56 (m, 2H, Alkyl1-CH2), 5.39–5.26
(m, 1H, 6-CH), 7.99 (sbr, 2H, NH2).
13C-NMR (126 MHz, CDCl3): δ (ppm) = 12.12, 18.98, 19.51, 21.32, 22.79, 23.04, 24.10,
24.53, 27.13, 28.24, 28.40, 28.46, 32.10, 32.16, 36.01, 36.42, 37.01, 37.29, 38.98, 39.74,
39.90, 40.00, 42.54, 50.36, 56.39, 56.95, 67.24, 80.09, 122.09, 140.31.
ESI-MS (m/z): 444.4 [M+H]+.
HR-MS (ESI): calc. for [C30H54NO] ([M+H]+): 444.4200, found: 444.4199.








Commercially available cholesterol (3.86 g, 10.0 mmol, 1.00 eq) was dissolved in dry
DCM (40 mL) under argon atmosphere and cooled to 4 ℃. NEt3 (2.08 mL, 15.0 mmol,
1.50 eq, dried over molecular sieve 3 Å) was added. Methanesulfonyl chloride (1.20 g,
10.5 mmol, 1.05 eq) was dissolved in dry DCM (4 mL) and slowly added dropwise. Then,
the solution was stirred for 30 min at 4 ℃ and allowed to warm up to rt overnight.
Afterwards, the solvent was removed under reduced pressure. The residue was dissolved
in DCM (5 mL) and recrystallized by addition of MeOH (500 mL). The solid was filtered
of, washed with MeOH (5 mL) and the filtrate was recrystallized a second time. The
solid was dried under reduced pressure overnight yielding the product cholest-5-en-3-yl
mesylate (4.00 g, 8.6 mmol, 86 %) as a colourless solid.
TLC (pentane/EtOAc = 5:1 v/v): Rf=0.54.
1H-NMR (300 MHz, CDCl3): δ (ppm) = 0.67 (s, 3H, 18-CH3), 0.86 (dd, 3JH,H = 6.6,
1.3 Hz, 6H, 26-CH3, 27-CH3), 0.91 (d, 3JH,H = 6.5 Hz, 3H, 21-CH3), 2.60–0.94 (m, 31H,
19-CH3, 1-CH2, 2-CH2, 4-CH2, 7–9-CH, 11-CH2, 12-CH2, 14–17-CH, 20-CH, 22–25-CH2),
3.00 (s, 3H, S-CH3), 4.58–4.44 (m, 1H, 3-CH), 5.51–5.38 (m, 1H, 6-CH).
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13C-NMR (126 MHz, CDCl3): δ (ppm) = 12.08, 18.94, 19.41, 21.25, 22.77, 23.02, 24.04,
24.47, 28.21, 28.41, 29.19, 31.99, 32.08, 35.97, 36.38, 36.58, 37.11, 38.95, 39.37, 39.70,
39.86, 42.50, 50.13, 56.31, 56.80, 82.14, 123.85, 138.70.
ESI-MS (m/z): 482.4 [M+NH4]+, 487.3 [M+Na]+.
HR-MS (ESI): calc. for [C28H52NO3S] ([M+NH4]+): 482.3662, found: 482.3652; calc.








Under argon atmosphere, cholest-5-en-3-yl mesylate (2.70 g, 5.8 mmol, 1.00 eq) was
dissolved in dry DCM (15 mL). Trimethylsilyl azide (0.84 mL, 6.38 mmol, 1.10 eq)
and boron trifluoride etherate (1.47 mL, 11.6 mmol, 2.00 eq) were consecutively added
dropwise and the reaction mixture was stirred for 3 h at rt. Then, 2 M aq. NaOH-solution
(15 mL) was added and the reaction mixture was further stirred for 5 min at rt. After-
wards, the organic phase was isolated and the aqueous phase was extracted with DCM
(2 × 10 mL). The combined organic phases were washed with sat. aq. NaCl-solution (1
× 10 mL), dried over MgSO4 and the solvent was removed under reduced pressure. The
residue was dissolved in hexane (5 mL), filtered through a fritted glass funnel filled with
silica gel and the product was eluted with hexane with reduced pressure. The product
3β-azido-5-cholestene (1.80 g, 4.4 mmol, 75 %) was acquired as a colourless solid.
TLC (pentane/EtOAc = 5:1 v/v): Rf=0.91.
1H-NMR (400 MHz, CDCl3): δ (ppm) = 0.68 (s, 3H, 18-CH3), 0.87 (dd, 3JH,H =
6.6, 1.8 Hz, 6H, 26-CH3, 27-CH3), 0.91 (d, 3JH,H = 6.6 Hz, 3H, 21-CH3), 2.05–0.95 (m,
29H, 19-CH3, 1-CH2, 2-CH2, 7–9-CH, 11-CH2, 12-CH2, 14–17-CH, 20-CH, 22–25-CH2),
2.38–2.19 (m, 2H, 4-CH2), 3.26–3.15 (m, 1H, 3-CH), 5.46–5.30 (m, 1H, 6-CH).
13C-NMR (101 MHz, CDCl3): δ (ppm) = 12.01, 18.88, 19.44, 21.15, 22.72, 22.97, 23.99,
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24.43, 28.10, 28.17, 28.38, 31.97, 32.03, 35.94, 36.34, 36.77, 37.73, 38.31, 39.67, 39.88,
42.47, 50.26, 56.31, 56.88, 61.33, 122.69, 139.99.
EI-MS (m/z): 411.4 [M]+.
HR-MS (EI): calc. for [C27H45N3] ([M]+): 411.3613, found: 411.3622.







Under argon atmosphere, 3β-azido-5-cholestene (1.70 g, 4.1 mmol, 1.00 eq) was dissolved
in dry Et2O (35 mL) and cooled to 4 ℃. LiAlH4 (0.31 g, 8.2 mmol, 2.00 eq) was added
in five portions. The reaction mixture was stirred for 30 min at 4 ℃ and for 3 h at rt.
Afterwards, excess hydride was quenched by dropwise addition of icecold H2O until the
formation of H2-gas ceased. The solution was washed with icecold H2O (20 mL). Then,
the aqueous phase was extracted with EtOAc (2 × 20 mL) and the combined organic
phases were washed with sat. aq. NaCl-solution (1 × 20 mL). The organic phase was
dried over MgSO4 and the solvent was removed under reduced pressure. The product
cholesten-amine (0.40 g, 1.0 mmol, 25 %) was obtained as a colourless solid.
1H-NMR (400 MHz, CDCl3): δ (ppm) = 0.68 (s, 3H, 18-CH3), 0.87 (dd, 3JH,H
= 6.6, 1.8 Hz, 6H, 26-CH3, 27-CH3), 0.91 (d, 3JH,H = 6.6 Hz, 3H, 21-CH3), 1.63–0.94
(m, 25H, 19-CH3, 1-CH2, 2-CH2, 8-CH, 9-CH, 11-CH2, 12-CH2, 14-CH, 17-CH, 20-CH,
22–25-CH2), 2.09–1.71 (m, 6H, 7-CH2, 15-CH2, 16-CH2), 2.35–2.22 (m, 2H, 4-CH2),
3.28–3.09 (m, 1H, 3-CH), 5.43–5.33 (m, 1H, 6-CH).
13C-NMR (100 MHz, CDCl3): δ (ppm) = 12.01, 18.87, 19.44, 21.15, 22.72, 22.97, 23.99,
24.43, 28.10, 28.17, 28.37, 31.97, 32.03, 35.94, 36.34, 36.77, 37.73, 38.31, 39.67, 39.88,
42.46, 50.26, 56.31, 56.87, 61.32, 122.68, 139.99.
ESI-MS (m/z): 386.4 [M+H]+.
















Boc-β-Ala-OH (1.14 g, 6.0 mmol, 1.50 eq) and HATU (2.15 g, 5.6 mmol, 1.40 eq) were
dissolved in dry DCM (30 mL) and cooled to 0 ℃. First, DIPEA (2.46 mL, 14.1 mmol,
3.50 eq), then, cholesten-amine (1.56 g, 4.0 mmol, 1.00 eq) dissolved in dry DCM
(20 mL) were added and the solution was stirred for 1 h at 0 ℃. Afterwards, the
reaction mixture was stirred for 24 h at rt before the solvent was removed under reduced
pressure. The residue was adsorbed onto silica gel for subsequent purification by flash
column chromatography (hexane:EtOAc gradient from 8:2 to 6:4 v/v) and the product
Boc-β-Ala-NChol (1.62 g, 2.9 mmol, 72 %) was obtained as a colourless solid.
1H-NMR (300 MHz, CDCl3): δ (ppm) = 0.67 (s, 3H, 18-CH3), 0.86 (dd, 3JH,H
= 6.6, 1.4 Hz, 6H, 26-CH3, 27-CH3), 0.91 (d, 3JH,H = 6.5 Hz, 3H, 21-CH3), 1.74–0.93 (m,
32H, Boc-CH3, 19-CH3, 1-CH2, 2-CH2, 8-CH, 9-CH, 11-CH2, 12-CH2, 14-CH, 17-CH,
20-CH, 22–25-CH2), 2.54–1.75 (m, 10H, α-CH2, 4-CH2, 7-CH2, 15-CH2, 16-CH2), 3.38 (q,
3JH,H = 6.0 Hz, 2H, β-CH2), 3.77–3.57 (m, signal overlayed with solvent signal, 3-CH),
5.19 (s, 1H, Boc-NH), 5.40–5.29 (m, 1H, 6-CH), 5.71 (d, 3JH,H = 8.0 Hz, 1H, 3-NH).
13C-NMR (126 MHz, CDCl3): δ (ppm) = 12.10, 18.94, 19.56, 21.19, 22.78, 23.03, 24.05,
24.50, 28.22, 28.44, 28.63, 29.33, 32.05, 32.07, 36.00,36.39, 36.75, 36.90, 38.04, 39.46,
39.71,39.93, 42.49, 49.93, 50.26, 56.31, 56.86, 79.43, 122.05, 140.22, 156.21, 170.35.
ESI-MS (m/z): 557.5 [M+H]+, 579.5 [M+Na]+, 595.4 [M+K]+.
HR-MS (ESI): calc. for [C35H61N2O3] ([M+H]+): 557.4677, found: 557.4686; calc.
for [C35H60N2O3Na] ([M+Na]+): 579.4496, found: 576.4506; calc. for [C35H60N2O3Na]
([M+Na]+): 595.4236, found: 595.4237.
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Boc-β-Ala-NChol (1.62 g, 2.9 mmol, 1.00 eq) was dissolved in DCM (20 mL). TFA
(8.9 mL, 116.0 mmol, 40.00 eq) was added dropwise and the solution was stirred for
1 h at rt. Afterwards, the solution was concentrated under a nitrogen stream and the
residue was coevaporated with toluene (3 × 20 mL). The residue was dissolved in dioxane
(80 mL), frozen in liquid nitrogen and lyophilized to obtain the product H-β-Ala-Chol
(1.32 g, 2.9 mmol, quant.) as a white hygroscopic solid which was stored in the desiccator.
1H-NMR (300 MHz, CDCl3): δ (ppm) = 0.70 (s, 3H, 18-CH3), 0.88 (d, 3JH,H =
6.6 Hz, 6H, 26-CH3, 27-CH3), 0.94 (d, 3JH,H = 6.4 Hz, 3H, 21-CH3), 2.30–0.97 (m, 31H,
19-CH3, 1-CH2, 2-CH2, 4-CH2, 7-CH2, 8-CH, 9-CH, 11-CH2, 12-CH2, 14-CH, 15-CH2,
16-CH2, 17-CH, 20-CH, 22–25-CH2), 2.70–2.57 (m, 2H, α-CH2), 3.29–3.18 (m, 2H,
β-CH2), 3.67–3.49 (m, signal overlayed with dioxane signal, 3-CH), 5.32 (d, 3JH,H = 4.8
Hz, 1H, 6-CH), 6.89 (d, 3JH,H = 7.7 Hz, 1H, 3-NH), 8.10 (sbr, 2H, NH2).
13C-NMR (126 MHz, CDCl3): δ (ppm) = 12.18, 19.04, 19.58, 21.32, 22.80, 23.04, 24.34,
24.58, 28.21, 28.52, 28.68, 32.10, 32.54, 36.16, 36.52, 36.65, 36.74, 38.12, 38.84, 39.75,
40.12, 42.56, 50.27, 50.33, 56.62, 57.03, 121.80, 140.37, 16970.
ESI-MS (m/z): 456.4 [M+H]+.
HR-MS (ESI): calc. for [C30H53N2O] ([M+H]+): 457.4152, found: 457.4149.
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The peptide was synthesized on commercially available Boc-β-Ala-PAM resin (22.3 mg,
20 µmol, 1.00 eq, 0.9 mmol/g) following SOP2. After Fmoc-deprotection according to
SOP4, the free amine-group of the N -terminal β3-hlysine side chain was labelled with
7-nitrobenz-2-oxa-1,3-diazol-4-yl as described in SOP8. After washing the resin, it was
transferred to a screw top glass vial, dried under reduced pressure overnight and cleaved
following SOP9 to obtain the crude peptide as a brown solid. The crude peptide was
then purified by semi-preparative HPLC to yield peptide 56 (1.1 mg, 360 nmol) as an
orange solid.
HPLC (Semi-prep. (C18), solvents: standard-system, gradient: 20–30 % B in
30 min, λ in nm: 215, 254, 464): tR = 12.5 min.
ESI-MS (m/z): 615.7 [M+5H]5+, 769.4 [M+4H]4+, 1025.6 [M+3H]3+.
HR-MS (ESI): calc. for [C143H221N46O31] ([M+5H]5+): 615.7421, found: 615.7425; calc.
for [C143H220N46O31] ([M+4H]4+): 769.4258, found: 769.4260; calc. for [C143H219N46O31]








































































Peptide synthesis was performed on commercially available Boc-β-Ala-PAM resin




3-hlysine side chain was Fmoc-deprotected following SOP4, the free amino group was
labelled with 7-nitrobenz-2-oxa-1,3-diazol-4-yl following SOP8 and the washed resin was
transferred to a screw top glass vial. Then, the crude peptide was cleaved from the resin
as described in SOP9 and obtained as a brown solid. The crude product was purified
via semi-preparative HPLC yielding the peptide 57 (1.1 mg, 393 nmol) as an orange solid.
HPLC (Semi-prep. (C18), solvents: standard-system, gradient: 20–40 % B in
30 min, λ in nm: 215, 254, 464): tR = 12.5 min.
ESI-MS (m/z): 562.5 [M+5H]5+, 702.9 [M+4H]4+, 936.8 [M+3H]3+, 1404.7 [M+2H]2+.
HR-MS (ESI): calc. for [C129H191N48O25] ([M+5H]5+: 562.5025, found: 562.5020; calc.
for [C129H190N48O25] ([M+4H]4+: 702.8762, found: 702.8764; calc. for [C129H189N48O25]




























































































For this peptide, synthesis was conducted on commercially available Boc-β-Ala-PAM
resin (22.3 mg, 20 µmol, 1.00 eq, 0.9 mmol/g) following SOP2. Then, the amine-group
of the N -terminal β3-hlysine side chain was Fmoc-deprotected as described in SOP4
and the free amine-group was labelled with 7-nitrobenz-2-oxa-1,3-diazol-4-yl according
to SOP8. After washing, the resin was transferred to a screw top glas vial and
dried overnight under reduced pressure. Finally, cleavage was conducted as described
in SOP9 and the crude product was obtained as a brown solid. After purification by
semi-preparative HPLC, the peptide 54 (1.2 mg, 358 nmol) was yielded as an orange solid.
HPLC (Semi-prep. (C18), solvents: standard-system, gradient: 45–75 % B in
30 min, λ in nm: 215, 254, 464): tR = 11.5 min.




HR-MS (ESI): calc. for [C165H266N46O35] ([M+6H]6+): 575.3403, found: 575.3402; calc.
for [C165H265N46O35] ([M+5H]5+): 690.2069, found: 690.2072; calc. for [C165H264N46O35]
([M+4H]4+): 862.5068, found: 862.5078; calc. for [C165H263N46O35] ([M+3H]3+):














































































This peptide was synthesized according to SOP2 on commercially available Boc-β-Ala-
PAM resin (22.3 mg, 20 µmol, 1.00 eq, 0.9 mmol/g). The amine-group of the N -terminal
β
3-hlysine side chain was Fmoc-deprotected following SOP4, before the free amine-group
was labelled with 7-nitrobenz-2-oxa-1,3-diazol-4-yl as described in SOP8. Afterwards,
the washed resin was transferred to a screw top glass vial and cleavage according to
SOP9 was conducted, to obtain the crude peptide as a brown solid. Purification by
semi-preparative HPLC yielded the peptide 55 (1.3 mg, 420 nmol) as an orange solid.
HPLC (Semi-prep. (C4), solvents: standard-system, gradient: 30–70 % B in
30 min, λ in nm: 215, 254, 464): tR = 16.5 min.
ESI-MS (m/z): 637.0 [M+5H]5+, 796.9 [M+4H]4+, 1060.9 [M+3H]3+, 1590.9 [M+2H]2+.
HR-MS (ESI): calc. for [C151H235N48O29] ([M+5H]5+): 636.9672, found: 636.9671; calc.
for [C151H234N48O29] ([M+4H]4+): 795.9572, found: 795.9577; calc. for [C151H233N48O29]






























































The peptide was synthesized following a modified SOP3 on commercially available
Boc-β-Ala-PAM resin (18.8 mg, 15 µmol, 1.00 eq, 0.8 mmol/g). In the modified SPPS
protocol, Boc-deprotection was performed for 2 × 2 min, coupling was performed as a
single coupling for 1 h at 65 ℃ (35 W) with the reagents dissolved in DMF, the resin
was capped for 2 × 3 min and washing steps were performed with DMF/DCM (1:1 v/v,
3 × 2.0 ml), DMF/piperidine (95:5 v/v, 3 × 2.0 ml) and DMF (3 × 2.0 mL). After
SPPS, the washed resin was transferred to screw top glass vial and cleavage following
SOP9 was performed. The crude peptide obtained as an off-white solid was then puri-
fied by semi-preparative HPLC to yield the product 58 (1.6 mg, 670 nmol) as a white solid.
HPLC (Semi-prep. (C18), solvents: standard-system, gradient: 15–45 % B in
30 min, λ in nm: 215, 254, 280): tR = 13.1 min.
ESI-MS (m/z): 473.7 [M+5H]5+, 591.9 [M+4H]4+, 788.8 [M+3H]3+, 1182.7 [M+2H]2+.
HR-MS (ESI): calc. for [C113H195N32O23] ([M+5H]5+): 473.7009, found: 473.7028; calc.
for [C113H194N32O23] ([M+4H]4+): 591.8743, found: 591.8761; calc. for [C113H193N32O23]































































The peptide was synthesized on commercially available Boc-β-Ala-PAM resin (18.8 mg,
15 µmol, 1.00 eq, 0.8 mmol/g) following a modified SOP3. In the modified SPPS
protocol, coupling was performed with the reagents dissolved in DMF and as single
coupling for 45 min at 65 ℃ (35 W) for all building blocks except the nucleobase building
blocks which were coupled in double coupling steps. Afterwards, a 5 µmol fraction of the
resin was transferred to a PE-frit equipped syringe and Fmoc-deprotected as described in
SOP4. The resulting free amine-group of the N -terminal β3-hlysine side chain was then
acetylated according to SOP8. The washed resin was transferred to a screw top glass vial
and the peptide was cleaved following SOP9 to obtain the crude peptide as an off-white
solid. After purification by semi-preparative HPLC, the product 59 (1.2 mg, 494 nmol)
was yielded as a white solid.
HPLC (Semi-prep. (C18), solvents: standard-system, gradient: 20–40 % B in
30 min, λ in nm: 215, 254, 280): tR = 9.3 min.
ESI-MS (m/z): 482.1 [M+5H]5+, 602.4 [M+4H]4+, 802.8 [M+3H]3+.
HR-MS (ESI): calc. for [C115H197N32O24] ([M+5H]5+): 482.1030, found: 482.1028; calc.
for [C115H196N32O24] ([M+4H]4+): 602.3770, found: 602.3770; calc. for [C115H195N32O24]































































Synthesis for this peptide was performed as described for 59. After SPPS, a 5 µmol
fraction of the resin was transferred to a PE-frit equipped syringe and Fmoc-deprotection
following SOP4 was performed, before the free amine-group of the N -terminal β3-hlysine
side chain was labelled with 7-nitrobenz-2-oxa-1,3-diazol-4-yl according to SOP8. Then,
the washed resin was transferred to a screw top glass vial for cleavage as described
in SOP9 and the crude peptide was obtained as a brown solid. Purification by semi-
preparative HPLC yielded the peptide 60 (1.3 mg, 497 nmol) as an orange solid.
HPLC (Semi-prep. (C18), solvents: standard-system, gradient: 20–30 % B in
30 min, λ in nm: 215, 254, 464): tR = 21.9 min.
ESI-MS (m/z): 506.3 [M+5H]5+, 632.6 [M+4H]4+, 843.2 [M+3H]3+, 1264.2 [M+2H]2+.
HR-MS (ESI): calc. for [C119H196N35O26] ([M+5H]5+): 506.3013, found: 506.3015; calc.
for [C119H195N35O26] ([M+4H]4+): 632.6248, found:632.6250; calc. for [C119H194N35O26]




































































Peptide synthesis was performed as described for 59. A 5 µmol fraction of the resin
was transferred to a PE-frit equipped syringe, before Fmoc-deprotection following SOP4
was performed. Then, the free amine-group of the N -terminal β3-hlysine side chain was
labelled with 5-carboxyfluorescein according to SOP8. Afterwards, the washed resin was
transferred to a screw top glass vial for cleavage as described in SOP9 to obtain the
crude peptide as a brown solid. Purification by semi-preparative HPLC was performed
to yield the peptide 61 (0.3 mg, 121 nmol) as an orange solid.
HPLC (Semi-prep. (C18), solvents: standard-system, gradient: 15–45 % B in
30 min, λ in nm: 215, 254, 470): tR = 19.4 min.
ESI-MS (m/z): 545.3 [M+5H]5+, 681.4 [M+4H]4+, 908.2 [M+3H]3+.
HR-MS (ESI): calc. for [C134H205N32O29] ([M+5H]5+): 545.3105, found: 545.3109; calc.
for [C134H204N32O29] ([M+4H]4+): 681.3863, found: 681.3869; calc. for [C134H203N32O29]



































































Synthesis for this peptide was conducted as described for 59. Afterwards, a 5 µmol
fraction of the resin was transferred to a new PE-frit equipped syringe and the N -
terminal β3-hlysine side chain was Fmoc-deprotected according to SOP4. The resulting
free amine-group was labelled with 5(6)-carboxytetramethylrhodamine as described in
SOP8 and the washed resin was then transferred to a screw top glass vial for cleavage
following SOP9. The obtained crude peptide, which was a pink solid, was purified by
semi-preparative HPLC. Due to 5(6)-carboxytetramethylrhodamine being an isomer
mixture, the peptide eluted as a double peak. The corresponding fraction were combined
to yield the product 62 (0.9 mg, 331 nmol) as a pink solid. [182]
HPLC (Semi-prep. (C18), solvents: standard-system, gradient: 20–30 % B in
30 min, λ in nm: 215, 254, 540): tR1 = 23.0 min, tR2 = 25.4 min.
ESI-MS (m/z): 463.6 [M+6H]6+, 556.1 [M+5H]5+, 694.9 [M+4H]4+, 926.2 [M+3H]3+.
HR-MS (ESI): calc. for [C138H216N34O27] ([M+6H]6+): 463.6090, found: 463.6087; calc.
for [C138H215N34O27] ([M+5H]5+): 556.1294, found: 556.1289; calc. for [C138H214N34O27]






























































For this peptide, synthesis was conducted with commercially available Boc-β-Ala-PAM
resin (18.8 mg, 15 µmol, 1.00 eq, 0.8 mmol/g) with the same modified SOP3 as for
peptide 58. The washed resin was then transferred to a screw top glass vial for cleavage
following SOP9 to acquire the crude peptide as an off-white solid. After purification via
semi-preparative HPLC, the product 63 (4.6 mg, 1.92 µmol) was yielded as a white solid.
HPLC (Semi-prep. (C18), solvents: standard-system, gradient: 15–30 % B in
30 min, λ in nm: 215, 254, 280): tR = 16.9 min.
ESI-MS (m/z): 475.6 [M+5H]5+, 594.2 [M+4H]4+, 791.8 [M+3H]3+, 1187.2 [M+2H]2+.
HR-MS (ESI): calc. for [C113H194N35O219] ([M+5H]5+): 475.5032, found: 475.5053; calc.
for [C113H193N35O219] ([M+4H]4+): 594.1272, found: 594.1284; calc. for [C113H192N35C21]





























































Synthesis with commercially available Boc-β-Ala-PAM resin (18.8 mg, 15 µmol, 1.00 eq,
0.8 mmol/g) was performed with a modified SOP3, where coupling was conducted with
152
8.5. Syntheses
DMF as solvent and as single coupling for 45 min at 65 ℃ (35 W) for all building blocks
except for the nucleobase building blocks which were couplied in a double coupling step.
After SPPS, a 5 µmol fraction of the resin was transferred to a new PE-equipped syringe
for subsequent Fmoc-deprotection after SOP4 and acetylation of the free amine-group
at the N -terminal β3-hlysine side chain following SOP8. The washed resin was then
transferred to a screw top glass vial for cleavage according to SOP9 to obtain the crude
peptide as an off-white solid. Purification by semi-preparative HPLC yielded the product
64 (1.6 mg, 675 nmol) as a white solid.
HPLC (Semi-prep. (C18), solvents: standard-system, gradient: 20–30 % B in
30 min, λ in nm: 215, 254, 280): tR = 9.3 min.
ESI-MS (m/z): 483.9 [M+5H]5+, 604.6 [M+4H]4+, 805.8 [M+3H]3+.
HR-MS (ESI): calc. for [C115H196N35O22] ([M+5H]5+): 483.9053, found: 483.9055; calc.
for [C115H195N35O22] ([M+4H]4+): 604.6298, found: 604.6301; calc. for [C115H194N35O22]





























































Peptide synthesis was performed as described for 64, before a 5 µmol fraction of the resin
was transferred to a new PE-equipped syringe to conduct Fmoc-deprotection according
to SOP4. The resulting free amine-group of the N -terminal β3-hlysine side chain was then
labelled with 7-nitrobenz-2-oxa-1,3-diazol-4-yl following SOP8. The washed resin was
transferred to a screw top glass vial and the crude peptide was cleaved off as described
in SOP9 obtaining a brown solid. The crude peptide was purified by semi-preparative
HPLC to yield the product 65 (1.1 mg, 440 nmol) as an orange solid.
HPLC (Semi-prep. (C18), solvents: standard-system, gradient: 20–30 % B in
153
8. Experimental Part
30 min, λ in nm: 215, 254, 464): tR = 22.4 min.
ESI-MS (m/z): 508.1 [M+5H]5+, 634.9 [M+4H]4+, 846.2 [M+3H]3+.
HR-MS (ESI): calc. for [C119H195N38O24] ([M+5H]5+): 508.1036, found: 508.1038; calc.
for [C119H194N38O24] ([M+4H]4+): 634.8777, found: 634.8781; calc. for [C119H193N38O24]

































































For this peptide synthesis was conducted as for 64. Afterwards, a 5 µmol fraction of the
resin was transferred to a PE-frit equipped syringe and the Fmoc-protecting group of the
N -terminal β3-hlysine side chain was removed according to SOP4. The free amine-group
was then labelled with 5-carboxyfluorescein following SOP8. After washing, the resin
was transferred to a screw top glass vial for subsequent cleavage after SOP9 obtaining
the crude peptide as a brown solid. After purification via semi-preparative HPLC, the
product 66 (0.4 mg, 133 nmol) as an orange solid.
HPLC (Semi-prep. (C18), solvents: standard-system, gradient: 15–45 % B in
30 min, λ in nm: 215, 254, 470): tR = 19.3 min.
ESI-MS (m/z): 456.1 [M+6H]6+, 547.1 [M+5H]5+, 683.6 [M+4H]4+, 911.2 [M+3H]3+.
HR-MS (ESI): calc. for [C134H205N35O27] ([M+6H]6+): 456.0952, found: 456.0958; calc.
for [C134H204N35O27] ([M+5H]5+): 547.1128, found: 547.1132; calc. for [C134H203N35O27]




































































Synthesis for this peptide was conducted as described for 64. Then, a 5 µmol fraction
of the resin was transferred to a PE-frit equipped syringe and the N -terminal β3-hlysine
side chain was Fmoc-deprotected according to SOP4. The resulting free amine-group
was labelled with 5(6)-carboxytetramethylrhodamine as described in SOP8, before the
washed resin was transferred to a screw top glass vial for cleavage following SOP9. Then,
the obtained crude peptide, which was a pink solid, was purified by semi-preparative
HPLC. The peptide eluted as a double peak, due to 5(6)-carboxytetramethylrhodamine
being an isomer mixture. The fractions were combined to yield the product 67 (0.2 mg,
67 nmol) as a pink solid. [182]
HPLC (Semi-prep. (C18), solvents: standard-solvent, gradient: 20–30 % B in
30 min, λ in nm: 215, 254, 540): tR1 = 23.9 min, tR2 = 26.4 min.
ESI-MS (m/z): 465.1 [M+6H]6+, 557.9 [M+5H]5+, 697.2 [M+4H]4+, 929.2 [M+3H]3+.
HR-MS (ESI): calc. for [C138H215N37O25] ([M+6H]6+): 465.1109, found: 465.1103; calc.
for [C138H214N37O25] ([M+5H]5+): 557.9217, found: 557.9314; calc. for [C138H213N37O25]































































The peptide was synthesized with commercially available Boc-β-Ala-PAM resin (25.0 mg,
20 µmol, 1.00 eq, 0.8 mmol/g) by a modified SOP3. Coupling was performed in DMF
as solvent and except for nucleobase building blocks, all couplings were performed as
single couplings (45 min, 65 ℃, 35 W). For the next steps, a 5 µmol fraction of the
resin was transferred to a new syringe equipped with a PE-frit and Fmoc-deprotection
following SOP4 was performed, resulting in a free amine-group at the N -terminal
β
3-hlysine side chain. This amine-group was subsequently acetylated according to
SOP8 before the washed resin was transferred to a screw top glass vial for cleavage as
described in SOP9. The crude peptide was obtained as an off-white solid which was puri-
fied by semi-preparative HPLC to yield the peptide 68 (1.3 mg, 492 nmol) as a white solid.
HPLC (Semi-prep. (C18), solvents: standard-solvent, gradient: 30–40 % B in
30 min, λ in nm: 215, 254, 280): tR = 15.4 min.
ESI-MS (m/z): 515.7 [M+5H]5+, 644.4 [M+4H]4+, 858.9 [M+3H]3+.
HR-MS (ESI): calc. for [C127H221N32O24] ([M+5H]5+): 515.7406, found: 515.7400; calc.
for [C127H220N32O24] ([M+4H]4+): 644.4239, found: 644.4232; calc. for [C127H219N32O24]































































Synthesis for this peptide was performed as described for 68. For Fmoc-deprotection
following SOP4, a 5 µmol fraction of the resin was transferred to a new PE-equipped
syringe and the free amine-group of the N -terminal β3-hlysine side chain was labelled
with 7-nitrobenz-2-oxa-1,3-diazol-4-yl according to SOP8. Afterwards, the washed resin
was transferred to a screw top glass vial and cleavage was conducted following SOP9
obtaining the crude peptide as a brown solid. The crude product was purified by
semi-preparative HPLC yielding the peptide 69 (1.0 mg, 371 nmol) as an orange solid.
HPLC (Semi-prep. (C18), solvents: standard-system, gradient: 35–45 %, λ in
nm: 215, 254, 464): tR = 11.1 min.
ESI-MS (m/z): 539.9 [M+5H]5+, 674.7 [M+4H]4+, 899.2 [M+3H]3+.
HR-MS (ESI): calc. for [C131H220N35O26] ([M+5H]5+): 539.9388, found: 539.9386; calc.
for [C131H219N35O26] ([M+4H]4+): 674.6717, found: 674.6717; calc. for [C131H218N35O26]


































































This peptide was synthesized as described for 68 and a 5 µmol fraction of the resin was
then transferred to a new PE-frit equipped syringe. Fmoc-deprotection of the N -terminal
β
3-hlysine side chain was performed according to SOP4 and the free amine-group was
labelled with 5-carboxyfluorescein as described in SOP8. Afterwards, the washed
resin was transferred to a screw top glass vial and cleavage as described in SOP9
was conducted to obtain the crude peptide as a brown solid. After purification via
semi-preparative HPLC the product 70 (0.3 mg, 101 nmol) was yielded as an orange solid.
HPLC (Semi-prep. (C18), solvents: standard-system, gradient: 30–40 % B in
30 min, λ in nm: 215, 254, 470): tR = 21.0 min.
ESI-MS (m/z): 482.6 [M+6H]6+, 578.9 [M+5H]5+, 723.4 [M+4H]4+, 964.2 [M+3H]3+.
HR-MS (ESI): calc. for [C146H230N32O29] ([M+6H]6+): 482.6246, found: 482.6241; calc.
for [C146H229N32O29] ([M+5H]5+): 578.9480, found: 578.9470; calc. for [C146H228N32O29]




































































The peptide was synthesized as described for 68 before a 5 µmol fraction of resin was
transferred to a PE-frit equipped syringe for subsequrent Fmoc-deprotection according
to SOP4. Afterwards, the resulting free amine-group of the N -terminal β3-hlysine
side chain was labelled with 5(6)-carboxytetramethylrhodamine following SOP8. The
washed resin was then transferred to a screw top glass vial for cleavage as described
in SOP9 and the crude peptide was obtained as a pink solid. The crude peptide was
purified by semi-preparative HPLC and the peptide eluted as a double peak because of
5(6)-carboxytetramethylrhodamine being an isomer mixture. In the end, the product 71
(0.3 mg, 359 nmol) was yielded as a pink solid. [182]
HPLC (Semi-prep. (C18), solvents: standard-system, gradient: 30–40 % B in
30 min, λ in nm: 215, 254, 540): tR1 = 21.0 min, tR2 = 23.6 min.
ESI-MS (m/z): 491.6 [M+6H]6+, 589.8 [M+5H]5+, 737.0 [M+4H]4+, 982.3 [M+3H]3+.
HR-MS (ESI): calc. for [C150H240N34O27] ([M+6H]6+): 491.6403, found: 491.6399; calc.
for [C150H239N34O27] ([M+5H]5+): 589.7669, found: 589.7666; calc. for [C150H238N34O27]































































The peptide was synthesized with commercially available Boc-β-Ala-PAM resin (25.0 mg,
20 µmol, 1.00 eq, 0.8 mmol/g) following a modified SOP3. In the modified SPPS protocol,
coupling was performed with the reagents dissolved in DMF and as single coupling for
45 min at 65 °C (35 W) for all building blocks except for the nucleobase building blocks
which were coupled n a double coupling step. Afterwards, a 5 µmol fraction of the resin
was transferred to a new PE-frit equipped syringe and Fmoc-deprotected as described in
SOP4. The resulting free amine-group of the N -terminal β3-hlysine side chain was then
acetylated according to SOP8. The washed resin was transferred to a screw top glass vial
and the peptide was cleaved following SOP9 to obtain the crude peptide as an off-white
solid. After purification by semi-preparative HPLC, the product 72 (1.6 mg, 608 nmol)
was yielded as a white solid.
HPLC (Semi-prep. (C18), solvents: standard-system, gradient: 30–40 % B in
30 min, λ in nm: 215, 254, 280): tR = 14.8 min.
ESI-MS (m/z): 571.5 [M+5H]5+, 646.7 [M+4H]4+, 861.9 [M+3H]3+.
HR-MS (ESI): calc. for [C127H220N35O22] ([M+5H]5+): 517.5429, found: 517.5426; calc.
for [C127H219N35O22] ([M+4H]4+): 646.6768, found: 646.6767; calc. for [C127H218N35O22]































































Synthesis for this peptide was performed as described for 72. After SPPS, a 5 µmol frac-
tion of the resin was transferred to a new PE-frit equipped syringe and Fmoc-deprotection
following SOP4 was performed, before the free amine-group of the N -terminal β3-hlysine
side chain was labelled with 7-nitrobenz-2-oxa-1,3-diazol-4-yl according to SOP8. Then,
the washed resin was transferred to a screw top glass vial for cleavage as described
in SOP9 and the crude peptide was obtained as a brown solid. Purification by semi-
preparative HPLC yielded the peptide 73 (0.9 mg, 344 nmol) as an orange solid.
HPLC (Semi-prep. (C18), solvents: standard-system, gradient: 30–40 % B in
30 min, λ in nm: 215, 254, 464): tR = 23.1 min.
ESI-MS (m/z): 541.7 [M+5H]5+, 676.9 [M+4H]4+, 902.2 [M+3H]3+.
HR-MS (ESI): calc. for [C131H219N38O24] ([M+5H]5+): 541.7411, found: 541.7407; calc.
for [C131H218N38O24] ([M+4H]4+): 676.9246, found: 676.9244; calc. for [C131H217N38O24]



































































Peptide synthesis was performed as described for 72. A 5 µmol fraction of the resin was
transferred to a new PE-frit equipped syringe, before Fmoc-deprotection following SOP4
was performed. Then, the free amine-group of the N -terminal β3-hlysine side chain was
labelled with 5-carboxyfluorescein according to SOP8. Afterwards, the washed resin was
transferred to a screw top glass vial for cleavage as described in SOP9 to obtain the
crude peptide as a brown solid. Purification by semi-preparative HPLC was performed
to yield the peptide 74 (0.3 mg, 111 nmol) as an orange solid.
HPLC (Semi-prep. (C18), solvents: standard-system, gradient: 30–40% B in
30 min, λ in nm: 215, 254, 470): tR = 21.1 min.
ESI-MS (m/z): 580.8 [M+5H]5+, 725.7 [M+4H]4+, 967.2 [M+3H]3+.
HR-MS (ESI): calc. for [C146H228N35O27] ([M+5H]5+): 580.7503, found: 580.7493; calc.
for [C146H227N35O27] ([M+4H]4
2++): 725.6861, found: 725.6852; calc. for [C146H226N35O27]



































































Synthesis for this peptide was conducted as described for 72. Afterwards, a 5 µmol
fraction of the resin was transferred to a new PE-frit equipped syringe and the N -
terminal β3-hlysine side chain was Fmoc-deprotected according to SOP4. The resulting
free amine-group was labelled with 5(6)-carboxytetramethylrhodamine as described in
SOP8 and the washed resin was then transferred to a screw top glass vial for cleavage
following SOP9. The obtained crude peptide, which was a pink solid, was purified by
semi-preparative HPLC. Due to 5(6)-carboxytetramethylrhodamine being an isomer
mixture, the peptide eluted as a double peak, the corresponding fractions of which were
combined to yield the product 75 (0.8 mg, 267 nmol) as a pink solid. [182]
HPLC (Semi-prep. (C18), solvents: standard-system, gradient: 30–40 % B in
30 min, λ in nm: 215, 254, 540): tR1 = 20.6 min, tR2 = 23.7 min.
ESI-MS (m/z): 493.1 [M+6H]6+, 591.6 [M+5H]5+, 739.2 [M+4H]4+, 985.3 [M+3H]3+.
HR-MS (ESI): calc. for [C150H239N37O25] ([M+6H]6+): 493.1422, found: 493.1420; calc.
for [C150H238N37O25] ([M+5H]5+): 591.5692, found: 591.5695; calc. for [C150H237N37O25]


































































Commercially available Boc-β-Ala-PAM resin (0.8 mmol/g) was down-loaded with Boc-
β
3-hlys(Cbz-Cl)-OH as described in SOP1, to achieve a loading density of 0.25 mmol/g.
The resin (100 mg, 25 µmol, 1.00 eq, 0.25 mmol/g) was then used to synthesize the
peptide following SOP3. Before the N -terminal β3-hlys(Fmoc)-OH was coupled, the
β
3-hglutamic acid side chain was Allyl-deprotected according to SOP5, followed by side
chain modification with H-β-Ala-NChol as described in SOP7. Then, the last β3-hlysine
was coupled. Afterwards, a 12.5 µmol fraction of the resin was transferred to a new
PE-equipped syringe for subsequent Fmoc-deprotection after SOP4 and acetylation of
the free amine-group at the N -terminal β3-hlysine side chain following SOP8. The washed
resin was transferred to a screw top glass vial for cleavage according to SOP9 to obtain
the crude peptide as an off-white solid. Purification by semi-preparative HPLC proved
difficult since peak separation could not be achieved. The product 98 was acquired as a
white solid.
HPLC (Semi-prep. (C8), solvents: standard-system, gradient: 30–60 % B in
30 min, λ in nm: 215, 254, 280): tR = 10− 24 min.
ESI-MS (m/z): 569.8 [M+5H]5+, 712.0 [M+4H]4+, 949.0 [M+3H]3+, 1422.9 [M+2H]2+.
HR-MS (ESI): calc. for [C145H247N34O24] ([M+5H]5+): 569.7825, found: 569.1815; calc.
for [C145H246N34O24] ([M+4H]4+): 711.9763, found: 711.9754; calc. for [C145H245N34O24]




































































Peptide synthesis and modification with H-β-Ala-NChol were performed as described for
98, before a 12.5 µmol fraction of the resin was transferred to a new PE-equipped syringe
to conduct Fmoc-deprotection according to SOP4. The resulting free amine-group of the
N -terminal β3-hlysine side chain was then labelled with 7-nitrobenz-2-oxa-1,3-diazol-4-yl
following SOP8. The washed resin was transferred to a screw top glass vial and the
crude peptide was cleaved off as described in SOP9 obtaining a brown solid. Purification
of the crude peptide by semi-preparative HPLC proved difficult since peak separation
could not be achieved.. The product 93 was obtained as an orange solid.
HPLC (Semi-prep. (C8), solvents: standard-system, gradient: 30–60 % B in
30 min, λ in nm: 215, 254, 464): tR = 17.5− 19.4 min.
ESI-MS (m/z): 594.0 [M+5H]5+, 742.2 [M+4H]4+, 989.3 [M+3H]3+, 1483.4 [M+2H]2+.
HR-MS (ESI): calc. for [C149H246N37O26] ([M+5H]5+): 593.9807, found: 593.9802; calc.
for [C149H245N37O26] ([M+4H]4+): 742.2241, found: 742.2240; calc. for [C149H243N37O26]



































































For this peptide, commercially available Boc-β-Ala-PAM resin (0.8 mmol/g) was
down-loaded with Boc-β3-hlys(Cbz-Cl)-OH following SOP1 and the loading density was
reduced to 0.25 mmol/g. Then, the resin (100 mg, 25 µmol, 1.00 eq, 0.25 mmol/g) was
used to synthesize the peptide following SOP3. Before the N -terminal β3-hlys(Fmoc)-OH
was coupled, Allyl-deprotection was carried out as described in SOP5 followed by
modification of the β3-hglutamic acid side chain with H-β-Ala-NChol following SOP7.
Then, the last β3-hlysine was coupled. Afterwards, a 12.5 µmol fraction of the resin
was transferred to a new PE-equipped syringe for subsequent Fmoc-deprotection after
SOP4 and acetylation of the free amine-group at the N -terminal β3-hlysine side chain
following SOP8. The washed resin was transferred to a screw top glass vial for cleavage
according to SOP9 to obtain the crude peptide as an off-white solid. Purification by
semi-preparative HPLC proved difficult since peak separation could not be achieved.
The product 94 (0.8 mg, 273 nmol) was yielded as a white solid.
HPLC (Semi-prep. (C8), solvents: standard-system, gradient: 10–95 % B in
30 min, λ in nm: 215, 254, 464): tR = 12.0 min.
ESI-MS (m/z): 595.8 [M+5H]5+, 744.5 [M+4H]4+, 992.3 [M+3H]3+, 1487.9 [M+2H]2+.
HR-MS (ESI): calc. for [C149H245N40O24] ([M+5H]5+): 595.7831, found: 595.7830; calc.
for [C149H244N40O24] ([M+4H]4+): 744.4770, found: 744.4769; calc. for [C149H243N40O24]





















































Commercially available Boc-β-Ala-PAM resin (0.8 mmol/g) was down-loaded with Boc-
β
3-hlys(Cbz-Cl)-OH as described in SOP1 to achieve a loading density of 0.25 mmol/g.
The peptide synthesis was performed with the down-loaded resin (200 mg, 50 µmol,
1.00 eq, 0.25 mmol/g) following SOP3. After SPPS, a 25 µmol fraction of the resin
was transferred to a new PE-equipped syringe for subsequent Fmoc-deprotection after
SOP4 and labelling with 7-nitrobenz-2-oxa-1,3-diazol-4-yl of the free amine-group at the
N -terminal β3-hlysine side chain following SOP8. The washed resin was then transferred
to a screw top glass vial for cleavage according to SOP9 to obtain the crude peptide as
a brown solid. Purification by semi-preparative HPLC yielded the product 91 (3.9 mg,
1.7 µmol) as an orange solid.
HPLC (Semi-prep. (C18), solvents: standard-system, gradient: 30–40 % B in
30 min, λ in nm: 215, 254, 464): tR = 23.9 min.
ESI-MS (m/z): 455.3 [M+5H]5+, 568.9 [M+4H]4+, 758.5 [M+3H]3+, 1136.8 [M+2H]2+.
HR-MS (ESI): calc. for [C113H203N26O22] ([M+5H]5+): 455.3108, found: 455.3013; calc.
for [C113H202N26O22] ([M+4H]4+): 568.8866, found: 568.8869; calc. for [C113H200N26O22]




















































For this peptide, commercially available Boc-β-Ala-PAM resin (0.8 mmol/g) was
down-loaded with Boc-β3-hlys(Cbz-Cl)-OH following SOP1 and the loading density was
reduced to 0.17 mmol/g. Synthesis with the down-loaded resin (294 mg, 50 µmol,
1.00 eq, 0.17 mmol/g) was performed following SOP3. For the next steps, a 25 µmol
fraction of the resin was transferred to a new syringe equipped with a PE-frit and
Fmoc-deprotection following SOP4 was performed, resulting in a free amine-group at
the N -terminal β3-hlysine side chain. This amine-group was subsequently acetylated
according to SOP8 before the washed resin was transferred to a screw top glass vial for
cleavage as described in SOP9. The crude peptide was obtained as a brown solid which
was purified by semi-preparative HPLC to yield the peptide 90 (1.3 mg, 492 nmol) as an
orange solid.
HPLC (Semi-prep. (C18), solvents: standard-system, gradient: 20–40 % B in
30 min, λ in nm: 215, 254, 464): tR = 12.7 min.
ESI-MS (m/z): 526.8 [M+4H]4+, 702.1 [M+3H]3+, 1052.7 [M+2H]2+.
HR-MS (ESI): calc. for [C101H178N26O22] ([M+4H]4+): 526.8397, found: 526.8390; calc.
for [C101H177N26O22] ([M+3H]3+): 702.1171, found: 702.1188; calc. for [C101H176N26O22]






























































Commercially available Boc-β-Ala-PAM resin (0.8 mmol/g) was down-loaded with Boc-
β
3-hlys(Cbz-Cl)-OH as described in SOP1 to achieve a loading density of 0.17 mmol/g.
The resin (294 mg, 25 µmol, 1.00 eq, 0.17 mmol/g) was then used to synthesize the
peptide following SOP3. After SPPS, a 12.5 µmol fraction of the resin was transferred
to a new PE-equipped syringe for subsequent Fmoc-deprotection after SOP4 and
acetylation of the free amine-group at the N -terminal β3-hlysine side chain following
SOP8. The washed resin was then transferred to a screw top glass vial for cleavage
according to SOP9 to obtain the crude peptide as an off-white solid. After purification
by semi-preparative HPLC, the product 76 (3.0 mg, 1.2 µmol) was yielded as a white solid.
HPLC (Semi-prep. (C18), solvents: standard-system, gradient: 15–25 % B in
30 min, λ in nm: 215, 254, 280): tR = 24.4 min.
ESI-MS (m/z): 487.1 [M+5H]5+, 608.6 [M+4H]4+, 811.2 [M+3H]3+, 1216.2 [M+2H]2+.
HR-MS (ESI): calc. for [C115H196N35O23] ([M+5H]5+): 487.1043, found: 487.1038; calc.
for [C115H195N35O23] ([M+4H]4+): 608.6286, found 608.6289; calc. for [C115H194N35O23]





































































Synthesis for this peptide was performed as described for 76. After SPPS, a 12.5 µmol
fraction of the resin was transferred to a new PE-frit equipped syringe and Fmoc-
deprotection following SOP4 was performed, before the free amine-group of the
N -terminal β3-hlysine side chain was labelled with 5(6)-carboxytetramethylrhodamine
according to SOP8. Then, the washed resin was transferred to a screw top glass
vial for cleavage as described in SOP9 and the crude peptide was obtained as a
pink solid. Purification by semi-preparative HPLC was performed and due to 5(6)-
carboxytetramethylrhodamine being an isomer mixture, the peptide eluted as a double
peak, the corresponding fractions of which were combined to yield the product 77
(2.2 mg, 788 nmol) as a pink solid. [182]
HPLC (Semi-prep. (C18), solvents: standard-system, gradient: 20–30 % B in
30 min, λ in nm: 215, 254, 540): tR1 = 23.4 min, tR2 = 25.6 min.
ESI-MS (m/z): 467.8 [M+6H]6+, 561.1 [M+5H]5+, 701.2 [M+4H]4+.
HR-MS (ESI): calc. for [C138H215N37O26] ([M+6H]6+): 467.7768, found: 467.7766; calc.
for [C138H214N37O26] ([M+5H]5+): 561.1307, found: 561.1338; calc. for [C138H213N37O26]




























































For this peptide, commercially available Boc-β-Ala-PAM resin (0.8 mmol/g) was down-
loaded with Boc-β3-hlys(Cbz-Cl)-OH following SOP1 and the loading density was reduced
to 0.17 mmol/g. SPPS was performed with the down-loaded resin (284 mg, 50 µmol,
1.00 eq, 0.17 mmol/g) according to SOP3. Afterwards, a 10 µmol fraction of the resin
was transferred to a new PE-equipped syringe for subsequent Fmoc-deprotection after
SOP4 and acetylation of the free amine-group at the N -terminal β3-hlysine side chain
following SOP8. The washed resin was then transferred to a screw top glass vial for
cleavage according to SOP9 to obtain the crude peptide as an off-white solid. Purifica-
tion by semi-preparative HPLC yielded the product 78 (2.4 mg, 1.0 µmol) as a white solid.
HPLC (Semi-prep. (C18), solvents: standard-system, gradient: 15–25 % B in
30 min λ in nm: 215, 254, 280): tR = 19.2 min.
ESI-MS (m/z): 479.3 [M+5H]5+, 598.6 [M+4H]4+, 797.8 [M+3H]3+, 1196.2 [M+2H]2+.
HR-MS (ESI): calc. for [C114H196N33O23] ([M+5H]5+): 479.1031, found: 479.1031; calc.
for [C114H195N33O23] ([M+4H]4+): 598.6270, found: 598.6268; calc. for [C114H194N33O23]































































Peptide synthesis was performed as described for 78, before a 25 µmol fraction of the
resin was transferred to a new PE-equipped syringe to conduct Fmoc-deprotection
according to SOP4. The resulting free amine-group of the N -terminal β3-hlysine side
chain was then labelled with 7-nitrobenz-2-oxa-1,3-diazol-4-yl following SOP8. The
washed resin was transferred to a screw top glass vial and the crude peptide was cleaved
off as described in SOP9 obtaining a brown solid. The crude peptide was purified by
semi-preparative HPLC to yield the product 79 (3.6 mg, 1.4 µmol) as an orange solid.
HPLC (Semi-prep. (C18), solvents: standard-system, gradient: 20–30 % B in
30 min, λ in nm: 215, 254, 464): tR = 18.9 min.
ESI-MS (m/z): 503.3 [M+5H]5+, 628.9 [M+4H]4+, 838.2 [M+3H]3+, 1256.7 [M+2H]2+.
HR-MS (ESI): calc. for [C118H195N36O25] ([M+5H]5+): 503.3013, found: 503.3023; calc.
for [C118H194N36O25] ([M+4H]4+): 628.8748, found: 628.8763; calc. for [C118H193N36O25]
































































Commercially available Boc-β-Ala-PAM resin (0.8 mmol/g) was down-loaded with Boc-
β
3-hlys(Cbz-Cl)-OH as described in SOP1 to reduce the loading density to 0.17 mmol/g.
The down-loaded resin (284 mg, 50 µmol, 1.00 eq, 0.17 mmol/g) was used for peptide
synthesis following SOP3. For the next steps, a 12.5 µmol fraction of the resin was
transferred to a new syringe equipped with a PE-frit and Fmoc-deprotection following
SOP4 was performed, resulting in a free amine-group at the N -terminal β3-hlysine
side chain. This amine-group was subsequently acetylated according to SOP8 before
the washed resin was transferred to a screw top glass vial for cleavage as described in
SOP9. The crude peptide was obtained as an off-white solid which was purified by
semi-preparative HPLC to yield the peptide 80 (1.3 mg, 557 nmol) as a white solid.
HPLC (Semi-prep. (C18), solvents: standard-system, gradient: 15–25% B in
30 min, λ in nm: 215, 254, 280): tR = 24.8 min.
ESI-MS (m/z): 482.3 [M+5H]5+, 602.6 [M+4H]4+, 803.2 [M+3H]3+, 1204.2 [M+2H]2+.
HR-MS (ESI): calc. for [C114H196N33O24] ([M+5H]5+): 482.3021, found: 482.3008; calc.
for [C114H195N33O24] ([M+4H]4+): 602.6258, found: 602.6258; calc. for [C114H194N33O24]































































Synthesis for this peptide was performed as described for 80. For Fmoc-deprotection
following SOP4, a 10 µmol fraction of the resin was transferred to a new PE-equipped
syringe and the free amine-group of the N -terminal β3-hlysine side chain was labelled
with 7-nitrobenz-2-oxa-1,3-diazol-4-yl according to SOP8. Afterwards, the washed resin
was transferred to a screw top glass vial and cleavage was conducted following SOP9
obtaining the crude peptide as a brown solid. The crude product was purified by
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semi-preparative HPLC yielding the peptide 81 (0.2 mg, 61 nmol) as an orange solid.
HPLC (Semi-prep. (C18), solvents: standard-system, gradient: 20–30 % B in
30 min, λ in nm: 215, 254, 464): tR = 19.6 min.
ESI-MS (m/z): 506.5 [M+5H]5+, 632.9 [M+4H]4+, 843.5 [M+3H]3+.
HR-MS (ESI): calc. for [C118H195N36O26] ([M+5H]5+): 506.5003, found: 506.5009; calc.
for [C118H194N36O26] ([M+4H]4+): 632.8736, found: 632.8746; calc. for [C118H193N36O26]

































































Synthesis for this peptide was conducted as described for 80. Then, a 12.5 µmol fraction
of the resin was transferred to a new PE-frit equipped syringe and the N -terminal
β
3-hlysine side chain chain was Fmoc-deprotected according to SOP4. The resulting
free amine-group was labelled with 5(6)-carboxytetramethylrhodamine as described in
SOP8, before the washed resin was transferred to a screw top glass vial for cleavage
following SOP9. Then, the obtained crude peptide, which was a pink solid, was
purified by semi-preparative HPLC. The peptide eluted as a double peak, due to 5(6)-
carboxytetramethylrhodamine being an isomer mixture. The corresponding fractions
were combined to yield the product 82 (0.2 mg, 67 nmol) as a pink solid. [182]
HPLC (Semi-prep. (C18), solvents: standard-system, gradient: 20–30 % B in
30 min, λ in nm: 215, 254, 540): tR1 = 22.4 min, tR2 = 24.8 min.
ESI-MS (m/z): 463.8 [M+6H]6+, 556.3 [M+5H]5+, 695.2 [M+4H]4+, 926.5 [M+3H]3+.
HR-MS (ESI): calc. for [C137H215N35O27] ([M+6H]6+): 463.7749, found: 463.7761; calc.
174
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for [C137H214N35O27] ([M+5H]5+): 556.3284, found: 556.3294; calc. for [C137H213N35O27]






























































Before SPPS, commercially available Boc-β-Ala-PAM resin (0.8 mmol/g) was down-
loaded according to SOP1 with Boc-β3-hlys(Cbz-Cl)-OH reducing the loading density to
0.17 mmol/g. The peptide was synthesized with the down-loaded resin (294 mg, 50 µmol,
1.00 eq, 0.17 mmol/g) following SOP3. Afterwards, a 10 µmol fraction of the resin was
transferred to a new PE-frit equipped syringe and Fmoc-deprotected as described in
SOP4. The resulting free amine-group of the N -terminal β3-hlysine side chain was then
acetylated according to SOP8. The washed resin was transferred to a screw top glass vial
and the peptide was cleaved following SOP9 to obtain the crude peptide as an off-white
solid. After purification by semi-preparative HPLC, the product 83 (1.0 mg, 412 nmol)
was yielded as a white solid.
HPLC (Semi-prep. (C18), solvents: standard-system, gradient: 15–25 % B in
30 min, λ in nm: 215, 254, 280): tR = 23.8 min.
ESI-MS (m/z): 484.1 [M+5H]5+, 604.9 [M+4H]4+, 806.2 [M+3H]3+, 1208.8 [M+2H]2+.
HR-MS (ESI): calc. for [C114H195N36O22] ([M+5H]5+): 484.1044, found: 484.1047; calc.
for [C114H194N36O22] ([M+4H]4+): 604.8787, found: 604.8792; calc. for [C114H193N36O22]

































































Synthesis for this peptide was performed as described for 83. After SPPS, a 25 µmol frac-
tion of the resin was transferred to a new PE-frit equipped syringe and Fmoc-deprotection
following SOP4 was performed, before the free amine-group of the N -terminal β3-hlysine
side chain was labelled with 7-nitrobenz-2-oxa-1,3-diazol-4-yl according to SOP8. Then,
the washed resin was transferred to a screw top glass vial for cleavage as described
in SOP9 and the crude peptide was obtained as a brown solid. Purification by semi-
preparative HPLC yielded the peptide 84 (2.2 mg, 883 nmol) as an orange solid.
HPLC (Semi-prep. (C18), solvents: standard-system, gradient: 20–30 % B in
30 min, λ in nm: 215, 254, 464): tR = 18.8 min.
ESI-MS (m/z): 508.3 [M+5H]5+, 635.1 [M+4H]4+.
HR-MS (ESI): calc. for [C118H194N39O24] ([M+5H]5+): 508.3026, found: 508.3024; calc.































































The peptide was synthesized with commercially available Boc-β-Ala-PAM resin (62.5 mg,
50 µmol, 1.00 eq, 0.8 mmol/g) following SOP3. Afterwards, a 12.5 µmol fraction of
the resin was transferred to a new PE-frit equipped syringe and Fmoc-deprotected as
described in SOP4. The resulting free amine-group of the N -terminal β3-hlysine side
chain was then acetylated according to SOP8. The washed resin was transferred to a
screw top glass vial and the peptide was cleaved following SOP9 to obtain the crude
peptide as an off-white solid. After purification by semi-preparative HPLC, the product
85 (1.3 mg, 523 nmol) was yielded as a white solid.
HPLC (Semi-prep. (C18), solvents: standard-system, gradient: 30–40 % B in
30 min, λ in nm: 215, 254, 280): tR = 11.8 min.
ESI-MS (m/z): 515.9 [M+5H]5+, 644.7 [M+4H]4+, 859.2 [M+3H]3+.
HR-MS (ESI): calc. for [C126H220N33O24] ([M+5H]5+): 515.9396, found: 515.9396; calc.
for [C126H219N33O24] ([M+4H]4+): 644.6727, found: 644.6728; calc. for [C126H218N33O24]






























































Synthesis for this peptide was performed as described for 85. After SPPS, a 5 µmol frac-
tion of the resin was transferred to a new PE-frit equipped syringe and Fmoc-deprotection
following SOP4 was performed, before the free amine-group of the N -terminal β3-hlysine
side chain was labelled with 7-nitrobenz-2-oxa-1,3-diazol-4-yl according to SOP8. Then,
the washed resin was transferred to a screw top glass vial for cleavage as described
in SOP9 and the crude peptide was obtained as a brown solid. Purification by semi-
preparative HPLC yielded the peptide 86 (0.2 mg, 89 nmol) as an orange solid.
HPLC (Semi-prep. (C18), solvents: standard-system, gradient: 30–40 % B in
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30 min, λ in nm: 215, 254, 464): tR = 23.4 min.
ESI-MS (m/z): 515.9 [M+5H]5+, 644.7 [M+4H]4+, 859.2 [M+3H]3+.



































































Synthesis for this peptide was conducted as described for 85. Afterwards, a 12.5 µmol
fraction of the resin was transferred to a new PE-frit equipped syringe and the N -
terminal β3-hlysine side chain was Fmoc-deprotected according to SOP4. The resulting
free amine-group was labelled with 5(6)-carboxytetramethylrhodamine as described in
SOP8 and the washed resin was then transferred to a screw top glass vial for cleavage
following SOP9. The obtained crude peptide, which was a pink solid, was purified by
semi-preparative HPLC. Due to 5(6)-carboxytetramethylrhodamine being an isomer
mixture, the peptide eluted as a double peak, the corresponding fractions of which were
combined to yield the product 87 (1.6 mg, 523 nmol) as a pink solid. [182]
HPLC (Semi-prep. (C18), solvents: standard-system, gradient: 30–40 % B in
30 min, λ in nm: 215, 254, 540): tR1 = 17.8 min, tR2 = 20.7 min.
ESI-MS (m/z): 421.7 [M+7H]7+, 491.8 [M+6H]6+, 590.0 [M+5H]5+, 7737.2 [M+4H]4+,
982.6 [M+3H]3+.
HR-MS (ESI): calc. for [C149H240N35O27] ([M+7H]7+): 421.6921, found: 421.6911; calc.
for [C149H239N35O27] ([M+6H]6+): 491.8062, found: 491.8062; calc. for [C149H238N35O27]
([M+5H]5+): 589.9660, found: 589.9660; calc. for [C149H237N35O27] ([M+4H]4+):
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Synthesis with commercially available Boc-β-Ala-PAM resin (18.8 mg, 15 µmol, 1.00 eq,
0.8 mmol/g) was performed according to SOP3. After SPPS, a 10 µmol fraction of the
resin was transferred to a new PE-equipped syringe for subsequent Fmoc-deprotection
after SOP4 and acetylation of the free amine-group at the N -terminal β3-hlysine side
chain following SOP8. The washed resin was then transferred to a screw top glass vial for
cleavage according to SOP9 to obtain the crude peptide as an off-white solid. Purification
by semi-preparative HPLC yielded the product 88 (10.9 mg, 358 nmol) as a white solid.
HPLC (Semi-prep. (C18), solvents: standard-system, gradient: 30–40 % B in
30 min, λ in nm: 215, 254, 280): tR = 12.3 min
ESI-MS (m/z): 517.7 [M+5H]5+, 646.9 [M+4H]4+, 862.2 [M+3H]3+.
HR-MS (ESI): calc. for [C126H219N36O22] ([M+5H]5+): 517.7419, found: 517.7423; calc.
for [C126H218N36O22] ([M+4H]4+): 646.9256, found: 646.9261; calc. for [C126H217N36O22]































































Peptide synthesis was performed as described for 88, before a 25 µmol fraction of the
resin was transferred to a new PE-equipped syringe to conduct Fmoc-deprotection
according to SOP4. The resulting free amine-group of the N -terminal β3-hlysine side
chain was then labelled with 7-nitrobenz-2-oxa-1,3-diazol-4-yl following SOP8. The
washed resin was transferred to a screw top glass vial and the crude peptide was cleaved
off as described in SOP9 obtaining a brown solid. The crude peptide was purified by
semi-preparative HPLC to yield the product 89 (1.6 mg, 607 nmol) as an orange solid.
HPLC (Semi-prep. (C18), solvents: standard-system, gradient: 30–40 % B in
30 min, λ in nm: 215, 254, 464): tR = 20.2 min.
ESI-MS (m/z): 541.9 [M+5H]5+, 677.2 [M+4H]4+, 902.6 [M+3H]3+, 1353.3 [M+2H]2+.
HR-MS (ESI): calc. for [C130H218N39O24] ([M+5H]5+): 541.9402, found: 541.9406; calc.
for [C130H217N39O24] ([M+4H]4+): 677.1734, found: 677.1738; calc. for [C130H216N39O24]


































































Commercially available Boc-β-Ala-PAM resin (0.8 mmol/g) was down-loaded with Boc-
β
3-hlys(Cbz-Cl)-OH as described in SOP1 to achieve a loading density of 0.31 mmol/g.
The resin (161 mg, 50 µmol, 1.00 eq, 0.31 mmol/g) was then used to synthesize the
peptide following SOP3. After SPPS, a 12.5 µmol fraction of the resin was transferred to
a new PE-equipped syringe for subsequent Fmoc-deprotection after SOP4 and acetylation
of the free amine-group at the N -terminal β3-hlysine side chain following SOP8. Then,
the β3-hglutamic acid side chain was Allyl-deprotected according to SOP5 followed by
side chain modification with H-β-Ala-NChol as described in SOP7. The washed resin was
transferred to a screw top glass vial for cleavage according to SOP9 to obtain the crude
peptide as an off-white solid. Purification by semi-preparative HPLC proved difficult
since peak separation could not be achieved and water-addition to a C=C-bond of the
peptide was observed.
HPLC a) (Semi-prep. (C8), solvents: HFIP-system, gradient: 15–85 % B in
30 min, λ in nm: 215, 254, 280): tR = 15− 24 min.
b) (Semi-prep. (C18), solvents: 1-PrOH-system, gradient: 35–45 % B in 30 min, λ in
nm: 215, 254, 280): tR = 12.4 min.
ESI-MS (m/z): 570.0 [M+5H]5+, 712.2 [M+4H]4+, 949.3 [M+3H]3+.
HR-MS (ESI): calc. for [C144H246N35O24] ([M+5H]5+): 569.9816, found: 569.9818; calc.



































































Peptide synthesis and modification with H-β-Ala-NChol were performed as described
for 99, before a 5 µmol fraction of the resin was transferred to a new PE-equipped
syringe to conduct Allyl-deprotection of the β3-hglutamic acid side chain according
to SOP5 followed by Fmoc-protection of the N -terminal β3-hlysine side chain after
SOP6. Afterwards, the β3-hglutamic acid side chain was modified with H-β-Ala-NChol
as described in SOP7 and the β3-hlysine side chain was Fmoc-deprotected according to
SOP4. The resulting free amine-group of the N -terminal β3-hlysine side chain was then
labelled with 7-nitrobenz-2-oxa-1,3-diazol-4-yl following SOP8. The washed resin was
transferred to a screw top glass vial and the crude peptide was cleaved off as described
in SOP9 obtaining a brown solid. The crude peptide was purified by semi-preparative
HPLC but purification proved difficult since peak separation could not be achieved..
HPLC (Semi-prep. (C8), solvents: HFIP-system, gradient: 15–85 % B in 30 min, λ in
nm: 215, 254, 464): tR = 16− 26 min.
ESI-MS (m/z): 495.3 [M+6H]6+, 594.2 [M+5H]5+, 742.5 [M+4H]4+.
HR-MS (ESI): calc. for [C148H246N38O26] ([M+6H]6+): 495.3177, found: 495.3185; calc.
for [C148H245N38O26] ([M+5H]5+): 594.1798, found: 594.1789; calc. for [C148H244N38O26]
































































For this peptide, commercially available Boc-β-Ala-PAM resin (0.8 mmol/g) was
down-loaded with Boc-β3-hlys(Cbz-Cl)-OH following SOP1 and the loading density was
reduced to 0.31 mmol/g. Then, the resin (161 mg, 50 µmol, 1.00 eq, 0.31 mmol/g) was
used to synthesize the peptide following SOP3. Afterwards, a 12.5 µmol fraction of the
resin was transferred to a new PE-equipped syringe for subsequent Fmoc-deprotection
after SOP4 and acetylation of the free amine-group at the N -terminal β3-hlysine side
chain following SOP8. Subsequently, Allyl-deprotection was carried out as described in
SOP5 followed by modification of the β3-hglutamic acid side chain with H-β-Ala-NChol
following SOP7. The washed resin was transferred to a screw top glass vial for cleavage
according to SOP9 to obtain the crude peptide as an off-white solid. Purification by
semi-preparative HPLC proved difficult since peak separation could not be achieved.
HPLC (Semi-prep. (C18), solvents: 1-PrOH-system, gradient: 40–80 % B in
30 min, λ in nm: 215, 254, 280): tR = 8.9 min.
ESI-MS (m/z): 476.7 [M+6H]6+, 571.8 [M+5H]5+, 714.5 [M+4H]4+, 952.3 [M+3H]3+,
1428.5 [M+2H]2+.
HR-MS (ESI): calc. for [C144H246N38O22] ([M+6H]6+): 476.6544, found: 476.6547; calc.
for [C144H245N38O22] ([M+5H]5+): 571.7839, found: 571.7836; calc. for [C144H244N38O22]























































Commercially available Boc-β-Ala-PAM resin (0.8 mmol/g) was down-loaded with Boc-
β
3-hlys(Cbz-Cl)-OH as described in SOP1 to achieve a loading density of 0.31 mmol/g.
The resin (161 mg, 50 µmol, 1.00 eq, 0.31 mmol/g) was then used to synthesize the
peptide following SOP3. A 25 µmol fraction if resin was transferred to a new PE-frit
equipped syringe and the β3-hglutamic acid side chain was Allyl-deprotected according
to SOP5. Then, Fmoc-protection as described in SOP6 was conducted before the free
carboxyl group was modified with H-β-Ala-NChol following SOP7. The washed resin was
then transferred to a screw top glass vial for cleavage according to SOP9 to obtain the
crude peptide as a brown solid. Purification by semi-preparative HPLC proved difficult
since peak separation could not be achieved.
HPLC (Semi-prep. (C18), solvents: 1-PrOH-System, gradient: 30–100 % B in
30 min, λ in nm: 215, 254, 464): tR = 20− 28 min.
ESI-MS (m/z): 509.4 [M+5H]5+, 636.4 [M+4H]4+, 848.2 [M+3H]3+, 1271.9 [M+2H]2+.
HR-MS (ESI): calc. for [C131H229N28O22] ([M+5H]5+): 509.3527, found: 509.3531; calc.
for [C131H228N28O22] ([M+4H]4+): 636.4390, found: 636.4400; calc. for [C131H227N28O22]































1,000 2,000 3,000 4,000 5,000
3,180.7936b)
Figure A.1. Deconvoluted mass spectra of 55 before (a) and after (b) NBD labelling






























1,000 2,000 3,000 4,000 5,000
3,074.6731
b)
Figure A.2. Deconvoluted mass spectra of 56 before (a) and after (b) NBD labelling
and purification. The corresponding m/z signals are labelled with the de-
termined masses.
A.2. Temperature-dependent UV spectra of Bifacial
β-PNA
Figure A.3. Temperature-dependent UV spectra of 56 and 57 with a concentration of
8 µM (a) or 10 µM (b) each measured at pH 7.5 in 10 mM TRIS-HCl buffer.
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A.3. Mass Spectra of Monofacial β-PNA



























1,000 2,000 3,000 4,000 5,000
b) 2,536.4852
Figure A.4. Deconvoluted mass spectra of 65 before (a) and after (b) NBD labelling





























1,000 2,000 3,000 4,000 5,000
b)
2,695.6683
Figure A.5. Deconvoluted mass spectra of 69 before (a) and after (b) Fmoc deprotection,
NBD labelling and purification. The corresponding m/z signals are labelled
with the determined masses.
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A.4. CD Spectra of Monofacial β-PNA
Figure A.6. CD spectra of the indicated myristyl-modified β-PNA strands recorded at
20 ℃ and at pH 7.5 in DOPC-LUV suspensions with 10 mM TRIS-HCl
buffer.
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Figure A.7. CD spectra of the indicated β-PNA strands recorded at 20 ℃ and at pH 7.5
in 10 mM TRIS-HCl buffer.
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A.5. Temperature-dependent UV spectra of
Monofacial β-PNA
Figure A.8. Temperature-dependent UV spectra of the complementary β-PNA com-
binations 59+64 (TTA/TAA, a), 76+78 (GTA/TAC, b) and 80+83
(GTC/GAC, c) with a concentration of 8 µM each, measured at pH 7.5
in 10 mM TRIS-HCl buffer.
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A.6. FRET Measurements of Monofacial β-PNA
A.6. FRET Measurements of Monofacial β-PNA
Figure A.9. Relative change of NBD fluorescence intensity (F/F0) at 530 nm of all β-
PNA combinations with 59/62 (TTA, a), 76/77 (GTA, b), 80/82 (GTC, c)
as well as of the complementary combinations (d) 59/62+65 (TTA/TAA),
76/77+79 (GTA/TAC) and 80/82+84 (GTC/GAC) at 10 ℃ as a function
of increasing χA of the TAMRA-labelled β-PNA strand measured at pH 7.5
in 10 mM TRIS-HCl buffer.
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Figure A.10. Relative change of NBD fluorescence intensity (F/F0) at 530 nm of all
β-PNA combinations with 59/62 (TTA, a), 76/77 (GTA, b), 80/82
(GTC, c) as well as of the complementary combinations (d) 59/62+65
(TTA/TAA), 76/77+79 (GTA/TAC) and 80/82+84 (GTC/GAC) at
20 ℃ as a function of increasing χA of the TAMRA-labelled β-PNA strand
measured at pH 7.5 in 10 mM TRIS-HCl buffer.
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A.7. Mass Spectra of Monofacial β-PNA with Cholesterol Modification




























1,000 2,000 3,000 4,000 5,000
b)
2,965.8609
Figure A.13. Deconvoluted mass spectra of 93 before (a) and after (b) purification. The



























1,000 2,000 3,000 4,000 5,000
b) 2,988.8841
2,974.8713
Figure A.14. Deconvoluted mass spectra of 94 before (a) and after (b) purification. The































1,000 2,000 3,000 4,000 5,000
a)
2,542.7311
Figure A.15. Deconvoluted mass spectra of 95 before (a) and after (b) purification.
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Abbreviations
General: Amino acids are abbreviated using the standard three-letter code. While l-
amino acids are abbreviated with capital letters, the d-amino acids are abbreviated with
small letters. Nucleobases in the β-peptide sequences are abbreviated with capital letters




























































PNA peptide nucleic acid
prep. preparative
PrOH propanol






SOP standard operating protocol
SPPS solid-phase peptide synthesis
SRB sulforhodamine B





TLC thin layer chromatography
TMS trimethylsilan
TRIS tris(hydroxymethyl)aminomethane
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